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Cancer
Cancer is the collective term for a large group of diseases characterized by the uncontrolled 
growth of abnormal cells that have the capacity to migrate and invade other tissues. Cancer 
is one of the major causes of death in the Western world and even the second cause of death 
in developing countries, with a global growing incidence of 22.2 million estimated cases in 
2030 1-3. One in two men and one in three women will develop cancer during their lifetime 
4. In 2012, 14.1 million people were diagnosed with cancer and 8.2 million cancer deaths 
were counted 5. The increase in cancer incidence is because of the aging and growth of the 
population in combination with earlier detection 4. Even though cancer mortality declines 
because of more effective early detection in combination with early treatment, the burden on 
society remains enormous. 
The treatment of the majority of the cancer patients consists of a combination of surgery and/
or chemo- and radiotherapy. Because not all cancers can be cured with these conventional 
methods, an urgent need for other therapies exists. More recently, other therapies like 
immunotherapy became of great interest. The major aims of immunotherapy are to trigger the 
patient’s immune system to enhance the response against cancer cells or to supply immune 
cells or components to the patient providing a strong immune reaction after administration. 
Within the field of cancer immunotherapy, a multitude of approaches exist, like immune 
modulating agents, anti-tumour antibodies, cancer vaccines and adoptive cellular therapies. 
Thus far, one of the most successful forms of immunotherapy is antibody therapy. A well-
known example is anti-CD20/Rituximab that is used as therapy for B cell lymphomas 6. 
These antibodies induce cell-mediated cytotoxicity of CD20 expressing cells, eliminating 
malignant cells but also healthy B cells. Another successful antibody therapy with immune 
modulating effects is anti-cytotoxic T lymphocyte associated protein-4 (anti-CTLA-4)/
Ipilimumab used in the treatment of melanoma patients. It enhances anti-tumour effects 
because of neutralizing inhibitory signals on T cells resulting in enhanced survival of 
advanced melanoma patients of ~3.5 months 7, 8. In the field of cellular immunotherapy, 
currently only one cell-based vaccine, sipuleucel-T/Provenge®, has been clinically 
approved in 2010 for the treatment of metastatic hormone-refractory prostate cancer 9. 
This vaccine consists of the patient’s own peripheral blood mononuclear cells (PBMCs) 
including antigen presenting cells (APCs) that have been activated ex vivo and loaded 
with a prostate specific protein called prostatic acid phosphatase, stimulating the patient’s 
immune system to induce anti-tumour activity resulting in a prolonged survival of 4.1
months 9. Although the accomplished successes, where the above mentioned strategies only 
represent a fraction of existing therapies, immunotherapy is often only effective in certain 
patients and results in moderate prolonged survival instead of complete remission. Many 
other immunotherapies are currently under investigation as extensively reviewed by others 
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10-12. Some studies target the improvement of current therapies, while others focus on the 
generation of novel cancer immunotherapies, for example adoptive immunotherapy where 
immune cells are used in the battle against cancer. 
Haematopoietic stem cell transplantation as cancer therapy
Although chemotherapy, with or without radiotherapy, is the standard treatment for various 
haematological malignancies, in many patients this is not sufficient for complete remission. 
The addition of haematopoietic stem cell transplantation (HSCT) to the treatment reduces the 
risk of relapse 13. HSCT is the most common cellular immunotherapy used for the treatment 
of haematological malignancies but also for some solid tumours, anemia and autoimmune 
disorders 14. Allogeneic HSCT from human leukocyte antigen (HLA) matched donors is the 
transplant of choice for a variety of haematological diseases. 
Unfortunately, in only 30% of the cases a HLA matched donor is found 15. Moreover, finding 
a matched unrelated donor (MUD) in the required time period is limited because of the 
complexity of the HLA matching and logistic challenges, especially for ethnic minorities 16, 
17. An alternative source of stem cells for transplantation is umbilical cord blood (CB). CB 
grafts allow a higher HLA disparity between donor and recipient, they contain less T cells 
and because of cryopreservation, grafts are directly available 18. Unfortunately, obtained cell 
numbers are low and are therefore not suitable for every patient. Furthermore, the use of 
double CB transplantation - aiming for higher cell numbers - increases the risk of graft versus 
host disease (GVHD) 19. Besides exploring the use of CB for transplantation because of a lack 
of HLA-matched related or unrelated donors 20, haplo-identical transplants are introduced in 
the last two decades. Each parent, child and 50% of the patient’s siblings could immediately 
serve as a donor. Donor granulocyte-colony stimulating factor (G-CSF) treatment results in 
HSC mobilization from the bone marrow (BM) to the periphery, via apheresis and subsequent 
CD34+ cell isolation, adequate cell numbers can be obtained. Furthermore, the same donor 
could be used for additional adoptive immunotherapy. Nonetheless, initial studies with 
transplantation across the HLA-barrier resulted in high treatment related mortality because of 
severe GVHD 21. Extensive T cell depletion in combination with a mega dose of HSCs resulted 
in less GVHD and overcame graft rejection 22. A preliminary study showed that removal of 
αβ CD3+ T cells and CD19+ B cells instead of CD34+ HSC selection, leaving other cells that 
may be important for immune function in the graft, resulting in minor GVHD risk and 
promoted faster immune recovery in children receiving haplo-identical transplantation for 
non-malignant disorders. This protocol is currently also tested in patients with malignancies 
23, 24. A major advantage of HLA-mismatched transplantation is the strong beneficial graft 
versus leukaemia (GVL) effect mediated by the alloreactive natural killer (NK) cells 25.
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Immune recovery after haematopoietic stem cell transplantation
Delayed immune reconstitution is common to all types of HSCT. However, this delay is more 
pronounced for CB and haplo-idential HSCT 26. Major reasons are extensive T cell depletion, 
HLA mismatching, immunosuppressive regimens to prevent GVHD and a decreased thymic 
function because of age-related involution, treatment and GVHD 15, 27. As a consequence, 
patients suffer from uncommon and opportunistic infections resulting in high mortality 19, 
22, 28. 
Immune recovery, as illustrated in Figure 1, depends on several factors such as disease, 
age, conditioning, transplant type and graft manipulation, e.g. T cell depletion and the HSC 
selection method 26. In general, the innate immunity recovers within weeks, while adaptive 
immunity recovers only within months to years. In more detail, neutrophils, monocytes, 
macrophages, dendritic cells (DCs, in blood) and NK cells recover within weeks,  while CD8+ 
T cells and B cells recover in months. Especially CD4+ T cells recover slow, which may take 
up to several years (reviewed in 26, 29). Specifically, the new development of naive CD4+ or 
CD8+ T cells takes several years because of thymus dependency. Low CD4+ T cell counts 
are associated with increased infection score 30. Moreover, patients with low thymic output 
after allogeneic HSCT are at higher risk of experiencing infections 31. Most patients suffer 
from Cytomegalovirus (CMV) infection or reactivation and fungal infection (Aspergillosis) 
15. Furthermore, slow T cell reconstitution is associated with risk of graft rejection and relapse. 
Relapsing patients are characterized by less naive T cells counts compared to non-relapsing 
patients 32. Recovery of the immune system partially depends on peripheral expansion of 
residual or graft derived immune cells. However, generation of immune cells from stem cells 
is required for the recovery of a robust and protective immune system.
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Figure 1: Approximate immune cell counts after myeloablative haematopoietic stem cell 
transplantation. Immune cell counts are represented as percentage of normal (80-100%). The dashed 
light blue line represents innate immune cells (for example, neutrophils, monocytes and NK cells). 
The dotted dark blue line represents the recovery of CD8+ T cells and B cells. The dashed green line 
represents the recovery of relatively radiotherapy/chemotherapy resistant cells such as plasma cells and 
tissue dendritic cells (DCs). The red line represents CD4+ T cells, the recovery of which is influenced 
primarily by the T cell content of the graft and patient age (faster in children than in adults). Figure is 
based on reference 26.
Haematopoiesis
Haematopoietic stem cells are located in the bone marrow. The unique features of stem cells 
are self-renewal capacity and multi-lineage potential. This multi-lineage potential results in 
the generation of all mature blood cells, a process defined as haematopoiesis. Mature blood 
cells consist of erythrocytes, thrombocytes (cell fragments) and leukocytes. Leukocytes are 
the cells of the immune system and can be divided into the myeloid and lymphocyte lineage. 
The myeloid lineage consists of granulocytes, monocytes, macrophages and dendritic cells, 
whereas the majority of lymphocytes consist of B cells, T cells, NK cells and NKT cells. 
The development from stem cell to mature blood cell is a highly organized process. Of each 
lineage, different (multi-potent) progenitor cell types exist that have the capacity to grow into 
mature effector cells. For more than 30 years, the classical model of branching was the gold 
standard 33. This model describes a clear separation between a common myeloid-erythroid 
progenitor (CMEP) and a common lymphoid progenitor (CLP) as illustrated in Figure 2A. 
However, recent research proposed an alternative model: the myeloid-based model as shown 
in Figure 2B. In this model myeloid potential is reserved after the segregation of erythroid, 
B and T cells 34. 
Lineage differentiation is dependent on genetic and epigenetic control. Lymphocytes 
are generated through a lineage restriction process, starting with pluripotent stem cells. 
Concerning lineage differentiation from HSC, for B cell differentiation the transcription 
factors PAX5, E2A and EBF are important while Notch1, TCF and GATA3 are important for 
T lineage development and Id2 for NK cell development 35, 36. 
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Figure 2: Models of haematopoiesis. A: The classical model proposes that HSCs first diverge into 
common myeloid-erythroid progenitors (CMEPs) and common lymphoid progenitors (CLPs). E, M, 
T and B represent the progenitor potential for erythroid, myeloid, T and B cells, respectively. B: The 
myeloid-base model proposes that the first branching point generates CMEPs and common myeloid-
lymphoid progenitors (CMLPs). The myeloid potential persists in the T and B cell branches (myeloid-T 
cell progenitor (MTP) and myeloid-B cell progenitor (MBP) respectively) even after these lineages have 
diverged. Figure is based on reference 34.
T cell development and the thymus
T lymphocytes are involved in cell-mediated immunity and express T cell receptors (TCRs) 
enabling these cells to recognize major histocompatibility complex (MHC)-bound antigens. 
Upon TCR triggering of naive T cells, proliferation and differentiation towards a specific 
immune response occurs. T cells can be divided based on their TCR expression, namely αβ 
or γδ. Over 90% of the T cells express TCRαβ and are either CD4+ and MHCII restricted 
or CD8+ and MHCI restricted 37. CD4αβ T cells can polarize towards different T helper or 
regulatory subsets and facilitate activation of other immune cells. CD8αβ T cells differentiate 
into cytotoxic T lymphocytes (CTLs) capable of killing virus infected or tumour cells. TCRαβ 
T cells are mainly found in the blood, thymus and lymph nodes while γδ T cells mainly reside 
in the epithelium and mucosa-associated lymphoid tissues 37-39. 
The thymus
The bone marrow supports the differentiation of multi-potent haematopoietic stem cells 
towards specific haematopoietic lineages, but is insufficient for T cell maturation what makes 
migration of early progenitors to the thymus essential 40. 
General Introduction
15
           
      1
The thymus is a highly structured organ located behind the sternum just above the heart 
and originates at least in part from the third pharyngeal pouch (Figure 3A) 41. The thymus is 
encapsuled by a thick layer of mesenchymal cells. The organ itself is composed of developing 
T lymphocytes that closely interact with the thymic stroma. The stroma provides the structure 
of the thymus and consists of thymic epithelial cells (TECs), mesenchymal cells, connective 
tissue and endothelial cells that form the vasculature 42. The three dimensional (3D) thymic 
microenvironments consist of cortical thymic epithelial cells (cTECs) in the outer regions 
and medullary TECs (mTECs) in the center regions 43. These cells are phenotypically and also 
functionally different but may originate from a common bipotent thymic epithelial progenitor 
cell 44. At the cortico-medullary junction, thymic seeding progenitor (TSPs) enter the thymus 
via blood vessels. The interactions between the thymocytes and the TECs, a process that is 
commonly termed thymic crosstalk, are required for proper thymus and T cell development 
45-50. TECs provide important signals varying from adhesion molecules, chemokines, 
cytokines, Notch ligands, and MHC to thymocytes to proliferate and differentiate from early 
progenitors to highly specialized T cells with either helper, killer or regulatory function 51. In 
turn, thymocytes generate signals to which TECs can respond and also differentiate to either 
cortical or medullary TECs 45. However, TECs do not only need thymocyte derived signals, 
they can also be influenced by mesenchymal fibroblast derived signals 52, 53. It has been shown 
that for proper TEC network development, production of epidermal growth factor (EGF), 
transforming growth factor-α (TGF-α) 54 and fibroblast growth factors (FGFs) 55 is necessary. 
Besides providing signalling required for TEC development and to provide structure in the 
thymus, the mesenchymal network provides interleukin (IL)-7 56 and extracellular matrix 
components needed for proper T cell development 57. In contrast to the knowledge of T cell 
and TEC development, the formation of the mesenchymal network in the thymus remains to 
be elucidated.
The thymus undergoes age-associated involution, although the exact mechanisms of involution 
are not yet understood, they are believed to be intrinsic and extrinsic 58. Initially it was 
believed to be dependent on increased levels of steroid hormones during puberty. However, 
other factors like HSC function, changes in the thymic stroma and intrathymic cytokine 
production are thought to be involved as well 59. Involution is characterized by expansion of 
adipocytes and stroma, simultaneous with a decrease of the cortical and medullary regions 
together with loss of tissue organization 60. Thymic function is measured by T cell receptor 
excision circles (TRECs), which are circular DNA fragments released as a result of T cell 
receptor rearrangement during thymocyte development 61. TRECs are stable and do not 
replicate, therefore only recent thymic emigrants (RTE) have high TREC counts. Thymic 
output, and thereby TREC levels, reduces during aging, but the thymus keeps producing T 
cells throughout life 62.
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Figure 3: The thymus. A: Electron microscopic picture of the cortical area of a murine thymus, kindly 
provided by Prof. dr. Willem van Ewijk. B: Schematic overview of a human thymic microenvironment 
with migrating and developing thymocytes. Migration of thymocytes (ETP: early thymic progenitor, 
DP: double positive, SP: single positive) through the defined regions of the thymus, in combination 
with stroma cell (TECs: thymic epithelial cells, DC: dendritic cell) interaction, is required for proper 
differentiation to mature T cells.
Migration of thymocytes to and through the thymus
Migration of progenitors from the bone marrow to the thymus is required for T cell 
development. During murine foetal development, progenitors are derived from the foetal 
liver. The thymic anlage is initially colonized by T lineage committed progenitor cells 63, 64. 
These progenitors can be defined by the expression of paired immunoglobulin-like receptors 
in the foetal blood and liver 65. In the subsequent murine foetal to neonatal stage, the thymus 
is colonized by progenitors that retain B and myeloid potential 66. In contrast, the identity of 
TSPs in adults is not yet known. Multiple progenitors can contribute to T cell development in 
vitro and in vivo and are therefore candidate TSPs. Furthermore, thymus settling is a very rare 
event, which makes the contribution of each population under physiological conditions very 
difficult to assess 66-69. Additionally, it has been shown that early progenitors in the murine 
thymus can sustain T cell development for months when no TSPs enter, suggesting the presence 
of primitive progenitors with self-renewing capacity 70, 71. TSPs lost their megakaryocyte-
erythrocyte lineage potential, however, cells are not fully T lineage restricted 72. 
Both movement through defined thymic regions and interaction with certain cell types are 
required for thymocyte maturation 73, as depicted in Figure 3B. Chemokines expressed in 
the thymic microenvironments have a pivotal role in directing thymocyte migration, while 
thymocytes on their turn express sequentially different chemokine receptors 74. Furthermore, 
integrins in combination with CCR7 and CCR9 are important for thymocyte recruitment to 
the thymus and thymic settling 75. When TSPs enter the thymus in the cortical-medullary 
junction, they first migrate through the cortex to the subcapsular zone before they migrate 
back to the medulla 76. Chemokines important in this process are PSGL-1 during thymus 
entry, CXCR4, CCR7 and CCR9 for migration through the cortex and subcapsular zone, 
CCR7 for subsequent medulla migration and CXCL12 with S1P1 for thymus egress 74, 77, 78. 
In addition, many other factors like chemokines, integrins, selectins, matrix proteins and 
metalloproteinases are thought to be involved in this process but their precise role still needs 
to be elucidated. Further research is also needed with regard to the human translatability of 
these results, since the majority of these studies are performed in mice.
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Stages of T cell development
The different stages of T cell development can be characterized by the expression of surface 
markers and the rearrangement of T cell receptor genes (Figure 4).
T cell development can be divided based on the expression of CD4 and CD8, and can be 
separated into double negative (DN), double positive (DP) and single positive (SP) stages in 
both mice and men 79. The earliest DN thymocytes are located in the cortex. Murine DN stages 
are divided into DN1-4 stages, characterized by their expression of CD25 and CD44 or c-Kit 
80. In humans, these DN stages are subdivided into proT1, proT2 and preT cell stages that can 
be characterized by the reduction in expression of the HSC marker CD34 and acquisition 
of CD7, CD5 and CD1a, respectively 81-84. CD1a expression in the preT cell stage defines T 
lineage commitment 85. DN stages are followed by the expression of CD8 in mice and CD4 in 
humans (immature SP cells). In the subsequent CD4+CD8+ DP stage, thymocytes also express 
CD3 and TCRαβ 81, 86, 87.
During the DP stage, positive selection occurs in the cortex. Low to moderate interaction 
of TCR with self-peptides-MHC complexes presented on cTECs is essential for thymocyte 
selection and further maturation to the SP CD4+ (MHCII restricted) or CD8+ (MHCI 
restricted) stage. DP T cells that fail to interact with MHC complexes will die by neglect 37. 
cTECs use an unique proteasome, β5T, to generate self-peptides that are presented in MHCI 
and MHCII. Self-reactive lymphocytes are eliminated by negative selection in the medulla 88. 
Defects in the medulla result in autoimmunity 89. Because of promiscuous gene expression, to 
a large extend mediated by AIRE (autoimmune regulator), mTECs express peripheral tissue-
specific self-antigens and present these to thymocytes 43, 90, 91. Furthermore, different DC 
subsets sample blood-borne and mTEC derived self-antigens, all required to induce central 
tolerance 88. 
Non self-reactive, fully matured naive T cells will exit the thymus and enter the bloodstream 
to circulate through peripheral lymphoid tissues where they keep scanning DCs to encounter 
TCR-matching antigens. Upon TCR interaction and CD28 co-stimulation, T cells proliferate 
in response to autocrine IL-2, differentiate into effector cells and exert their helper, regulatory 
or cytotoxic function.
Briefly, CD4+ helper T cells activate macrophages at specific tissue sites via cytokine production 
and help B cells to differentiate into antibody producing plasma cells in the peripheral 
lymphoid tissues. Furthermore, they produce cytokines stimulating CTL differentiation 
directly or via APC stimulation. The CD4+ regulatory T cell subset controls the immune 
response by for example expression of IL-10, inhibiting macrophage and DC function and 
TGF-β, inhibiting macrophage and lymphocyte function. CD8+ cytotoxic T cells eliminate 
virus-infected and tumour cells via degranulation and activate phagocytes via cytokine 
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production. The generation of a memory T cell pool guarantees rapid responses upon re-
encounter with the antigen 37, 92.
T cell receptor rearrangement
Rearrangement of T cell receptor genes is necessary to generate a T cell pool that can 
recognize a broad spectrum of peptides presented on the MHC of other cells. The receptor 
consists of either an α- and β-chain or a γ and δ-chain, linked by disulfide bonds. Each chain 
consists of a constant and variable region. The variable domains of TCRA, TCRB, TCRG 
and TCRD genes are responsible for the recognition of peptide-MHC complexes and are 
assembled by rearrangement of variable (V), diversity (D) and joining (J) gene segments 
during V(D)J recombination 37. In addition to the combinatorial diversity, non-homologous 
DNA end joining generates additional junctional diversity after cleavage of gene segments. 
Rearrangement starts during the DN stage and is mediated by recombinant activating 
gene (RAG)1 and RAG2 93. The rearrangement process starts within the proT1 stage with 
the TCRD gene followed by TCRG gene, resulting in TCRγδ expression or further TCRB 
rearrangement, TCRD deletion and subsequent TCRA rearrangement resulting in TCRαβ 
expression. The recombination process starts with D to J rearrangement followed by V to D-J 
rearrangement in case of TCRB and TCRD genes. TCRA and TCRG genes undergo directly 
V to J rearrangement 81.
Regarding αβ T cell formation, completion of TCRB gene rearrangement results in expression 
of the TCRβ chain protein on the cell surface in association with an invariant protein, the pre-
Tα. Together with CD3 and ζ it forms the pre-T cell receptor complex that is expressed during 
the late DN stage. β selection, which is mediated through pre-TCR signalling, is important for 
proliferation, survival and transition to the CD4+CD8+ DP stage. When TCRA rearrangement 
is completed in the DP stage, expression of TCR complex consisting of CD3 and ζ protein and 
the TCRαβ heterodimers occurs and positive and negative selection are initiated 81, 94, 95.
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Figure 4:  Schematic overview of human T cell development from CD34+ stem cells. During T 
lineage development several clusters of differentiation (CD) are upregulated, representing different 
developmental stages. (HSC: haematopoietic stem cell, iSP, immature single positive, DP: double 
positive, SP: single positive). T cell receptor (TCR) rearrangement is initiated during early development 
where different TCR genes rearrange at specific stages during development. 
Regulation of T cell development
Many pathways and transcription factors are involved in T cell development, from which 
most are studied in mice. Examples are Notch, GATA3, E-box proteins, Bcl11b, Ikaros and 
Wnt signalling 35, 36, 96, 97. Concerning the scope of this thesis, only Notch signalling will be 
described in further detail. 
Crucial for T cell development is the interaction of the Notch receptor on progenitor cells 
with Notch ligands provided by the thymic stroma 98. The evolutionary conserved Notch 
signalling pathway plays a key role in the fate decision of multipotent precursor cells and 
differentiation processes during foetal and postnatal development. TECs provide ligands for 
the Notch receptor that initiate and support T cell maturation 99. Notch signalling is essential 
for T cell development, especially during the T/B lineage decision where Notch1 induces 
differentiation towards the T cell lineage and blocks development towards the B cell lineage 
100, 101. Notch is for example also involved in TCR rearrangement, β selection and αβ or γδ 
lineage determination 102-104. Both Notch ligands Delta-like ligand 1 (DLL1) and DLL4 are 
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able to drive T lineage development in vitro 105, while in vivo only DLL4 gives the instructive 
signal to the thymus seeding cells 106, 107. Notch signalling is high before β selection and is 
downregulated as a result of pre-TCR signalling 108. Especially DP thymocytes have low levels 
of Notch signalling, probably because positive and negative selection are the main signalling 
events at this stage 98.
Notch encodes transmembrane receptors (in mammals Notch1-4) that can be activated by 
cell surface ligands; Delta (Delta-1, -3 and -4) and Serrate (Jagged-1 and -2). Ligand binding 
initiates a series of proteolytic cleavages in the transmembrane domain of the receptor. The 
Notch extracellular domain is proteolytically cleaved by the ADAM metalloprotease TACE 
(tumour-necrosis factor α-converting enzyme) that is endocytosed by the ligand expressing 
cell 109, 110. A presenilin complex dependent γ-secretase releases the intracellular domain of the 
Notch receptor, NICD 98. NICD subsequently translocates to the nucleus where it interacts 
with nuclear proteins to activate target genes expression, like hairy enhancer of split (HES), 
cell cycle proteins and genes for early T lineage commitment; GATA3, IL7Rα, TCF1 and pTα 
96, 111. 
Cytokines involved in T cell development
Cytokines also play an important role in T cell development 112. The thymic stroma produces 
a wide range of cytokines, however, only few cytokines are crucial for T cell development as 
has been investigated in knock out mice 113.
IL-7 signalling plays a crucial role in the development, survival and homeostasis of T cells. 
A variety of cells including thymic and bone marrow stromal cells produce IL-7 114. The IL-7 
receptor is a heterodimer consisting of an IL-7 Receptor alpha unit and the common gamma 
chain (IL2RG). The latter is shared with IL-2, -4, -9, -15 and -21 cytokine receptors. IL-7R 
on thymocytes increases upon the encounter with Notch1, while the expression gradually 
decreases towards the DP stage, which is required for β selection and T lineage commitment 
69, 115, 116. However, this decrease is less pronounced in humans 117. Elimination of IL-7 or IL-7R 
in mice results in a complete loss of T and B cells 118, 119. Moreover, mutations in the IL-7RA 
cause severe combined immune deficiency (SCID) in humans, characterized by the absence 
of T cells 120.
Stem cell factor (SCF) receptor, or c-Kit, is expressed on HSCs and on early DN thymocytes. 
Mutations in this receptor or its ligand result in severe reduction of HSCs and the earliest 
DN thymocytes, suggesting a regulatory role for the expansion and differentiation of early 
thymocytes 80, 121. The role of the cytokine FMS-like tyrosine kinase 3-ligand (Flt3-L) is 
debatable, since knock-out studies do not show severe abnormalities, however, in vitro 
cultures show great benefit. Although Flt-3L does not seem crucial for T cell development, it 
does enhance proliferation of thymocytes 122, 123.
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In vitro T cell development
Already in the 1970s, attempts to generate T cells in vitro were performed. In a foetal thymic 
organ culture (FTOC) using murine foetal thymic lobes, T cell development was studied in 
a 3D environment 124, 125. Seeded HSCs can develop to fully mature SP T cells in this culture 
126. Later, also xenogeneic models using murine thymus lobes, depleted from resident T 
cell progenitors with deoxyguanosine, seeded with human HSCs were successfully applied 
127. Reaggregate thymus cultures (RTCs) were introduced to study the role of individual 
thymic stromal components required for T cell development 128. For a long time, the organ 
based cultures were the only cultures that could successfully support T cell development. 
Unfortunately, these cultures were very laborious and expensive. Furthermore, removal of 
thymocytes from the thymic microenvironment resulted in subtle changes in the environment. 
Moreover, reconstitution of murine lobes with human HSCs remained low. Therefore, many 
attempts to generate T cells on stromal cells have been performed.
In mice, foetal liver or bone marrow LKS (Lin-c-Kit+Sca1+) cells are used as haematopoietic 
stem cell source 129. In humans, CD34+Lin- cells from bone marrow, cord blood or (G-CSF 
mobilized) peripheral blood are used as haematopoietic stem/progenitor cell sources as 
both clinical and research source 130. Different bone marrow derived cell lines, S17, MS5 and 
the OP-9 cell line generated from macrophage colony-stimulation factor (M-CSF) deficient 
mice, are able to support haematopoietic differentiation from murine and human HSCs. 
Especially OP-9 is supportive for the development of B cells because M-CSF is important 
for myeloid development that is excluded in OP-9 cells 131. However, neither of these cell 
lines supported T lineage development. Unfortunately, thymic stromal cells rapidly lose their 
ability to support T cell development in vitro. For example, culturing thymic stomal cells in 
monolayer culture results in loss of MHC class II expression 132. The murine thymic fibroblast 
cell line TSt-4 was also able to support T cell development. However, T lineage development 
from murine progenitor cells was incomplete as only CD4+ SP cells developed while other 
lineage cells developed as well 133. In the meantime, several studies showed the importance 
of Notch signalling for T cell development 100, 101. After confirmation of the presence of the 
Notch ligand in the thymus, several previously tested cell lines were genetically modified to 
express Notch ligands. Jaleco and colleagues developed the S17/DL-1 cells. In combination 
with human CD34+ HSCs, T/NK progenitors and low numbers of DP cells developed 134. Co-
culture of human G-CSF mobilized and CB HSCs with TSt-4 cells expressing DLL1 or DLL4 
resulted in a mixture of early DN progenitors 83, 135. In this culture, only murine DP but no 
human DP or SP cells could be generated. After introduction of DL1 in the OP-9 cell line, T 
lineage development from murine foetal liver and bone marrow stem cells could be supported 
to the SP stage 136. This system has also shown to support the full range of T cell development 
from human HSCs to CD4+ and CD8+ SP αβ T cells 137-139. Knowing that DLL4 is the natural 
ligand in the thymus, also OP-9/DL4 cells were generated. In Delta ligand over-expressing co-
cultures, both ligands are efficient. However, limited expression levels of both ligands revealed 
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that DLL4 is still efficient in inducing T cell development at low levels in contrast to DLL1 
140. Importantly, not all stromal cells genetically engineered to express DLLs are capable of 
supporting T lineage development 141.
To study the essentials required for T cell development and to produce T cells suitable for 
therapy, efforts have been made to generate T cell progenitors in vitro without the use of 
(genetically modified) feeder cells. First attempts to induce Notch signalling with soluble DLL 
were unsuccessful. Only when the extracellular domains of the DLL were fused to the Fc-
fragment of human IgG and were plate-bound offered to HSCs, proper Notch signalling was 
induced 142. These stromal-free cultures in the presence of cytokine cocktails resulted in the 
development of both murine DN2 and human proT1 T cells 143-146. These human progenitor 
populations are capable of CD3+ T cell reconstitution in the thymi of immunodeficient mice 
145, 146. The addition of Wnt3a to the human culture resulted in more cells expressing CD7 and 
iCD3, but not further development 147. By reducing IL-7 concentration in the murine stromal-
free DLL culture, Ikawa and colleagues were able to generate murine DP cells 115. Also by the 
addition of the CXCL4 ligand CXCL12 in the murine DLL4 culture, DP cells were generated 
148. Fernandez et al. showed that CB HSCs cultured with immobilized DLL1, MHC-tetramers, 
anti-CD28, anti-CD3 and OP-9/DL1 conditioned medium resulted in the generation of a 
small population of antigen specific cytotoxic CD8+ cells 149. However, feeder based cultures 
are more efficient in supporting T cell development, arguing that not all crucial factors for 
proper T lineage development have been identified. 
Lineage potential of T cell progenitors
Lineage potential of early T cell progenitors is well studied in mice, while human data is limited 
available. TSPs retain besides T lineage potential also myeloid, B and NK cell potential. After 
bifurcation of the B and T cell lineage 150, both populations still possess myeloid potential also 
when cells already entered the thymus 72. The thymocytes retain besides myeloid (macrophage 
and dendritic cell) potential also NK cell potential 72. Within the DN2 stage, T lineage 
commitment occurs at the transition from DN2mt (Myeloid-T cell) to DN2t (T cell) marked 
by Bcl11b expression 72, 96, 115. Also in humans it is known that after Notch signalling, B cell 
potential of CD34+ HSC is shut off, while at least NK cell potential is still present 151. Previously, 
we showed that a mixed population of early T cell progenitors retained NK cell potential, 
however, it was unsure from which population these cells developed 83. Weerkamp and 
colleagues determined the lineage potential of CD34+CD1a- and CD34+CD1a+ progenitor T 
cells and showed T lineage commitment of the CD1a+ population, while the CD1a- cells where 
besides T cells able to differentiate to B cells, NK cells and myeloid cells 85. Unfortunately, this 
CD1a- population was not further separated for example based on CD7 or CD5 expression. 
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Natural killer cells
Besides B and T cells, NK cells are the most prominent lymphocyte subset covering up to 
20% of the blood lymphocyte population. NK cells are group 1 innate lymphoid cells that can 
exert rapid effector functions without direct prior sensitization to infected, malignant cells, 
and MHC mismatched grafts 152. NK cells have a broad repertoire of activating and inhibitory 
receptors, where the balance of these receptors results in cytokine, chemokine production 
and/or cytotoxicity. In humans, NK cells are defined as CD56+ and CD3-. In blood, two major 
NK cell populations exist, CD56dim and CD56bright cells 153. The bright population represents 
10% of the circulating NK cells that have regulatory functions by the production of cytokines 
like IFN-γ, TNFα and GM-CSF, while the dim population (~90%) has enhanced cytotoxicity 
capacity marked by high intracellular perforin levels and high expression of the low affinity 
FC receptor III allowing them to mediate antibody-dependent cell-mediated cytotoxicity 
(ADCC) 154. 
The bone marrow is considered as the major site of NK cell development, subsequently there 
is further differentiation in secondary lymphoid tissues like the liver, spleen, lymph nodes 
and thymus 154. Different NK cell stages are described in literature but the complete pathway 
has not yet been described 155. Education during NK cell development is important, resulting 
in mature NK cells that are fully functional (“licensed to kill”) and are tolerant to self. This 
means that the NK cells require encounter with a MHC class I ligand before it can become 
activated because of the absence of that specific ligand 156.
NK cell activation is dependent on both receptors/ligands expressed by the potential target 
cell and the NK cell itself (Figure 5). NK cells recognize the absence of self MHC class I 
to discriminate between normal and stressed cells (e.g. tumour cells), called “missing self ” 
157. In the normal situation, NK cell activation is inhibited by the interaction of killer 
immunoglobulin-like receptors (KIRs) that interact with MHC class I. Each NK cell expresses 
a different combination of inhibitory and activating receptors so that at least one inhibitory 
KIR specific for a self MHC class I is present. Additionally, NK cells express receptors that are 
specific for other ligands on target cells. A mechanism called “stress-induced self recognition” 
is exerted when target cells express activating ligands that can overcome inhibitory signals 158, 
159.
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Natural killer cells
Besides B and T cells, NK cells are the most prominent lymphocyte subset covering up to 
20% of the blood lymphocyte population. NK cells are group 1 innate lymphoid cells that can 
exert rapid effector functions without direct prior sensitization to infected, malignant cells, 
and MHC mismatched grafts 152. NK cells have a broad repertoire of activating and inhibitory 
receptors, where the balance of these receptors results in cytokine, chemokine production 
and/or cytotoxicity. In humans, NK cells are defined as CD56+ and CD3-. In blood, two major 
NK cell populations exist, CD56dim and CD56bright cells 153. The bright population represents 
10% of the circulating NK cells that have regulatory functions by the production of cytokines 
like IFN-γ, TNFα and GM-CSF, while the dim population (~90%) has enhanced cytotoxicity 
capacity marked by high intracellular perforin levels and high expression of the low affinity 
FC receptor III allowing them to mediate antibody-dependent cell-mediated cytotoxicity 
(ADCC) 154. 
The bone marrow is considered as the major site of NK cell development, subsequently there 
is further differentiation in secondary lymphoid tissues like the liver, spleen, lymph nodes 
and thymus 154. Different NK cell stages are described in literature but the complete pathway 
has not yet been described 155. Education during NK cell development is important, resulting 
in mature NK cells that are fully functional (“licensed to kill”) and are tolerant to self. This 
means that the NK cells require encounter with a MHC class I ligand before it can become 
activated because of the absence of that specific ligand 156.
NK cell activation is dependent on both receptors/ligands expressed by the potential target 
cell and the NK cell itself (Figure 5). NK cells recognize the absence of self MHC class I 
to discriminate between normal and stressed cells (e.g. tumour cells), called “missing self ” 
157. In the normal situation, NK cell activation is inhibited by the interaction of killer 
immunoglobulin-like receptors (KIRs) that interact with MHC class I. Each NK cell expresses 
a different combination of inhibitory and activating receptors so that at least one inhibitory 
KIR specific for a self MHC class I is present. Additionally, NK cells express receptors that are 
specific for other ligands on target cells. A mechanism called “stress-induced self recognition” 
is exerted when target cells express activating ligands that can overcome inhibitory signals 158, 
159.
Figure 5: Natural killer cell tolerance and activation. Natural killer (NK) cell tolerance is achieved 
when there is a balance between activating signals and inhibitory signals provided by healthy cells in 
favour of inhibition. Missing self NK activation is induced when tumour cells lost expression of MHC 
class I molecules. Stressed-induced self NK cell activation is induced when stressed cells (e.g. tumour or 
virus infected cells) upregulate activating ligands. Upon NK cell activation, NK cells produce cytotoxic 
mediators for immediate cytotoxicity or cytokines for indirect elimination. 
Natural killer cell therapy
Adoptive transfer of NK cells is a promising approach to induce anti-tumour responses and 
is currently under extensive investigation. Pre-clinical and clinical studies have shown that 
NK cells can be used to eliminate malignant cells 160. As source, autologous and allogeneic 
NK cells are used, and cells from both sources are able to effectively eliminate cancer cells 
in vitro 161, 162. Allogeneic NK cell transfer could lead to higher tumour cytotoxicity because 
of KIR-ligand mismatching, which lowers the activation threshold of NK cells. Ruggeri and 
colleagues first demonstrated the potential of allogeneic KIR-ligand mismatched NK cells 
in the HLA mismatched transplantation setting where patients receiving haplo-identical 
transplants enabling KIR-ligand incompatibility resulted in improved survival as compared 
to patients receiving KIR-ligand matched transplants 25. In addition, NK cells could also kill 
patient’s APCs, leading to reduced activation of the alloreactive donor T cells and thereby 
reducing GVHD 163. Besides effects seen in haematological cancers, NK cells are also able to 
respond to solid tumours as shown in both a mouse model and in patients 164, 165. Although 
clinical studies show that administration of alloreactive NK cells is safe, the efficacy of in vivo 
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responses are limited, providing room for improvement 160, 162, 165, 166. Major aims of current 
research are the production of sufficient NK cell numbers with the correct phenotype for 
therapy. The latter is important since we showed in multiple myeloma and in breast cancer 
that KIR-ligand mismatched NK cells are much more efficient in eliminating tumour cells 
than matched NK cells 164, 167. 
T cell reconstitution after haematopoietic stem cell transplantation
T cell reconstitution after HSCT can occur via thymus dependent and thymus independent 
mechanisms. The thymus independent reconstitution occurs via homeostatic peripheral 
expansion (HPE) of mature T cells that survived treatment regimen or expansion of mature T 
cells from the graft. Though, the T cell repertoire of this population is limited. Furthermore, 
the high expansion induced by relative high homeostatic cytokine levels (because of low T cell 
counts) and recognition of endogenous antigens results in a high number of apoptotic cells 
168. The HPE can provide some initial immune competence, but is insufficient for broad range 
and long term protection 169.
Only de novo thymus dependent T cell generation can result in a naive T cell pool with a 
broad TCR repertoire. Unfortunately, delivery of progenitors to the thymus limits T lineage 
reconstitution after transplantation 170. Furthermore, the thymus structure is influenced 
by treatment regimen and GVHD 171. Moreover, thymic involution is accompanied by a 
decreased thymus size and function resulting in slower recovery after treatment, especially in 
older patients. The generation of naive T cells from the thymus requires 6-12 months in child 
patients and may take up to several years in adult patients 172, 173.
Adoptive T cell progenitor therapy
Both the generation of thymic seeding progenitors and thymus entry are known to be limiting 
steps for thymus dependent T cell reconstitution after HSCT 170. Because of the low frequency 
and incomplete characterization of these TSPs, simple donor isolation and transfer is not 
possible 69. Therefore, the generation of T cell progenitors from HSCs is currently under 
investigation as a strategy to improve T cell counts after HSCT. As described above, different 
culture methods are currently available for the production of T cell (progenitors) in a feeder-
based setting. In vivo immune reconstitution experiments with TSt-4/DLL derived T/NK 
progenitor cells from mobilized and CB derived proT cells from OP-9/DL1 co-cultures 
showed that these stroma culture derived progenitors home to the thymi of immune deficient 
mice and complete their development into mature T cells faster than non-manipulated stem 
cells 83, 86, 87. Additionally, Eyrich et al. detected extrathymic mature T cells in mice after 
injection of T cell progenitors derived from OP-9/DL1 co-culture 174. Moreover, injection of 
human CB derived T cell progenitors can restore thymus architecture in immune deficient 
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mice 87. Currently, the generation of a clinical applicable culture system is under investigation. 
Expansion of CB CD34+ cells in the presence of immobilized DLL1 or DLL4 and cytokines 
resulted in the development of a CD34+CD7+ lymphoid progenitor population capable of 
CD3+ T cell reconstitution in the thymi of immune deficient mice 145, 146. T cells were also 
observed in the spleen and peripheral blood in a subgroup of the injected mice 146. Moreover, a 
phase I clinical study with the transfer of CB CD34+ DLL1 culture derived progenitors showed 
enhanced engraftment and myeloid reconstitution 175. However, the lack of improvement in T 
cell reconstitution in these patients indicates the need for more efficient methods for in vitro 
generation of T cell progenitors for adoptive therapy.
Chapter 1
28
           
          1
Scope of the thesis
The field of immunotherapy is a growing area of interest, where both fundamental and 
translational research is performed. Although great progress has already been made, there is 
still an urgent need for improvement since current cellular immunotherapies are only effective 
in certain patient populations and many therapies are still in pre-clinical stages. Furthermore, 
the success of certain immunotherapies like allogeneic mismatched HSCT that can result 
in complete remission is hampered by post-treatment complications, in this case immune 
deficiency resulting in high morbidity and mortality.
The major aim of this thesis is the development of a clinical grade T cell progenitor therapy 
suitable for the adoptive transfer to immunocompromised patients after haematopoietic 
stem cell transplantation. Currently, research protocols are being optimized by searching for 
factors that are required for T cell development and factors that accelerate this development. 
Moreover, an increase in cell expansion is of high interest because great cell numbers are 
required for therapy. Hereafter, these protocols need to be translated into clinical protocols 
and clinical trials have to assess the feasibility of this suggested therapy. 
As described previously, T cells require in vivo the microenvironment of the thymus to fully 
mature. We initiated this research with a fundamental study of the thymus to elucidate the 
role of mesenchymal network development in the thymus in chapter 2. Moreover, insight in 
thymus formation could contribute to the development of thymus rejuvenation therapies for 
patients with an involuted thymus, resulting in better thymopoiesis. In combination with T cell 
progenitor therapy, this could result in higher thymic output and faster recovery of patient’s 
T cell levels. A major challenge of various immunotherapies is the generation of sufficient cell 
numbers required for treatment. There are different methods to achieve this, for example the 
expansion of the cells of interest or the expansion of haematopoietic stem/progenitor cells to 
use as starting population for the generation of specialized immunotherapy products. Here, we 
aimed to develop a method to expand stem cells by blocking their differentiation in chapter 3. 
Hereafter, we focused on the production of specialized cell types suitable for immunotherapy. 
In chapter 4, we evaluated a skin explant system as surrogate thymus to produce T cells 
suitable for adoptive therapy. We continued with creating a more straightforward clinical 
grade culture method for the generation of T cell progenitors in chapter 5. In this system 
we used immobilized DLL4 to induce Notch signalling, previously provided by feeder cells, 
generating a more controllable system suitable for the generation of T cell progenitors 
applicable for therapy. In this culture, we found vitamin C, also known as ascorbic acid (AA), 
as a potent enhancer of T cell development. Furthermore, vitamin C enhances expansion of 
T cell progenitors within this culture. Current pitfalls of NK cell therapy are the generation 
of insufficient cell numbers in combination with anti-cancer activity of only certain NK cell 
populations. Because T and NK cells share a common precursor, we assessed the effect of 
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vitamin C on the generation of NK cells suitable for anti-cancer immunotherapy in chapter 
6. Because of the potent effect of vitamin C on both T cell and NK cell development and 
expansions, we determined vitamin C levels in haematological oncology patients in chapter 
7, anticipating on a potential clinical benefit resulting from vitamin C supplementation. 
In chapter 8, the impact of our findings in relation to other strategies to enhance T cell 
reconstitution in patients after HSCT is discussed.
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Abstract
It is established that thymic epithelial cells (TECs) and thymocytes influence each other 
during their growth and differentiation, a process called thymic crosstalk. In the earliest step 
of thymic organogenesis, mesenchymal cells support the growth of TECs. However, little is 
known about the influence of developing thymocytes or TECs on mesenchymal cells. Here, 
we show that during normal thymus development fibroblast ingrowth occurs towards hypoxic 
areas. Similar overgrowth of mesenchymal cells is seen in a foetal thymic organ culture system 
under low oxygen conditions. When thymocytes were depleted by deoxyguanosine treatment, 
mesenchymal cells were also induced, precluding the direct effect of hypoxia. In the foetal 
thymus of hCD3εTg mice, which have an early block in T cell development, an overgrowth of 
mesenchymal cells can be seen at a very early stage of thymic organogenesis. The growth of the 
mesenchymal cells is due to their extensive proliferation rather than enrichment. With RNA 
sequence analysis comparing hCD3εTg TECs with wild type TECs, we identified candidate 
factors that correlate with an increased mesenchymal network formation and thus may be 
causally linked to the formation of an irregular thymic microenvironment.
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Introduction
The central organ for T cell development in jawed vertebrates is the thymus. The thymus is 
located just above the heart and originates at least in part from the third pharyngeal pouch 
1. The organ is composed of developing T lymphocytes that closely interact with thymic 
stroma. The stroma provides the unique 3D structure of the thymus and consists of thymic 
epithelial cells (TECs), mesenchymal cells, connective tissue and endothelial cells that form 
the vasculature 2, 3. Haematopoietic progenitor cells originate in the bone marrow, settle in 
the unique environments of the thymus and mature into T cells during a highly organized 
process. After positive selection for major histocompatibility complex (MHC)-restriction and 
deletion of self-reactive cells, these events result in the output of naive T cells with a broad T 
cell receptor (TCR) repertoire. T cells have an important function in combatting infections 
and eradicating tumour cells. 
Thymocytes and TECs directly interact with each other and determine their maturation, a 
process that is commonly termed thymic crosstalk 4-7. TECs provide important signals like 
adhesion molecules, chemokines, cytokines, Notch ligands like DLL4, and MHC molecules 
inducing T cells to proliferate and differentiate from early progenitors to highly specialized 
T cells with either helper, killer or regulatory functions 8. In turn, T cells generate signals to 
which TECs can react and also differentiate to either cortical or medullary TECs 9. One of 
the possible signalling pathways that has been demonstrated to be involved in this process is 
again the Notch-Delta-Like ligand pathway 10. Furthermore, TNF receptor family members 
generated by T cells, like RANKL, CD40L and LTβR ligands, play an important role in TEC 
development, maintenance and thereby self-tolerance 11-15. 
TECs do not only need T cell derived signals for their development, they can also be influenced 
by mesenchymal fibroblast derived signals. Regular TEC network development is dependent 
on the production of EGF, TGF-α 16 and various FGFs 17. Besides providing signalling required 
for TEC development and to provide structure in the thymus, the mesenchymal network 
provides IL-7 18 and extracellular matrix components needed for proper T cell development 
19. In contrast to the wealth of cellular and molecular insight regarding T cell-TEC crosstalk, 
the mechanisms that form the mesenchymal network remain largely elusive.
During embryonic development, epithelial and mesenchymal interactions are essential for 
the formation of structures throughout the body 20. Mesenchymal cells have been shown to 
play an essential role in foetal thymus organogenesis and are derived from neural crest cells. 
In contrast to their role in formation of the 3D network of TECs in the thymus 4, in many 
other epithelial organs, mesenchymal cells produce an extracellular matrix in the form of a 
basement membrane on which polarized epithelial cells can adhere and grow in a 2D fashion 
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4, 21. Whether TECs influence mesenchymal cells on their turn is unknown, though in other 
organs, epithelial cells produce signals like epidermal growth factor (EGF), desert hedgehog 
(DHH) or platelet-derived growth factor (PDGF) that are crucial for mesenchyme growth 20. 
In our previous experiments on T cell-TEC crosstalk 9, 22, we noticed that mesenchymal cell 
growth was paradoxically suppressed in the areas where T cell reconstitution had occurred, 
which in turn was depended on the supply of high oxygen. In contrast, mesenchymal cells 
were enhanced in poorly reconstituted areas due to hypoxic conditions 9. Thus, mesenchymal 
network formation and TEC development is a more complex process than commonly believed. 
We therefore sought to investigate the mesenchymal network formation in the thymus. On 
the one hand the possibility exists that mesenchymal cells grow and autonomously invade 
the epithelium to form networks. On the other hand, several instructive mechanisms may 
cause the mesenchymal network to develop. One possible mechanism for the induction of 
the mesenchymal network formation is a consequence of thymic crosstalk between TECs 
and thymocytes that in turn promote fibroblast differentiation. Alternatively, stress factors 
such as hypoxia and/or malnutrition could be responsible to directly induce the mesenchymal 
network formation. A third possibility is that hypoxia does not directly induce mesenchymal 
network formation, but that hypoxia and/or malnutrition causes blockage of thymic 
crosstalk, resulting in underdevelopment of TEC structures and thereby indirectly inducing 
the mesenchymal network formation. In this manuscript, we investigate how the formation 
of the mesenchymal network in the thymus occurs and provide evidence for a molecular 
mechanism operational in this formation.
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Materials and Methods
Mice 
C57BL/6 (B6) mice were purchased from CLEA Japan Inc. (Tokyo, Japan). CD3εTg mice, 
Foxn1-cre and CAG-CAT-EGFP reporter mice 23 were maintained in our animal facility. 
Embryos at various stages of gestation were obtained from time-mated pregnant mice. The 
day of finding the vaginal plug was designated as 0 dpc.
Immunohistochemistry
All thymic lobes were embedded in OCT compound (Sakura FineTek, Tokyo, Japan) and snap-
frozen in liquid nitrogen, using Leica Histomolds (Leica Microsystems, Wetzlar, Germany). 
Frozen blocks were cut into serial 5μm sections using a Leica CM3050S cryostat and mounted 
onto MAS-coated slides (Matsunami Glass Ind. LTD, Osaka, Japan). After acetone fixation 
for a few seconds, sections were incubated with primary antibodies, washed with PBS/0.05% 
Tween, followed by incubation with the proper secondary reagent when no directly labelled 
antibodies were available. Nuclei were counterstained with DAPI (Molecular Probes, Eugene, 
OR, USA).
The following antibodies were used: anti-K8 (PROGEN, Heidelberg, Germany), rabbit 
anti-cytokeratin (Dako, Glostrup, Denmark), rabbit anti-IKAROS, anti-ER-TR7 24 and 
Hypoxyprobe™-1-Mab1, as primary antibody or reagent, followed by Alexa Fluor488 donkey 
anti-rat IgG (H+L) conjugate, Alexa Fluor488 goat anti-rabbit IgG (H+L) conjugate, Alexa 
Fluor488 goat anti-rabbit IgG conjugate, Alexa Fluor546 goat anti-rat IgG (H+L) conjugate, 
Alexa Fluor546 goat anti-rabbit IgG (H+L) conjugate, Alexa Fluor546 streptavidin conjugate 
(all from Molecular Probes), as secondary reagents. 
In bromodeoxyuridine (BrdU) labelling experiments, BrdU (100μM, Sigma-Aldrich, St. 
Louis, MO, USA) was added to the medium of a thymic organ culture for one day at the end of 
the culture period. Lobes were frozen and sectioned. Sections were incubated with ER-TR7, 
followed by incubation with goat anti-rat IgG (H+L)-Alexa Fluor546 conjugate. Subsequently, 
sections were re-fixed with 70% ethanol at -20ºC for 10min and treated with 2N HCl for 
30min at room temperature for DNA denaturation. After neutralization with 0.1M Na2B4O7, 
sections were incubated with anti-BrdU mAb (3D4, BD Pharmingen, San Diego, CA, USA), 
followed by the incubation with Alexa Fluor488 anti-mouse IgG, Highly Cross-Absorbed 
(Molecular Probe). 
 
ER-TR7+ areas were determined with Axiovision 4 software (Carl Zeiss, Oberkochen, 
Germany).
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Detection of hypoxia 
Hypoxia marker and the administration hypoxia marker, pimonidazole hydrochloride 
(Hypoxyprobe™-1), and the detecting FITC-labelled mouse monoclonal antibody were 
obtained from NPI, Inc. (Belmont, MA, USA). Pimonidazole hydrochloride was dissolved in 
DPBS (Wako). Pregnant mice (13 to 15 dpc.) were intraperitoneally injected with pimonidazole 
hydrochloride (60mg/kg mice). After 2h, embryos were removed from the uterus of pregnant 
females, thymi were isolated and frozen in OCT compound (Sakura FineTek, Tokyo, Japan) 
for immunohistochemistry. 
Preparation of foetal cells 
Embryos were separated from the placenta using fine forceps. Embryos were placed in a Petri 
dish containing tissue culture medium while the foetal thymus (FT) was isolated by dissection. 
Foetal thymic organ culture
To prepare thymocyte-depleted FT lobes, FT from 15 dpc embryos were cultured on 
polycarbonate filters (pore size 8.0μm, Nucleopore Co., Pleasanton, CA, USA) floating on 
culture medium containing 1.35mM dGuo (Nacalai Tesque, Kyoto, Japan) for a period of 6 
days. 
Preparation of foetal TECs and Fluorescent Activated Cell Sorting
To obtain single cell suspension of thymic epithelial cells, lobes were dissected by forceps and 
digested in RPMI 1640 (Sigma) containing 1mg/ml collagenase D (Roche, Basel, Switzerland) 
and 10% FCS and incubated at 37ºC for 2h. After washing, cells were passed through 40μm 
nylon mesh. Viable cells were counted using trypan blue dye exclusion.
After preparation of single cell suspension, cells were stained with CD45 (30-F11 eBioscience, 
San Diego, CA, USA), EpCAM (clone G8.8, BD Pharmingen) and PDGFRα (clone APA5, 
eBioscience) and sorted by using FACSAriaIII (BD, Franklin Lakes, NJ, USA). Sorted cells 
(CD45- EpCAM+ PDGFRα- cells) were pooled and lysed in TRIzol Reagent (Life Technologies, 
Carlsbad, CA, USA) and RNA was extracted. 
RNA sequencing
The RNA library was prepared by the TruSeq RNA Sample Prep Kit (Illumina, San Diego, CA, 
USA). The sequence was read on a HiSeq 1000 (Illumina). RNA-sequences were mapped with 
TopHat2 25 and FPKMs (Fragments Per Kilobase of exon per Million reads) were calculated 
with Cufflinks 26. Scatter plots were made in Excel (Microsoft). The GEO ID number is 
GSE60520.
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Results
In vivo network development of thymic mesenchymal cells 
In our previous studies of murine foetal thymic organ cultures (FTOC), we observed under 
low oxygen submersion (LOS) conditions an increased mesenchymal network 9. Therefore, 
we initiated this study and examined the normal development of the mesenchymal network. 
The 13 dpc foetal thymus (FT) is completely surrounded by mesenchymal cells as was 
characterized by ER-TR7 staining only detectable around the lobes, indicating that the 
capsular region was already formed (Fig. 1). During ontogeny, invagination of mesenchymal 
cells becomes visible at 14 dpc mainly in the cortical areas where pancytokeratin (panK+) cells 
are less densely packed. At 15 dpc, large strings of ER-TR7+ cells can be seen, stretching from 
the capsular region, deep into the developing thymus crossing the cortex into the immature 
medullary areas as defined by dense panK+ cells. In the neonatal thymus, such strings of ER-
TR7+ cells can mainly be seen in medullary regions.
Figure 1: Epithelial cells develop together with mesenchymal cells to form the adult thymus. 
Immunohistochemical micrographs of thymi during ontogeny from day 13 dpc to the neonatal thymus. 
The sections of the developing thymi were stained in two colours with anti-panK (green) to detect 
epithelial cells and ER-TR7 (red) to detect mesenchymal fibroblasts. Scale bar indicates 100μm.
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Developing thymic lobes are hypoxic
FTOCs grown under LOS conditions showed an increased mesenchymal network 9. Therefore, 
we decided to study whether hypoxia exists in the developing thymus that may trigger 
the development of a mesenchymal network structure. On 13 and 15 dpc, pimonidazole 
hydrochloride (HypoxiaprobeTM-1) was injected intraperitoneally in pregnant mice that 
were sacrificed after 2h and thymi from recovered embryos were frozen. Pimonidazole forms 
irreversible covalent adducts with cellular proteins when the oxygen tension is lower than 
10mmHg and these adducts can be detected immunohistochemically 27. Frozen sections 
were stained with ER-TR7 and the HypoxiaprobeTM specific detecting polyclonal antibody. 
On 13 dpc, the thymus is completely surrounded by a ring of ER-TR7+ fibroblasts (Fig. 2, 
upper row). A hypoxic area is detected in the center of the small developing thymus. The 
gradual decrease in staining intensity from the center to the outer rim suggests a gradient 
of hypoxia 28. Similarly on 15 dpc, thymic hypoxic areas are detected at locations distant 
from the developing mesenchymal network with the strongest signal the furthest away from 
the ER-TR7+ cells (Fig. 2, lower row). These observations together suggest that it is possible 
that a stressful condition such as hypoxia is involved in inducing the mesenchymal network 
development in the early thymus. 
Figure 2: Hypoxic areas in the developing thymus. Immunohistochemical micrographs of thymi 
during ontogeny from 13 dpc and 15 dpc. The sections of the developing thymi were stained with FITC 
labelled anti-pimonidazole (HypoxyprobeTM-1, green) to detect hypoxic areas, ER-TR7 (red) to detect 
mesenchymal fibroblasts and nuclei were counterstained with DAPI (blue). Hypoxic areas are distant 
from invaginating fibroblasts. Scale bar indicates 100μm in the left panel and 20μm in the middle and 
right panel. These data are representative for four analysed thymi.
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Impaired thymocyte-TEC crosstalk induces development of mesenchymal cells
To determine whether hypoxia directly or indirectly induces the development of the 
mesenchymal cells, we examined 13 dpc FT, and cultured them under high oxygen 
submersion (HOS) and LOS conditions for 2 and 4 days (for the experimental scheme see 
Fig. 3A). In the pre-culture 13 dpc FT, the mesenchymal cells (ER-TR7+) are surrounding 
the developing thymus and many lymphocytes (IKAROS+) are found between the expanding 
TECs (panK+, Fig. 3B). If the thymocyte-TEC crosstalk induces the mesenchymal network 
to grow, invagination of fibroblasts into the lobe is expected to occur only under HOS 
conditions. In contrast, if hypoxia induces the invagination, this patterning would only occur 
under LOS conditions. Figure 3C shows that already after 2 days under HOS conditions the 
lobes were enlarged compared to the lobes under LOS conditions (upper vs. lower figures). 
This change in size was mainly due to an increased number of TECs and thymocytes and was 
largely independent of mesenchymal cells. Indeed, only a very small number of these cells 
had invaginated into the lobe (upper panels, upper row), which slightly increased at day 4 
(lower panels, upper row). In contrast, lobes cultured under LOS conditions remained small 
and showed large invaginations of mesenchymal cells. Although thymocytes (IKAROS+) can 
be seen, the size of the lobe suggests that these thymocytes have not proliferated although 
they are still alive after 4 days (lower rows of both panels in Fig. 3C). These data support the 
hypothesis that low oxygen conditions are important for the induction of the mesenchymal 
cellular network. 
We then investigated whether this mesenchymal cellular network is a direct consequence of 
hypoxia or a secondary effect of impaired thymocyte-TEC crosstalk. To this aim, we cultured 
13 dpc FT lobes under HOS conditions, with or without deoxyguanosine (dGuo), which 
impairs thymus crosstalk by killing thymocytes while leaving TECs alive. After two days of 
dGuo exposure, the immunohistological analysis revealed a large increase in mesenchymal 
cells surrounding the lobes as well as in the trabeculae invaginating the lobes (Fig. 4, upper 
panel lower row). The mesenchymal cell outgrowth was even more prominent at day 4 when 
compared to untreated controls where only few ER-TR7+ cells were visible at day 2 and 4 (Fig. 
4, both panels, upper rows). 
These data (Fig. 3 and 4) together strongly suggest that the impaired thymocyte-TEC crosstalk, 
rather than hypoxia directly induces the mesenchymal cell network. 
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Figure 3: The mesenchymal cellular network develops under low oxygen conditions. A: The 
experimental procedure. 13 dpc thymi were isolated and cultured for 2 or 4 days under HOS or LOS 
conditions. B: Pre-cultured lobes of 13 dpc thymi. IKAROS+ (green) lymphocytes are scattered between 
panK8+ TECs (red) throughout the developing lobe (left panel). ER-TR7+ (red) cells can only be seen in 
the surrounding capsule (middle and enlarged in right panel). C: Lobes after 2 and 4 days of culturing 
under HOS (panels in row 1 and 3) or LOS (panels in row 2 and 4) conditions. Staining was similar as 
in (B). Under LOS conditions, mesenchymal cells invaginate and are increasing in time throughout the 
lobes. Scale bars indicate 100μm in the left and middle panels and 50µm in the right panels.
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Figure 4: Impaired thymocyte-TEC crosstalk induces development of mesenchymal cells. 
Immunohistochemical micrographs of 13 dpc thymi in HOS cultures without treatment (rows 1 and 3) 
or after dGuo treatment to remove thymocytes (rows 2 and 4) after 2 days (rows 1 and 2) or 4 days (rows 
3 and 4) of culture. The right panels are enlargements of the left panels showing details of fibroblast 
outgrowth (ER-TR7, red) only after abrogation of thymic crosstalk by dGuo. After this treatment, TECs 
have collapsed (PanK, green). Scale bars indicate 100μm in the left panels and 50µm in the right panels.
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Mesenchymal network develops extensively in the absence of thymocyte-TEC 
crosstalk
To confirm independently that an impaired thymocyte-TEC crosstalk induces the growth 
of mesenchymal cells in vivo, 15 dpc thymi from hCD3εTg mice were investigated and 
compared with wild type mice. In hCD3εTg mice, thymocytes cannot differentiate due to 
a T cell autonomous block at an early developmental stage, consequently, this results in the 
absence of most functional TECs due to a lack of cross talk signals 29. If the lack of thymocyte-
TEC crosstalk indeed accounts for the increased mesenchymal network formation, we would 
expect these stromal changes to be particularly noticeable in hCD3εTg mice. Although thymi 
of hCD3εTg mice at 15 dpc were similar in size, they were very different in their stromal 
composition compared to wild type mice. In contrast to the normal 3D thymic epithelial 
network of wild type mice, hCD3εTg mice demonstrate an extensive network of ER-TR7+ 
mesenchymal cells (Fig. 5A), and show a 79% increase in percentage of ER-TR7+ surface area 
(Fig. 5B, p=0.0012). Furthermore, similar to the lobes grown under hypoxic conditions, a more 
strongly developed capsule is also seen in these thymi in vivo. Since the possibility remains 
that the increase of the ER-TR7+ cell area is just a relative occurrence due to the decrease 
of PanK+ TECs, the absolute area or ER-TR7+ cells per lobe on these stained samples was 
calculated quantitatively, and found indeed to be increased by 1.5 fold (Fig. 5C). Therefore, 
we concluded that T cell-TEC crosstalk derived signals do not directly induce mesenchymal 
network formation. Rather, the absence of crosstalk itself allows specific instructive signals 
to promote the mesenchymal network formation and hypoxia may be one of the triggers to 
initiate this process.
Increase of mesenchymal cells is achieved by proliferation
Our previous experiments with the FTOC method showed that a 6 day dGuo treatment of 
thymic lobes completely removed thymocytes, and that the TECs were replaced by fibroblasts 
9. In a time course after starting dGuo treatment of 15 dpc thymic lobes and culturing under 
normal atmospheric air (Fig. 6A), we confirmed our previous findings and observed a dramatic 
increase in the number of ER-TR7+ fibroblasts (Fig. 6B). The organization of a mesenchymal 
network was already visible 3 days after culture when most T cells had disappeared. The extent 
of network was increased dramatically at day 6 of culture (Fig. 6B). To determine whether 
the fibroblasts actively proliferated, BrdU labelling experiments were performed. In the 
recovered lobes, we observed that the increase in fibroblast number was due to proliferation 
as is clearly shown by the presence of many BrdU+ cells in ER-TR7+ fibroblasts (Fig. 6C). 
These results indicate that most of the mesenchymal network can be formed by proliferation 
of mesenchymal cells.
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Figure 5: Thymic mesenchymal network develops extensively in the absence of thymocyte-TEC 
crosstalk. A: Immunohistochemical micrographs of thymi from wild type (WT; left figures) and 
hCD3εTg mice (right figures). The lobes are representative for 6 thymi analysed. The lobes were stained 
in two colours with anti-panK (green) to detect epithelial cells and ER-TR7 (red) to detect mesenchymal 
fibroblasts. The lower figures are magnifications of the inserts of the upper figures. Nuclei were counter-
stained in blue with DAPI. Right panels show the extensive mesenchymal network formation in thymi 
where thymocytes-TEC crosstalk is absent due to a genetic defect. Scale bars indicate 100μm in the 
upper panels and 50µm in the lower panels. B: The percentage of ER-TR7+ area and C: the absolute ER-
TR7+ area in WT and hCD3εTg thymi are shown as median with interquartile range. Mann Whitney U 
tested, ** denotes statistical significance (p<0.01).
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Increase of mesenchymal cells is not due to epithelial-mesenchymal 
transdifferentiation
The observed increase in mesenchymal proliferating cells in dGuo treated thymic lobes 
was most likely the result of mesenchymal cell proliferation, but an epithelial-mesenchymal 
transdifferentiation could however not be excluded. To rule out this latter possibility directly, 
we employed a genetic labelling method to trace the fate of TECs. For this purpose, FoxN1-cre 
mice were crossed with CAG-CAT-EGFP reporter mice to irreversibly mark cells expressing 
FoxN1, the master regulator of TEC development. 15 dpc FT lobes from the F1 offspring were 
treated with dGuo, and analysed after 6 days (Fig. 6D). Because none of the ER-TR7+ cells 
were GFP+ (Fig. 6E), we concluded that the increase in thymic fibroblasts following dGuo 
treatment was not the consequence of epithelial-mesenchymal transdifferentiation, but from 
a straight fibroblast lineage from mesenchymal origin that form the network by proliferation. 
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Figure 6: Thymic mesenchymal cell growth and network formation can be induced by depletion of 
thymocytes and is not due to epithelial-mesenchymal transdifferentiation. A: Experimental procedure. 
FT lobes at 15 dpc were treated with dGuo for 6 days to deplete thymocytes. B: Immunohistochemical 
micrographs of lobes obtained on days 1, 3 and 6 after the start of dGuo treatment are shown. The lobes 
were stained with anti-IKAROS (red), ER-TR7 (green) and nuclei were counter-stained in blue with 
DAPI. C: Mesenchymal cells divide to form the network. Sections from 15 dpc FT dGuo treated lobes 
were stained in with ER-TR7 (red) and anti-BrdU (green). Nuclei were counter-stained in blue with 
DAPI. The higher magnified insert shows the presence of BrdU labelling in nuclei of red ER-TR7+ cells. 
D: Experimental procedure. FoxN1-Cre mice were mated with Lox-GFP animals. From the offspring, 
FT lobes at 15 dpc were treated with dGuo for 6 days to deplete thymocytes. E: Immunohistochemical 
micrograph of a thymic lobe from a WT mouse. The lobe was stained with ER-TR7 (red) while GFP 
(green) expression can be seen after Cre gets activated by FoxN1 in the epithelial cells. Nuclei were 
counter-stained in blue with DAPI. The picture shows the mesenchymal network formation of fibroblasts 
(red) and the clustered TECs (green). None of the fibroblasts have GFP expression indicating that they 
were not transdifferentiated from epithelial cells.
Gene expression analysis reveals candidate factors involved in mesenchymal 
network formation
To identify candidate factors involved in mesenchymal network formation, gene expression 
profiles of hCDεTg FT TECs were compared to WT FT TECs. In Figure 7, changes in 
transcripts of growth factors (A), cytokines (B) and chemokines (C) are shown. Examples 
of genes which expression is at least 3 fold higher in hCDεTg FT TECs are EGF, BMP4, 
FGF10, IL-33, and CXCL14 and are likely to contribute to mesenchymal network formation. 
Furthermore, expression of genes like BMP3, IL-6, CXCL9 are at least 3 fold downregulated 
compared to the WT TECs and are probably involved in the normal inhibition of fibroblast 
growth.
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Figure 7: Expression analysis reveals candidate factors involved in mesenchymal network 
formation. Scatter plots showing fold changes of expression levels of hCDεTg TECs compared to WT 
TECs of growth factors (A), cytokines (B) and chemokines (C) are shown. Diagonal line represents 
equal expression. Dotted lines represent a 3 times fold change. Each dot represents one gene. Orange 
dots are considered as differentially expressed.
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Discussion and Conclusion
In the current chapter we show that an absence of successful thymic crosstalk, in this case 
caused by hypoxia, is responsible for the growth of mesenchymal cells and for the construction 
of a network structure of mesenchymal cells during thymus development.
We investigated the interaction between epithelial cells and mesenchyme in the foetal thymus. 
Since the developing thymus contains hypoxic areas at a distance from the developing 
mesenchymal network, we hypothesized that hypoxia is the driving force to induce the 
mesenchymal network development. Hypoxia has been reported to be a normal phenomenon 
in the adult thymus, as shown by pimonidazole staining that is present in a gradient away 
from blood vessels 27. Furthermore, it is believed that hypoxia plays an important role in T cell 
development and effector function 30. In tumours, hypoxia results in angiogenesis to provide 
more oxygen and nutrients for the cancer cells to grow 31. This is regulated by the increased 
expression of many hypoxia-responsive genes; however, in the thymus no such genes are 
upregulated, suggesting that the mature thymus has adapted to constant hypoxia 27. 
Our data suggest that although hypoxic areas are found in the developing thymus, in such 
areas thymocyte-TEC crosstalk is impaired, resulting in the development of a mesenchymal 
network. This was shown by mesenchymal network formation under HOS condition in 
the absence of thymocyte-TEC crosstalk. Furthermore, hCD3εTg mice that lack proper 
thymocyte crosstalk show an extensive network of mesenchymal cells. Moreover, thymi 
from Runx-/- mice have a defect in thymocytes resulting in impaired crosstalk and show 
an increased fibroblast expansion inside the lobes as well as a very thick capsule (data not 
shown). Impaired crosstalk likely allows the formation of new blood vessels guided by the 
mesenchymal cells to bring oxygen to the areas where it is needed and restoring thymocyte-
TEC crosstalk, forming network structures of mesenchymal cells and ultimately leading to T 
cell differentiation.
Possible mechanisms for the enhanced growth of mesenchymal cells in the absence of 
thymocyte-TEC crosstalk could be proliferation or epithelial-mesenchyme transition. For 
instance in cardiogenesis, the epicardium undergoes epithelial-mesenchymal transformation 
that results in the formation of fibroblasts that in turn play an important role in the further 
development of the myocardium, the coronary vasculature and the Purkinje fiber network 32. 
Among the factors that are responsible for coronary vascular development, FGFs have been 
identified as a major factor signalling to the FGF receptors 1 and 2 33. FGFR triggering results 
in hedgehog activation, in turn leading to VEGF and angiopoietin 2 expression with blood 
vessel formation as result 34. These hedgehog molecules are also expressed in the thymus by 
thymic epithelial cells and influence different stages of T lineage development 35-37. However, 
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our experiments indicated that in the developing thymus, the mesenchymal network grows 
not because of transdifferentiation but by proliferation. 
In the search for factors produced by TECs that are responsible for the invagination and 
proliferation of the mesenchymal cells, we performed gene expression profiling of TECs from 
wild type and hCDεTg TECs. Our focus was on growth factors, cytokines and chemokines 
as they are the likely molecules involved in the process. Based on these findings in light 
of published findings, we suggest a series of factors that could contribute to mesenchymal 
network formation in the thymus. The growth factors BMP4 and FGF10 are both upregulated 
in hCD3εTg TECs, which are known to have effects on thymocyte development 38. 
Furthermore, it is known that abrogation of BMP4 expression results in drastically reduced 
thymus size and interference with stromal development 39, 40. BMP signals are involved 
in the development of multiple organs, for example the lung, heart and tooth, were BMP 
is involved in epithelial mesenchymal interactions 41-43. Together, this suggests BMP4 as a 
possible inducer of mesenchyme development in the thymus. FGFs are growth factors 
known to be involved in tissue development. FGF receptors are present on epithelial cells 
and their ligands are produced by mesenchymal cells 44. For proper thymus development, 
FGF Receptor signalling via FGF7 and 10 produced by mesenchymal cells is required 45, 
suggesting FGF10 as another interesting candidate involved in fibroblast development in 
the thymus. As mentioned earlier, EGF is important for mesenchyme development in other 
tissues. EGF is also upregulated in hCD3εTg TECs suggesting its importance in thymus 
mesenchyme formation. Interestingly, the chemokine CXCL14 was upregulated in hCD3εTg 
TECs. CXCL14 can stimulate the growth and migration of fibroblasts in an autocrine 
manner in cancer 46, revealing CXCL14 as an interesting candidate for the maintenance of 
fibroblast growth in normal tissue development. Previously it was shown that mesenchymal 
cells have crucial roles in epithelial cell differentiation 47. In the absence of proper cues for 
TEC development from the mesenchyme, it is conceivable that TECs are unable to produce 
other growth factors to stimulate mesenchyme growth resulting in a disorganized thymus 
development. These potential candidates are downregulated in hCD3εTg TECs compared to 
WT TECs. Another possibility is that TECs produce less growth factors because of impaired 
crosstalk with thymocytes. One of these factors could be IL-6, which is known to be produced 
by TECs and is important for T cell development 48. Taken together, it is highly unlikely that 
just one factor is involved in thymus mesenchymal network formation and our expression 
analysis yielded several potential factors. However, further research is needed to elucidate the 
role and interplay of these candidate proteins for the establishment of a regular mesenchymal 
network.
In Figure 8A, we propose 2 models for the induction of the thymic mesenchymal network. 
Model 1 suggests that crosstalk between thymocytes and TECs results in TEC derived 
signals that inhibit mesenchyme proliferation. Under conditions where this crosstalk is 
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abrogated, mesenchymal cells enter the cell cycle because signals that inhibit mesenchymal 
cell proliferation are missing. In contrast, model 2 foresees the regulation of fibroblast growth 
to be independent when physiological thymocyte-TEC crosstalk is present. Only when 
this crosstalk is abrogated, signals will be released from TECs that stimulate mesenchymal 
fibroblast to proliferate.
Translating these findings to in vivo thymus development, it can be envisioned that initially 
the anlage grows until it reaches a size where in the middle a hypoxic area develops. As a 
result, TECs and T cells are stressed resulting in a reduced crosstalk between the two cell 
types. This hypoxic state may, in analogy to metastatic cancerous cells, induce the signals to 
fibroblasts to invaginate and allow blood vessels to be formed to meet the metabolic need for 
oxygen and nutrients. After that, the T cell-TEC crosstalk can continue and the developing 
thymus grows until several new areas of hypoxia develop followed by new stress signals that 
in turn further extend the mesenchymal network. This process continues until a fully-grown 
thymus has developed (Fig. 8B). Although it has been argued that a continuous state of 
hypoxia exists in cell levels deep away from the blood vessels that is required for thymocytes 
to develop normally 27, our data suggest that hypoxia in principal is a negative regulator of T 
cell development, and when it occurs, the mesenchymal network is formed to reduce hypoxic 
places in the thymus.
In conclusion, our results suggest that (temporary) abrogation of thymic crosstalk initiated by 
hypoxia-induced stress induces the formation of a network structure of mesenchymal cells. 
This process is necessary for the development of a normal thymus.
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Figure 8: Proposed models through which the mesenchymal network can develop. A: Model 1 
proposes that when under normal conditions thymocytes and TECs cross-talk, an active inhibition of 
mesenchymal network by TEC signals is present. When crosstalk is abrogated, fibroblasts can 
autonomously develop. Model 2 favours an independent regulation of fibroblasts during physiological T 
cell-TEC crosstalk conditions. When crosstalk is abrogated, TECs promote fibroblast proliferation. B: 
Schematic overview of thymus growth.
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Abstract
Self-renewal potential and multipotency are hallmarks of a stem cell 1-3. It is generally 
accepted that acquisition of such “stemness” requires rejuvenation of somatic cells through 
reprogramming of their genetic and epigenetic status. We show here that a simple block of 
cell differentiation is sufficient to induce and maintain stem cells. By overexpression of the 
transcriptional inhibitor Id3 in murine haematopoietic progenitor cells and cultivation under 
B cell induction conditions, the cells undergo developmental arrest and enter a self-renewal 
cycle. These cells can be maintained in vitro almost indefinitely and the long-term cultured 
cells exhibit robust multi-lineage reconstitution when transferred into irradiated mice. These 
cells can be cloned and re-expanded with 50% plating efficiency, indicating that virtually 
all cells are self-renewing. Equivalent progenitors were produced from human cord blood 
stem cells and these will ultimately be useful as a source of cells for immune cell therapy.
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Introduction
Somatic tissues with high turn-over rates, such as skin, intestinal epithelium, and 
haematopoietic cells, are maintained by the activity of self-renewing stem cells, which are 
present in only limited numbers in each organ 4-6. For example, the frequency of haematopoietic 
stem cells (HSCs) in the mouse is about 1 in 105 of total bone marrow cells 7. Once HSCs 
begin the differentiation process, their progeny cells have hardly any self-renewal capacity, 
indicating that self-renewal is a very special feature endowed only to stem cells. 
Cells such as embryonic stem (ES) cells that retain self-renewal potential and multipotency 
only in vitro can also be included in the category of stem cells. Such stemness of ES cells is 
thought to be maintained by formation of a core transcriptional network and an epigenetic 
status unique to ES cells 8-10. Indeed, a stem cell equivalent to ES cells, called the induced 
pluripotent stem cells (iPS cells), can be produced from somatic cells by over-expression of 
only a few specific transcription factors (Oct3/4, Sox2, Klf4, and c-Myc), which are thought to 
be the essential components in forming the core network of transcriptional factors that define 
the status of ES cells 11-13. It is thus generally conceived that acquisition of such a network for 
a somatic cell depends on the “reprogramming” of both the genetic and epigenetic status of 
that cell. 
On the other hand, it could be envisioned that the self-renewing status of cells represents a 
state where their further differentiation is inhibited. It is known, for example, that to maintain 
ES/iPS cells, factors such as LIF and bFGF are required for mouse and human cultures 
respectively 14, 15, and these factors are thought to block further differentiation of the cells. In 
this context, it has previously been shown that systemic disruption of transcription factors 
essential for the B cell lineage, such as PAX5, E2A, and EBF1, leads to the emergence of self-
renewing multipotent haematopoietic progenitors, which can be maintained under specific 
culture conditions 16-19. Therefore, it would seem theoretically possible to make a stem cell 
by inducing inactivation of these factors at particular developmental stages. Conditional 
depletion of PAX5 in B cell lineage committed progenitors as well as mature B cells resulted 
in the generation of T cells from the B lineage cells 16, 20, 21. These studies, however, were mainly 
focused on the occurrence of cell-fate conversion by “de-differentiation” of target cells. 
Therefore, the minimal requirement for the acquisition of self-renewal potential remains 
undetermined. 
Our ultimate goal is to obtain sufficient number of stem cells by expansion to overcome 
the limitation of cell numbers for immune therapies. We hypothesize that stem cells can be 
produced by simply blocking differentiation.
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Materials and methods
Mice
C57BL/6 (B6) and B6Ly5.1 mice were purchased from CLEA Japan Inc (Tokyo, Japan). NOD/
Shi-scid, IL2Rγnull (NOG) mice were purchased from the Central Institute for Experimental 
Animals (Kanagawa, Japan). 6 to 8 week old female mice were used for the transfer 
experiments. Embryos at various stages of gestation were obtained from timed pregnancies. 
The day of observing the vaginal plug was designated as 0 dpc. 
Antibodies 
The following antibodies were purchased from BD PharMingen (San Jose, CA): Ly5.1 (A20), 
Ly5.2 (104), c-Kit (2B8), Sca-1 (D7), erythroid lineage cells (TER119), Mac1 (M1/70), Gr1 
(RB6-8C5), CD11c (HL3), B220 (RA3-6B2), Thy1.2 (53-2.1), CD8 (53-6.7), CD4 (H129.19), 
NK1.1 (PK136), CD3ε (145-2C11), CD19 (1D3), anti-class II (M5/114), F4/80 (BM8), CD25 
(PC61), human CD11c (B-ly6), human CD19 (H1B19), human CD33 (P67.6), human CD56 
(B159) and human HLA-DR (D46-6). TER119, Mac1, Gr1, B220, CD19, NK1.1, CD3ε, CD4, 
and CD8 were used as Lin markers.
Growth factors
Recombinant murine (rm) SCF, IL-1α, IL-3, IL-7, IL-15, Flt3-ligand, G-CSF, M-CSF and GM-
CSF and recombinant human (rh) SCF, IL-7, IL-15, Flt3-ligand, GM-CSF and TNFα were 
purchased from R&D (Cambridge, MA).
Isolation of haematopoietic progenitors
Single cell suspensions of foetal liver (FL) cells from 13-15 dpc embryos or bone marrow 
(BM) cells of B6CD45.1 mice were prepared as described previously 24. Cells were then 
incubated with monoclonal antibodies specific for anti-Lineage markers (TER119, Mac1, 
Gr1, B220, Thy1.2) for 20min on ice. Lin+ cells were depleted with Dynabeads Sheep anti-Rat 
IgG (Invitrogen) according to the manufacturer’s protocol. The Lin- cells were used for cell 
sorting. The procedure for isolating Lin-c-Kit+Sca-1+ (LKS) populations from FL and BM and 
Pro B cells (IgM-B220+CD19+CD43+) and Immature B (IgM+B220+CD19+) cells from BM has 
been described elsewhere 17, 23. 
Retroviral constructs, viral supernatants and transduction
The TAC retroviral vector (pCSretTAC) is based on S-001 retrovirus construct (obtained from 
H. Spits) and was generated by replacing the coding sequence of EGFP with the human IL2RA 
gene encoding CD25. The full-length cDNA for murine Id3 (Inhibitor of DNA binding 3) was 
cloned into the pCSretTAC vector (mId3-TAC). The Id3-ERT2 fusion construct containing 
the full-length cDNA for human Id3 fused to the mutated ligand-binding domain of the 
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human estrogen receptor (ERT2) was cloned into the pMCS retrovirus vector, a gift from T. 
Kitamura. The human Id3 cDNA was cloned into the pMX retrovirus construct (obtained 
from T. Kitamura). Virus was generated by transfection of the various constructs into the Plat 
E packaging cell line using FuGENE 6 Transfection Reagent (Roche). For generating mouse 
induced haematopoietic progenitor mIdHP cells, FL LKS progenitors from B6Ly5.1 mice 
(CD45.1+) were isolated as described above. The LKS cells were transduced with pCSretTAC 
(control) and mId3-TAC virus supernatants as described previously 17. After spin infection, 
the cells were cultured at 37°C, 5% CO2 for 2 days. The transduced cells were harvested and 
stained with anti-human (h)CD25 antibody and the hCD25+ cells were sorted and cultured 
on TSt-4 stromal cells in the presence of 10ng each of rmSCF, rmIL-7 and rmFlt3-ligand. 
In the case of hIdHP cells, CD34+ cells in human cord blood cells were used as a source 
of progenitors. Human CD34+ cells were transduced with pMX-hId3 retrovirus in a same 
manner as the mIdHP cells. After two days, the GFP+ cells were isolated and cultured on TSt-4 
stromal cells in the presence of rhSCF, rhTPO, rhIL-7 and rhFlt3-ligand. 
Co-culture with stromal cells 
To assess granulocyte/macrophage potential of murine Id3-IdHP cells, 1x104 cells per 
well were cultured with TSt-4 stromal cells in the presence of rmG-CSF (10ng/ml) for 14 
days. Generated cells were counted, stained with Mac1, and FACS-sorted Mac1+ cells were 
centrifuged onto glass slides for Wright’s staining. For the detection of B and myeloid potential 
of progenitors, mIdHP cells were cultured with TSt-4 cells for 14 days. Generation of myeloid 
and B cells was detected by flow cytometric analysis of Mac1 versus CD19 expression. For 
the detection of T cell potential, TSt-4 cells that had been retrovirally transduced with the 
murine dll1 gene (TSt-4/DLL1 cells) 19 were used. Medium was supplemented with rmSCF 
(2ng/ml), rmIL-7 (2ng/ml) and rmFlt-3L (2ng/ml). Generation of T cells was detected by 
subsequent flow cytometric analysis. To assess NK and DC potential of hIdHP cells, 1x104 
cells were cultured with TSt-4 cells in the presence of rhIL-15 (for NK cells) or rhSCF, rhGM-
CSF and rhTNFα (for DCs). All co-cultures were maintained in RPMI 1640 medium (Gibco 
BRL, Grand Island, NY) supplemented with 10% FCS, L-glutamine (2mM), sodium pyruvate 
(1mM), sodium bicarbonate (2mg/ml), nonessential amino acid solution (0.1mM, Gibco 
BRL), 2-ME (5x10-5M), streptomycin (100mg/ml), and penicillin (100U/ml). 
Cloning of mIdHP cells
Single mIdHP cells were seeded on TSt-4 cells in the presence of SCF, IL-7 and Flt3-ligand in 
a 96 well plate. The colonies of single mIdHP cells were picked up and expanded in the same 
condition in larger plates for approximately 4 weeks. The cloned mIdHP cells were harvested, 
stained with specific markers and analysed by flow cytometry. 
CFU-C assay 
LKS, control and IdHP cells (1x104 cells per dish) were cultured in triplicate for 7 days in 
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αMEM (Gibco/BRL) containing 30% FCS, 1% methylcellulose, 1% bovine serum albumin, 
2-ME (5x10-5M), L-Glutamine (1mM), rmSCF (10ng/ml), rmIL-3 (10ng/ml), rmGM-CSF 
(10ng/ml), rmIL-1α (10ng/ml), rmG-CSF (10ng/ml) and rmM-CSF (10ng/ml).
Adoptive transfer of mIdHP and hIdHP cells 
For mIdHP transfer, 1x106 mIdHP cells (CD45.1+) were intravenously injected into the tail 
vain of sublethally irradiated (650 rad) Rag1-deficient mice (CD45.2). Mice were analysed 4-6 
weeks after reconstitution for donor chimerism in BM, spleen and thymus. For hIdHP transfer, 
1x106 hIdHP cells were intravenously injected into the tail vain of sublethally irradiated (240 
rad) NOG mice. Mice were analysed 6-10 weeks after reconstitution for donor chimerism in 
BM, spleen and thymus.
PCR analysis of IgH gene rearrangement
The analysis of IgH gene rearrangement was performed as previously described 17. In brief, 
genomic DNA was prepared from CD45.1+ cells derived from thymus, spleen and BM in 
IdHP transplanted mice using DNeasy tissue kit (Qiagen). The reaction volume was 20μl, 
containing 2ul of genomic DNA (approximately equivalent to 104 cells), 2μl of 10xPCR buffer, 
0.16μl of 25mM dNTPs 4pmol of each primer, and 0.6U of Taq polymerase (GE healthcare). 
The PCR reactions were performed as follows: 5min at 94°C followed by 35 cycles of 1min at 
94°C, 1min at 60 °C, 2min at 72°C, and finally 10min at 72°C. Amplified DNA products were 
analysed on an agarose gel followed by ethidium bromide staining.
RNA extraction and Quantitative RT-PCR 
Total RNA was isolated using a RNeasy kit (Qiagen). cDNA synthesis was performed using 
Superscript III (Invitrogen) following the manufacturer’s protocol. Real-time PCR was 
performed using SYBR Premix EX Taq (Takara) and analysed by StepOnePlus (Applied 
Biosystems). The reactions were performed in duplicate at 95°C for 10sec, followed by 40 
cycles of 95°C for 5sec, 55°C for 30sec. The primer sequences used are shown in Supplemental 
Table 1.
Microarray analysis 
RNA extraction was performed as described above. The expression profiles were analysed 
using the 3D-Gene Mouse Oligo chip 24K (Toray Industries, Tokyo, Japan). The fluorescence 
intensities were detected using the Scan-Array Lite Scanner (Perkin-Elmer, Waltham, MA). 
The PMT levels were adjusted to achieve 0.1%-0.5% pixel saturation. Each TIFF image was 
analysed using the Gene Pix Pro 6.0 software (Molecular Devoices, Sunnyvale, CA). The 
data were filtered to remove low-confidence measurements and were globally normalized 
per array, such that the median of the signal intensity was adjusted to 50 after normalization 
(accession number: GSE46158).
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Results
As mentioned above, self-renewing multipotent progenitors can be produced by culturing 
E2A-deficient haematopoietic progenitors in B cell inducing conditions 17. Since it remains 
unclear at which developmental stage the acquisition of self-renewing potential has occurred 
in the case of such a systemic deletion, we thought to develop a method in which E2A function 
could be inactivated and reactivated in an inducible manner. We decided to use the Id3 protein 
for this purpose, because it is known that Id proteins serve as dominant negative inhibitors 
of E-proteins 19, 22. Murine haematopoietic progenitors isolated as Lin-c-Kit+Sca-1+ (LKS) cells 
from foetal liver (FL) were transduced with a retroviral vector containing Id3 or a control 
vector (control), and the transduced cells were cultured under B cell inducing conditions 
(Fig. 1A). The LKS cells transfected with the control vector differentiated into CD19+ B cells, 
but the Id3 over-expressing cells showed developmental arrest at the B220lowCD19- stage (Fig. 
1B). Transcript levels of B lineage-associated genes (e.g. CD79a, CD79b and VpreB) in Id3-
induced haematopoietic progenitor (IdHP) cells were at least 10 fold lower than those in 
control cells. Instead, the IdHP cells prominently express genes associated with other lineages 
(e.g. GATA3, GATA1, and c/EBPα, Supplemental Fig. 1). Moreover, only IgH D-J but not 
V-DJ recombination was detectable in IdHP cells (Supplemental Fig. 2). These data indicate 
that the IdHP cells are phenotypically equivalent to so-called pre-pro B cells, and are almost 
indistinguishable from the previously reported E2A-deficient multipotent progenitors 17.
The IdHP cells are relatively large blastic cells, morphologically similar to pre-pro B cells (Fig. 
1C, D), and their gene expression profile is very similar to E2A-deficient progenitors (Fig. 
1E). The IdHP cells expanded exponentially, i.e. 107 fold in one month (Fig. 1F), and could be 
maintained for several months. When transferred to culture conditions inductive for myeloid, 
B or T lineages, the IdHP cells exhibited the potential to produce all these cell types (Fig. 1G, 
Supplemental Fig. 3); however, erythroid potential was hardly detected (data not shown). B 
cells were presumably produced by silencing of the retroviral expression of Id3 as described 
below.
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.
Figure 1: Generation of IdHP cells from murine haematopoietic stem/progenitor cells. A: Schematic 
representation of Id3-IdHP cell generation. B: Flow cytometric analysis of control (empty vector) 
and Id3-overexpressing FL progenitor cells. C: Photomicrograph of IdHP cells. Scale bar, 10μm. D: 
Wright’s staining of IdHP cells, LKS cells, pro B cells and Immature B cells from bone marrow. Scale 
bars, 10μm. E: Microarray analysis of gene expression in LKS cells, E2A-/- HP cells, IdHP cells, and pro 
B cells derived from cultures of control vector-expressing FL progenitors. F: In vitro expansion of IdHP 
and control cells. Viable cells were counted at each time point. G: CFU-C assay of LKS, control and 
IdHP cells. H: Myeloid and B cell generation from IdHP cells in vitro. Flow cytometric profiles of IdHP 
cells cultured on TSt-4 stromal cells for 14 days are shown. I: T cell generation from IdHP cells in vitro. 
Flow cytometric profiles of control and IdHP cells cultured on TSt-4/DLL1 stromal cells for 12 days are 
shown.
B220
M
ac
1
C
D
19
c-
ki
t
2 week culture in 
B cell induction 
condition
Fetal liver
LKS cells
Feeder cells
Retroviral
vector
Transfection marker
2 days
Cell sorting
Feeder cells
C
on
tro
l 
Id
3
B220 B220
IdHP
Immat BProB
LKS
A C
D
E G
C
on
t.
Id
H
PC
FU
-C
/1
03
H
LK
S
100
50
0
B
F
C
D
4
CD8
Control IdHP
13 49
3.0
0 0
0C
D
19
Mac1
34
47
Id
H
P
C
on
tro
l
LK
S
E
2A
-/-
Bcl11a
Lmo2
Mpo
Cebpb
Sfpi1
Irf4
Spib
Ccl7
Gata2
Tal1
Runx1
Ccl5
Dtx4
Jun
Tox
Ccl4
Ccr2
Irf7
Bcl2
1
102
104
106
108
Culture days
Fo
ld
 e
xp
an
si
on
Control 
IdHP
10 20 30 40
I
77
                     
      3
Induction of self-renewal activity in haematopoietic progenitors
We then tested the developmental potential of IdHP cells in vivo. A total of 1x106 IdHP cells 
(CD45.1)/mouse were transferred intravenously into sublethally irradiated Rag1-deficient 
mice (CD45.2, Fig. 2A). After 4 weeks, myeloid cells (Mac1+CD19- cells), NK cells (CD3-NK1.1+ 
cells), and T cells (CD3+NK1.1- cells) were observed in the CD45.1+ fraction in peripheral 
blood of the recipient mice (Fig. 2B). A substantial number of B cells were also detected in 
these recipients. In these B cells, down-regulated expression of the retroviral reporter, hCD25 
was seen (Supplemental Fig. 4), which often occurs with a retrovirally introduced gene. Such B 
cell generation indicates that IdHP cells have the potential to produce B cells, a clear difference 
from E2A-deleted progenitors. T, B, and myeloid cells were generated in thymus, spleen and 
BM of mice reconstituted with the IdHP cells at 7 weeks of transplantation (Supplemental Fig. 
5A, B). The CD4+ T cells in spleen generated from the IdHP cells normally proliferated upon 
anti-CD3/28 stimulation (Supplemental Fig. 5C), confirming the multilineage differentiation 
potential and functionality of the IdHP cells. 
To examine whether IdHP cells retain self-renewal potential, a total of 96 IdHP cells were 
individually seeded and cultured in the same conditions (Fig. 2C). Each clone was expanded 
with a plating efficiency of 50%. All the clones were able to proliferate unlimitedly like IdHP 
cells as long as the cells were properly cultured. Three randomly selected clones were further 
expanded and the cells (1x106 cells/mouse) were subsequently transferred into sublethally 
irradiated recipient mice. In the peripheral blood of these recipients, reconstitution of myeloid 
cells, B cells, NK cells and T cells derived from transferred cells was observed (Fig. 2D). 
Mice transplanted with clone 5 cells were sacrificed 8 weeks after the transfer and cells from 
the thymus, spleen and BM were analysed. In BM, Mac1+Gr1+ myeloid cells were observed 
among the CD45.1+ cells (Fig. 2E, Supplemental Fig. 6). CD45.1+CD4+CD8+ DP cells, as well 
as CD4+ SP and CD8+ SP cells were seen in the thymus, and CD45.1+B220+IgM+ mature B cells 
were found in the spleen (Fig. 2E, Supplemental Fig. 6). These data indicate that production 
of several lineages of cells is ongoing in recipient mice. Since IdHP cells are originally derived 
from pre-pro B stage cells, they usually bear at least single allele of DH-JH rearrangements of 
the IgH genes. Clone 5 had a rearrangement involving the JH3 gene segment, and all lineages 
of cells from various tissues in recipient animals transferred with clone 5 cells had the same 
rearrangement (Fig. 2F), indicating that all progeny cells were in fact derived from clone 5.
To determine whether IdHP cells can also be generated from adult BM progenitors, the LKS 
cells in BM of B6Ly5.1 mice were transduced with a retroviral vector containing Id3 and the 
transduced cells were cultured under B cell inducing conditions. The IdHP cells were generated 
in one month, just like FL-derived IdHP cells. The BM-derived IdHP cells exponentially 
expanded and could be maintained at least for several months similar to the FL-IdHP cells. 
To determine the developmental potential of the BM-IdHP cells in vivo, 1x106 IdHP cells/
mouse were transplanted into sublethally irradiated immunodeficient (NOG) mice. After 7 
weeks, Mac1+Gr1+ myeloid cells were observed among the CD45.1+ cells in BM (Supplemental 
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Fig. 7). CD45.1+CD4+CD8+ DP cells, as well as CD4+ SP and CD8+ SP cells were seen in the 
thymus, and CD45.1+B220+IgM+ mature B cells were found in the spleen (Supplemental Fig. 
7). The CD4+ T cells in the spleen generated from BM-IdHP cells proliferated and secreted 
various cytokines in response to anti-CD3/28 stimulation in vitro (Supplemental Fig. 8). 
These data indicate that the self-renewing IdHP cells with similar developmental potential 
and functionality can be generated from adult BM.
To examine whether IdHP cells are really arrested early in B cell development, we utilized the 
Id3 protein fused with estrogen receptor, Id3-ER, a more controllable system for the expression 
of Id3, in which Id3-ER protein normally resides in the cytoplasm but goes into the nucleus 
and functions as a transcriptional inhibitor for E-proteins only when 4-hydroxytamoxifen (4-
OHT) is added 23. LKS cells from FL of B6Ly5.1 mice that had been transduced with the Id3-
ER retrovirus and cultured in the presence of 4-OHT showed a similar developmental arrest 
and entered a self-renewal cycle similar to IdHP cells (Fig. 2G, H). Removal of 4-OHT did 
not have any impact on cell growth for at least 10 days, but virtually all cells became CD19+ 
within 7 days (Fig. 2I), indicating that arrested cells restarted differentiation towards B cells 
upon removal of 4-OHT. These results indicate that IdHP cells represent cells differentiating 
towards the B cell lineage but are arrested just prior to the B cell lineage determination step, 
waiting for appropriate developmental cues.
Thus, by definition, IdHP cells satisfy the criteria of “stem cells”, that are restricted to 
production of leukocytes. We therefore designate these cells iLS (induced leukocyte stem) 
cells as a more general term. iLS cells are not reprogrammed or de-differentiated, but only 
developmentally arrested. Therefore, we propose that the blockage of differentiation due to 
the absence of developmental cues is sufficient to make stem cells. 
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Figure 2: Lympho-myeloid lineage potential of IdHP cells. A: Schematic representation of the in 
vivo model for investigating the developmental potential of IdHP cells. B: Flow cytometric analysis 
of cells in BM of mice transplanted with control or IdHP cells 4 weeks after injection. Donor derived 
peripheral blood mononuclear cells (PBMCs, CD45.1+) were analysed for the expression of Mac1 versus 
CD19 and CD3 versus NK1.1. C: Schematic representation of cloning of IdHP cells and analysis of the 
developmental potential of individual IdHP clones. D: Generation of lymphoid and myeloid lineage 
cells in Rag1-/- recipients transplanted with cloned IdHP cells. Flow cytometric profiles of donor 
type (CD45.1+) PBMCs are shown. E: Analysis of thymus, spleen, and bone marrow cells in the mice 
generated in experiment (B). F: Analysis of IgH D-J rearrangement in the donor type (CD45.1+) cells 
of thymus, spleen and BM of mice used in experiment (B and C). G: Developmental potential of foetal 
liver (LKS) progenitors transduced with control (ER) and Id3-ER retrovirus. After transduction, GFP+ 
cells were sorted and cultured on TSt-4 stromal cells supplemented with SCF, IL-7 and Flt3-ligand in the 
presence or absence of 4-OHT for 4 weeks. Flow cytometric profiles for CD19 versus B220 are shown. 
H: Expansion of foetal liver (LKS) progenitors transduced with control and Id3-ER retrovirus in the 
presence of 4-OHT. Viable cells were counted at the indicated time points. I: B cell generation from 
Id3-ER transduced cells after withdrawal of 4-OHT. The percentage of CD19+ cells at the indicated time 
points is shown. 
Self-renewing progenitor cells whose development can be controlled are a potential source 
for human immune cell therapy. We therefore attempted to produce human iLS cells. CD34+ 
cord blood cells were transduced with a retrovirus encoding the human Id3 gene and cultured 
under B cell inducing conditions. In the control vector group, cells differentiated into CD19+ 
B cells, although cells expressing the myeloid marker CD33 were also generated under this 
condition (Fig. 3A). In the Id3 over-expression group, cells exhibited higher forward/side 
scatter properties (Fig. 3A), with larger size and more cytoplasm (Fig. 3B), indicating that 
these are blastic cells. Just like murine iLS cells, human iLS cells showed exponential growth 
for at least several weeks (Fig. 3C), although with a slower growth rate. These human iLS cells 
retained the potential to give rise to NK cells and dendritic cells (DCs) in vitro (Fig. 3D, E). 
When transferred into sublethally irradiated NOG mice (Fig. 3F), human iLS cells gave rise 
to B cells (CD19+CD33-) and monocytes (CD33+CD14+) in BM of the reconstituted mice (Fig. 
3G, Supplemental Fig. 9). 
81
                     
      3
Induction of self-renewal activity in haematopoietic progenitors
Figure 3: Generation of IdHP cells from human cord blood HSCs. A: Flow cytometric analysis of cells 
derived from CD34+ human cord blood cells transduced with control and human Id3 retrovirus. After 
transduction, GFP+ cells were sorted and cultured on TSt-4 stromal cells in the presence of SCF, IL-7, 
Flt3-ligand and TPO for 4 weeks. B: Wright’s stain of human IdHP and control cells. Scale bars, 10μm. 
C: Expansion of human IdHP and control cells on TSt-4 stromal cells in the presence of human SCF, 
IL-7, Flt3-ligand and TPO. Viable cells were counted at indicated time points. D and E: NK cell and DC 
generation from human IdHP cells in vitro. Flow cytometric analysis is shown. F and G: Generation 
of CD19+ and CD14+ cells from human IdHP cells in NOG mice. Schematic representation of the 
examination of the developmental potential of human IdHP cells, shown in (F). Flow cytometric profiles 
for CD33 versus CD19 and CD33 versus CD14 of BM cells from transplanted mice, shown in (G).
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Discussion and Conclusion
In the present study, we showed that an artificially induced block of differentiation in 
uncommitted progenitors is sufficient to produce multipotent stem cells that retain self-
renewal activity. Once the differentiation block is released, the cells start differentiating into 
mature cells both in vivo and in vitro. Thus, this method could be applicable for establishing 
somatic stem cells from other organs in a similar manner, which would be useful for 
regenerative medicine. The relative ease of making stem cells leads us to conceive that a block 
in differentiation is also essential not only in other types of artificially engineered stem cells, 
such as ES cells and iPS cells, but also in any type of physiological somatic stem cell. In this 
context, it is tempting to speculate that it could have been easy for multicellular organism to 
establish somatic stem cells by this mechanism during evolution.
Immune cell therapy has become a major field of interest in the last decades. However, the 
required high cell numbers restrain application and success of immune reconstitution or anti-
cancer treatment. For example, DCs are already being used in cell therapy against tumours. 
One of the major limitations of DC vaccine therapy is the difficulty to obtain sufficient cell 
numbers, as DCs do not proliferate in the currently used systems. The novel method of making 
iLS cells could be applied to such cell therapies. Taken together, the simplicity of this method 
in combination with the high expansion rate and retainment of multilineage potential of the 
cells make this cell source appealing for regenerative medicine or immune cell therapy.
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Supplemental information
Supplemental Figure 1: Gene expression analysis of murine IdHP cells. A and B: Quantitative RT-
PCRs for the indicated genes in IdHP cells as well as control (control vector infected) cells are shown. 
Genes downregulated (A) and upregulated (B) in IdHP cells compared to Control cells are shown. 
Transcript levels of IdHP cells and control cells were normalized to the expression of acidic ribosomal 
protein (ARP) mRNA. Data are representative of three independent experiments.
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Supplemental Figure 2: Analysis of IgH D-J 
and V(D)J rearrangements in IdHP cells. 
Genomic DNA was isolated from IdHP cells, 
control (control vector infected) cells, TSt-4 
cells and BM cells are analysed by PCR for the 
presence of IgH DJ and V(D)J rearrangements 
using the indicated primers.
Supplemental Figure 3: In vitro generation of myeloid and T cells from IdHP cells. A: The number 
of Mac1+ cells generated from IdHP cells as well as control cells on TSt-4 stromal cells is shown. The 
FACS profile from IdHP cells is shown in Fig. 1H. B: The number of CD4+CD8+ cells generated from 
IdHP cells on TSt-4/DLL1 stromal cells is shown. The FACS profiles are shown in Fig. 1I. Data are 
representative of at least three independent experiments.
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Supplemental Figure 4: Loss of hCD25 expression 
by CD19+ cells generated from IdHP cells in 
Rag1-/- mice. Flow cytometric analysis of hCD25 
expression by Mac1-CD19+ cells was performed on 
the PBMCs of chimeras generated by the injection 
of IdHP cells into sublethally irradiated Rag1-
deficient mice. The mice were analysed 4 weeks 
after transplantation.
DH-JH
V7183-DJH
VJ558-DJH
VQ52-DJH
DJ1DJ2
DJ3
VDJ1VDJ2
VDJ3
VDJ1VDJ2
VDJ3
VDJ1VDJ2
VDJ3
Nu
mb
er 
of 
CD
4+ C
D8
+ c
ells
 x1
04
A B
0
0.5
1
1.5
2
Control IdHP
0
1
2
3
4
5
6
7
Control IdHP
Nu
mb
er 
of 
Ma
c1
+
ce
lls 
x1
04
88
                     
          3
Chapter 3
Supplemental Figure 5: In vivo generation of myeloid, B and T cells from FL-derived IdHP cells. 
IdHP cells were generated from LKS cells in FL of B6Ly5.1 mice. The FL-IdHP cells were cultured for 
two months on the TSt-4 stromal cells in the presence of SCF, IL-7 and Flt3-L. 1x106 FL IdHP cells were 
intravenously injected into sublethally-irradiated NOG mice. A: Flow cytometric analysis of cells in 
thymus, spleen and BM of mice transplanted with FL-IdHP cells 7 weeks after injection. B: The number 
of T (CD4+CD8+) cells in the thymus, B (IgM+) cells in the spleen and myeloid (Mac1+Gr1+) cells in the 
BM generated from the IdHP cells. C: CD4+ T cells in the spleen generated from IdHP cells were sorted 
and labelled with CFSE. The labelled cells were stimulated with plate–coated anti-CD3/28 for 4 days. 
Flow cytometric analysis of cells after stimulation is shown. Data are representative of three independent 
experiments.
0
4
8
12
16
T B Myeloid
(x105) Supplemental Figure 6: In vivo generation of T, B 
and myeloid cells from an IdHP clone. The 
number of T (CD4+CD8+) cells in the thymus, B 
(IgM+) cells in the spleen and myeloid (Mac1+Gr1+) 
cells in the BM of Rag1-/- recipients generated from 
cloned IdHP cells is shown. The mice were analysed 
at 6-8 weeks after the transplantation of IdHP 
clones. The representative FACS profiles of each 
lineage cells are shown in Fig. 2E. Data are 
representative of at least three independent 
experiments.
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Supplemental Figure 7: In vivo generation of myeloid, B and T cells from BM-derived IdHP cells. 
IdHP cells were generated from LKS cells in BM of B6Ly5.1 mice similar to FL-IdHP cells. The BM-
IdHP cells were cultured for two months in the same condition with FL-IdHP cells. 1x106 BM-IdHP 
cells were intravenously injected into sublethally-irradiated NOG mice. A: Flow cytometric analysis of 
cells in thymus, spleen and BM of mice transplanted with BM IdHP cells 7 weeks after injection. B: The 
number of T (CD4+CD8+) cells in the thymus, B (IgM+) cells in the spleen and myeloid (Mac1+Gr1+) 
cells in the BM generated from the IdHP cells. Data are representative of at least three independent 
experiments.
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Supplemental Figure 8: In vitro stimulation of CD4+ T cells isolated from spleen of NOG mice 
generated from BM-derived IdHP cells. A: CD4+ T cells in the spleen generated from BM IdHP cells 
were sorted and labelled with CFSE. The labelled cells were stimulated with or without plate–coated anti-
CD3/28 for 4 days. Flow cytometric analysis of cells after stimulation is shown. B: Cytokine secretion 
of the CD4+ T cells in response to plate-coated anti-CD3/28 stimulation for 4 days were measured by 
Bio-Plex analysis. Data are representative of at least three independent experiments.
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Supplemental Figure 9: Generation of B cells and monocytes in BM of NOG mice derived from 
hiLS cells. The number of B (CD33-CD19+) cells and monocytes (CD33+CD14+) in BM generated from 
hiLS cells are shown. Flow cytometric profiles are shown in Fig. 3G. Data are representative of three 
independent experiments.
Supplemental Table 1. RT-PCR primer sequences.
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Table S1. RT-PCR primers sequences
Gene Name Forward Reverse
CD79a TATGTCTGACTCCAGCATCC GGGAAGGACAAGATTAGGTG
CD79b CTCTGGGGATAGACTTGACC GAACCATGGTCCTCCTAGCA
l5 GTTCTAATGGGATGCTAGGC AGCGTCCTTCTCTTATCAGG
CD19 CAGTGATGGGACTAGCAGAC GTAGTGTTGCCAGAAACTCG
VpreB GAGTGGGAAGGAGAAAAGTC CCTTCCCATACCAGACTAGC
EBF1 TGGGTTACAGGTCATATTCG GAACTGCTTGGACTTGTACG
Pax5 CATTCGGACAAAAGTACAGC GATGCCACTGATGGAGTATG
GATA3 AGGCAAGATGAGAAAGAGTGCCTC CTCGACTTACATCCGAACCCGGTA
c-fms CTTAATGGCACAAAACAAGG ACGTCACAGAACAGGACATC
GATA1 ATTCCACAGGTTTCTTTTCC GTAGTAGGCCAGTGCTGTAG
Tcf-1 TGCTGTCTATATCCGCAGGAAG CGATCTCTCTGGATTTTATTCTCT
C/EBPa CAAGAACAGCAACGAGTACC GGTDATTGTCACTGGTCAAC
EpoR CCAGCTTTGAGTACACCATC TCGGACACCACAAGGTATAG
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Abstract
Haplo-identical haematopoietic stem cell (HSC) transplantation is very successful in 
eradicating haematological tumours, but the long post-transplant T-lymphopenic phase is 
responsible for high morbidity and mortality rates. Clark et al. have described a skin-explant 
system capable of producing host-tolerant donor-HSC derived T cells. Because this T cell 
production platform has the potential to replenish the T cell levels following transplantation, 
we set out to validate the skin-explant system.
Following the published procedures, while using the same commercial components, it was 
impossible to reproduce the skin-explant conditions required for HSC differentiation towards 
mature T cells. The keratinocyte maturation procedure resulted in fragile cells with minimum 
expression of Delta-like ligand (DLL). In most experiments the generated cells failed to adhere 
to carriers or were quickly outcompeted by fibroblasts. Consequently it was not possible to 
reproduce cell-culture conditions required for HSC differentiation into functional T cells. 
Using cell-lines over-expressing DLL, we showed that the antibodies used by Clark et al. were 
unable to detect native DLL, but instead stained 7AAD+ cells. Therefore, it is unlikely that the 
observed T lineage commitment from HSCs is mediated by DLL expressed on keratinocytes. 
In addition, we did confirm expression of the Notch-ligand Jagged-1 by keratinocytes.
Currently, and unfortunately, it remains difficult to explain the development or growth of 
T cells described by Clark et al., but for the fate of patients suffering from lymphopenia it is 
essential to both reproduce and understand how these co-cultures really “work”. Fortunately, 
alternative procedures to speed-up T cell reconstitution are being established and validated 
and may become available for patients in the near future.
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Introduction
Lymphopenia results in high mortality and morbidity among cancer patients receiving a 
haematopoietic stem cell (HSC) transplantation, or suffering from HIV infection 1-5. Eradication 
of haematological cancers is very successful using haplo-identical HSC transplantation 6, but 
many patients succumb to opportunistic infections that are the direct consequence of the 
lymphopenia, mainly involving the T cell pool 7; it often takes more than 200 days before 
(mainly CD4+) T cell levels have normalized again. This underlines the need for, and explains 
the general interest in, methods capable of enhancing T cell reconstitution 8, 9. 
Two important problems associated with slow recovery of T cell levels involve the thymus: 
slow thymic reconstitution by blood-borne progenitors and thymic involution 10-14. Because 
it is still not possible to control and/or reverse either of these processes, there is an obvious 
need to establish methods that generate a de novo T cell repertoire in vitro. However, the 
development of such systems is hampered because most processes that occur in the thymus are 
still enigmatic, especially how the thymus is capable to enforce self versus non-self recognition 
on developing thymocytes 15. Understanding the process of positive/negative selection, and 
reproducing this process in vitro, would potentially help to reduce lymphopenia, especially 
in older patients as the thymus involutes with age. In this context, the results on thymus-
independent T cell development previously described by Clark et al. are remarkable. This 
method involves a seemingly simple co-culture system consisting of skin keratinocytes and 
fibroblasts grown on a three dimensional (3D) tantalum covered scaffold (Statamatrix®) that, 
after 4 weeks of co-culture with allogenic HSCs, results in a population containing 3-5% T 
cells tolerant to the skin-donor 16. Even though T cells were detected, only a limited fraction of 
the expanded HSCs actually became T lineage committed; many cells differentiated towards 
Class II+ antigen presenting cells (APCs), a convenient aspect since it was suggested to be 
important for CD4+ T cell development 16. Additional explanations for the extra-thymic 
development of T cells were the co-incidental expression of various components known to 
be important for HSC differentiation and thymus-function, such as Delta-like ligand (DLL) 8 
and autoimmune regulator (AIRE) 17 by keratinocytes and fibroblasts 16, respectively.
Even though direct mechanistic explanations for the extra-thymic development of T cells are 
lacking, and despite limited numbers, it still remains the only published method potentially 
capable of generating functional, clinical-grade, mature T cells ex vivo. Because of the clinical 
importance, we made an effort to establish the skin-cell system in our laboratory and to 
characterize it in more detail. We observed that keratinocytes do express the Notch ligand 
Jagged-1, but we did not find the abundant expression of DLL protein previously reported by 
Clark et al. on keratinocytes. Furthermore, due to the growth characteristics of keratinocytes 
and fibroblasts in the Statamatrix®, we could not reproduce the co-cultures as described by 
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Clark et al. 16. As a result, we never observed any T lineage differentiation. The various reasons 
for the unsuccessful reproduction of this method are described in this report.
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Materials and methods
Cells 
Abdominal or breast-skin was obtained from healthy individuals (donor A-E) undergoing 
reconstructive surgery, and processed within 24h. When required, skin was kept in RPMI 
1640 (Sigma-Aldrich Co., St. Louis, MO) supplemented with 100IU/ml penicillin, 100μg/
ml streptomycin (P/S) and 0.5μg/ml fungizone (all from Invitrogen Ltd., Paisley, UK) until 
processing. After removal of subcutaneous fat (if applicable), skin was cut into small fragments 
and incubated in phosphate buffered saline (PBS, Sigma) containing 2.4U/mL Dispase 
II (Roche, Indianapolis, USA) overnight at 4°C. Epidermis and dermis were separated by 
tweezers.
To isolate keratinocytes, up to 20 epidermal sheets were digested using 2ml Trypsin/EDTA 
(Lonza, Verviers, Belgium) for 5min at 37°C. Following quick neutralization by Trypsin 
Neutralizing solution (TNS, Lonza), suspension was vortexed after which undigested tissue 
was removed by subsequent filtration through 500μm (Nedfilter, Almere, the Netherlands) 
and 70μm strainers (BD Biosciences, Erembodegem, Belgium). Cells were spun down at 250g 
for 10min, and resuspended at approximately 2x105 cells/ml in Keratinocyte-SFM medium 
containing 1% P/S, 0.39mM CaCl2, bovine pituitary extract (BPS) and epidermal growth 
factor (EGF) according to the manufacturer’s descriptions (keratinocyte medium, Invitrogen). 
Medium was changed after 2-3 days, and islands appeared after 1-2 weeks. Keratinocytes were 
passed to new flasks when islands contained 30-50 cells; overall density of flasks was kept at 
30-40%. For experiments, keratinocytes used were passaged 6x or less.
To isolate fibroblasts, 10-20 dermal fragments were incubated at 37°C for 1h in DMEM/F12 
(Invitrogen) medium containing 2.5mg/mL Trypsin, 0.2U/mL Liberase Bz3, and 0.2mg/ml 
DNAse. Following neutralization with DMEM/F12 containing 15% foetal calf serum (FCS, 
Greiner Bio-one, Solingen, Germany), cell-suspensions were filtrated and spun down as 
described above. Cells were seeded at 2x105 cells/ml in DMEM/F12 containing P/S, 15% FCS 
and 10ng/ml EGF (fibroblast medium). Fibroblast cultures were split when density reached 
100%. These cells were never split more than 8x before use in co-cultures.
Mobilized CD34+ stem cells
CD34+ cells were isolated from peripheral blood mononuclear cells (PBMC) obtained from 
healthy volunteers (V1-3) treated with G-CSF (Neupogen, Amgen Inc., Thousand Oaks, 
CA) at MUMC+ (Maastricht, the Netherlands). Isolation was performed with the Isolex 300i 
Magnetic cell selection system v2.5 (Baxter oncology, Brussels, Belgium) using the Isolex 
stem cell reagent kit (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) according to the 
manufacturer’s instructions. The positive fraction containing >94% CD34+ cells was frozen at 
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a concentration of 5x106 cells per ml per vial. CD133+ cell preparations were obtained from 
Lonza.
Skin and CD34+ stem cells were obtained according to protocols approved by, and guidelines 
stipulated by the local medical ethical committee, and with consent from the donors.
Maturation/differentiation of keratinocytes
Keratinocytes at 30-40% density were harvested using Trypsin/EDTA and TNS (Lonza), 
quantified and seeded at 100% density in a 1:1 (vol/vol) mix of Keratinocyte-SFM and DF-K 
medium. DF-K medium is a 1:1 (vol/vol) mix of DMEM and Ham’s F12 containing P/S, 
0.2ng/ml EGF, 25µg/ml BPS and 1.5mM L-Glutamine (Invitrogen). Medium was refreshed 
daily. This procedure only worked for keratinocytes isolated from breast-skin and not for 
abdominal skin.
The skin-cell construct
Sterilized Statamatrix® (Cytomatrix, Australia) were coated by incubation in PBS containing 
100µg/ml rat tail collagen I (Roche) at 37°C, after which the coated matrices were washed twice 
in PBS, and maintained in PBS until use. Prior to use, matrices were transferred to non-tissue 
culture treated petridishes (Greiner), and PBS was aspirated. Keratinocytes and fibroblasts 
were harvested, resuspended in a 1:1 mixture of keratinocyte and fibroblast-medium (ker-fib 
medium), and quantified. Subsequently, keratinocytes and fibroblasts were combined at 2x106 
and 1x106 cells/ml, respectively, and 50-100μl of this mix was dripped onto a matrix. After 3h 
at 37°C, 5% CO2, matrices were moved to 24-well plates and 2ml ker-fib medium was added. 
The skin-cell constructs were cultured for 6 days and medium was changed every other day.
Seeding of CD34+/CD133+ cells
After 6 days, medium was replaced by IMDM (Invitrogen) supplemented with 10% FCS 
(Greiner), 20ng/ml IL-7 and IL-15, and 100ng/ml Flt3-L (all R&D systems, Abingdon, UK), 
then 1x104 CD34+ or CD133+ cells were dripped onto each matrix. Half medium change was 
done 3 times weekly.
TSt-4
Thymic stromal cell lines TSt-4 and TSt-4 transduced with hDLL1 or hDLL4 were kindly 
supplied by Prof. dr. H. Kawamoto (RCAI-RIKEN, Yokohama, Japan) and maintained in 
RPMI 1640 containing 5% foetal bovine serum (FBS), 1% PS, 1mM sodium pyruvate, 0.1mM 
MEM non-essential amino acids (NEAA), and 5x10-5M 2-mercaptoethanol (bME) (all from 
Invitrogen Ltd., Paisley, UK).
Flowcytometry 
All antibodies, materials and equipment were obtained from BD Biosciences (Erembodegem, 
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Belgium), unless stated otherwise, and were used according to manufacturer’s instructions. 
At different time points, cells were analysed using different combinations of fluorescein 
isothiocyanate (FITC), R-phycoerithrin (PE), peridinin chlorophyll proteins (PerCP)-, and 
allophycocyanin (APC) conjugated monoclonal antibodies (mAbs). The following antibodies 
(clones) were used: CD1a (HI149), CD3 (UCHT1, SK7), CD4 (SK3), CD5 (UCHT2, L17F12, 
MEM32 – Immunotools, Friesoythe, Germany), CD7 (M-T701, 7F3 - Sanquin), CD8a (HIT8a, 
RPA T8), CD14 (M5E2), CD19 (HIB19), CD34 (8G12), CD38 (HB7), CD45 (2D1, HI30), 
CD45RA (HI100), CD46 (E4.3), CD56 (B159), CD90 (AS02, Dianova, Hamburg, Germany), 
CD271 (C40-1457), IFN-γ (25723.11), NKG2A (131411, R&D Systems, Minneapolis, MN), 
NKp46 (9E2), TCRαβ (IP26 - eBioscience), and TCRγδ (B1.1 - eBioscience). Unconjugated 
goat and rabbit antibodies used were DLL1 (#H20 and #H265), nitric oxide synthase 2 (NOS2), 
IFN-γ responsive factor 1 (IRF1), angiotensin-converting enzyme (ACE) (all Santa Cruz 
Biotechnology, Santa Cruz, USA), for which the following conjugates were used according 
to manufacturer’s instructions: donkey anti-goat FITC and donkey anti-rabbit FITC or APC 
(all Jackson ImmunoResearch, West Grove, USA). 7-amino-actinomycin D (7AAD) was 
used to differentiate between viable and dead cells. For intracellular stainings, cells were 
permeabilized using perm/wash. Cells were analysed on a FACSCalibur or FACScan with 
WinMDI (Joe Trotter, http://facs.scripps.edu/) software.
Fluorescence activated cell sorting 
Prior to differentiation, CD34+ cell preparations were depleted of CD38bright cells and 
contaminating T and NK cells by cell-sorting using conjugated anti-CD3, -CD4, -CD8, 
-CD38 and -CD56 antibodies. All CD34+ cell preparations had ≤0.05% contaminating mature 
lymphoid cells. Sorting was performed on a FACS ARIA (BD) with FACS DIVA software.
Immunofluorescence 
Upon aspiration of media, monolayers or cells were washed with PBS and fixed with cold 
methanol: acetone (Merck) 1:1 for 10min on ice. Following fixation, preparations were washed 
3 times with PBS at RT, with each wash for 4min on an orbital shaker. Blocking was done for 
30min with 1% normal donkey serum (JIR) in PBS, after which preparations were washed 
twice with PBS. The following primary antibodies were used, each at the proper, predetermined 
dilution: CD46 (BD Biosciences), CD90 (Dianova), DLL1, Jagged-1 (both Santa Cruz), pan-
cytokeratin (Acris, Hiddenhausen, Germany), Keratin-10 (RKSE60), -14 (RCK107) and -16 
(LL025) (all MuBio, Maastricht, the Netherlands). Preparations were incubated with primary 
antibodies for 1h at RT in the dark, after which they were washed 5 times with PBS, followed 
by incubation with secondary antibody for 1h at RT in the dark. Appropriate Texas Red or 
FITC-labelled donkey anti-rabbit, anti-goat or anti-mouse antibodies were obtained from 
Jackson Immunoresearch. Following another washing procedure, preparations were post-
fixed for 15min with 2% paraformaldehyde in PBS. Then, preparations were washed twice, 
and covered with mounting medium containing 4’,6-diamidino-2-phenylindole (Vector 
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Laboratories, Burlingame, USA). Preparations were analysed using an Axioplan 2 microscope 
and Axiovision software (Zeiss, Jena, Germany).
PCR analysis
RNA was extracted from immature and matured keratinocytes using Trizol according to 
manufacturer’s instructions (Invitrogen). Following quantification and DNAse treatment, 
cDNA was synthesized using Superscript III according to manufacturer’s instructions 
(Invitrogen). PCR was carried out in 20μl reaction volumes containing ≤80ng or 40ng RNA 
equivalent from keratinocytes or TSt-4 cells, respectively. All PCR components were used 
according to manufacturer’s instructions (iTaq, BioRad, Hercules, CA) 100nM of each primer 
(Eurogentec, Liege, Belgium). Primers used were (anneal temperature, optimal MgCl2): 
Keratin-14 f-CACCTCTCCTCCTCCCAGTT r-CATCGTGCACATCCATGAC (63°C, 
3mM), DLL1 f-CGTCGACTCCTTCAGTCTGC r-TTCTGTTGCGAGGTCATCAG (60.5°C, 
3mM), DLL4 f-TCCAACTGCCCTTCAATTTC r-ACTGCAGATGACCCGGTAAG (57°C, 
5mM), and Jagged-1 f-CGGCCTCTGAAGAACAGAAC r-CCTCAGAGGCTGAGTGTGTG 
(62°C, 3mM). All PCR products were validated by TA-cloning and sequencing according to 
standard procedures.
101
                     
      4
T cells fail to develop in the human skin-cell explant system
Results
The in vitro T cell development from donor CD34+ cells as described by Clark et al. 16 requires 
a co-culture of (recipient = patient) keratinocytes and fibroblasts. To confirm expression of 
determinants reported to be important for in vitro differentiation, and establish co-cultures, 
we prepared keratinocyte and fibroblast cell banks from various donors and different skin 
sources. Sufficient numbers of early passage stocks were available from 5 donors for all 
experiments. 
Is DLL expressed by keratinocytes? 
Many papers have described the necessity for Notch signalling in T cell determination 
and differentiation from CD34+ cells (reviewed in 8). One of the most obvious and logical 
explanations provided by Clark et al. 16 for the generation of T cells was the innate potential 
of matured keratinocytes to express DLL protein. To detect/confirm DLL expression on intact 
keratinocytes, we used three different methods.
FACS analysis
In the paper by Clark et al. 16, it was not specified at what stage the keratinocytes were 
harvested, and which DLL was detected by the polyclonal H265 antibody. In our hands, the 
differentiation procedure resulted in a mixture of undifferentiated and early-differentiated 
cells; none of the “differentiated” keratinocytes ever lost CK14 expression, which is a marker 
for mature keratinocytes (Fig. 1). By using murine cell-lines (genetically) over-expressing 
human DLL1 or 4 it became clear that the H265 antibody used for flowcytometry (FACS) and 
immunofluorescence does recognize DLL1, but not DLL4 (Fig. 2A). Using a murine stromal 
cell line transduced with human DLL1 as positive control, which shows intense staining of 
DLL1 on immunoblot (Fig. 2A), we found that it was possible to detect DLL1 on vital cells 
by FACS, albeit with difficulty (Fig. 2B). When matured keratinocytes were indirectly stained 
with H265 for analysis by FACS, we were never able to detect a specific signal from H265 on 
vital, 7AAD- keratinocytes (Fig. 3A). Other primary rabbit antibodies specific for intracellular 
antigens, normally not expressed by keratinocytes like NOS2 and IRF1, also stained 7AAD- 
keratinocytes (Fig. 3A), indicating that these antibody-preparations may not be suitable for 
analysis by FACS. We did find that 7AAD+/DAPI+ cells were intensely stained by all primary 
rabbit antibodies, including H265 (Fig. 3B), generating a false positive H265/SSC picture very 
similar as published by Clark et al. 16. Apparently, it is possible to use the FACS procedure in 
combination with H265 to detect DLL1 expression on the surface of DLL1-transfected cell-
lines, but it cannot be used to reliably stain DLL on vital keratinocytes.
Another question that arose was whether H265 is suitable for detection of intact DLL. Because 
the antibody was generated against a peptide spanning the membrane and the first twenty 
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amino-acids of the extracellular domain, it may recognize processed DLL only (the epitope 
could be shielded by the 3D folding of the protein), thereby underrepresenting the actual level 
of DLL surface-expression. Therefore, using a goat-polyclonal antibody capable of binding 
to a known, accessible epitope in the extracellular domain of DLL1, H20, we repeated the 
experiments with DLL-transduced cells (Fig. 2A and 2B) and keratinocytes (Fig. 3C), but no 
specific staining on intact keratinocytes was detected. When considering the weak specific 
signals obtained with either H20 or H265 on cell-lines over-expressing DLL, it is obvious to 
conclude that it is impossible to demonstrate spontaneous DLL expression on intact primary 
cells with these antibodies.
Immunofluorescence
To confirm DLL expression by FACS, Clark et al. 16 used immunofluorescence on fixed 
keratinocytes prepared by cytospin, which is an application reported suitable for both 
H265 and H20. However, again no detection of any DLL staining of intact, differentiated 
keratinocytes was observed; the occasional green cell we did see (resembling Fig. 5C in 16) 
proved to have no nucleus (Fig. 4A). In contrast, keratinocytes did stain positive for Notch 
ligand Jagged-1 (Fig. 4A).
PCR
Since it was not possible to reliably detect DLL1 or DLL4 protein, we reverted to PCR to find 
out whether matured keratinocytes are at least capable to express high levels of DLL RNA. 
As shown in Figure 4B, compared with gene-products normally expressed by keratinocytes, 
cDNA encoding for DLL4 required 35 cycles before detection. Clearly, expression of DLL is 
far from abundant in differentiated or immature keratinocytes (Fig. 4B). In contrast to DLL 
expression, the high level of Jagged-1 expression was confirmed by detecting PCR products 
after 30 cycles (Fig. 4B). This observation is in line with a previous report demonstrating high 
levels of Jagged-1 expression at various stages of keratinocyte-development 18.
In summary, using three different methods we could not detect any DLL expression by 
keratinocytes, which makes it unlikely that HSC differentiation towards T lineage as 
observed by Clark et al. 16 is initiated by T lineage commitment induced by DLL expressed on 
keratinocytes. Of course, we do not know whether (or why) keratinocytes start to express DLL 
during co-culture with fibroblasts, or whether DLL-expression by keratinocytes is actually 
required for the extra-thymic T cell development. On the other hand, keratinocytes do show 
abundant expression of Jagged-1. Even though Jagged-1 by itself is not particularly efficient in 
induction of T lineage differentiation of cord blood derived CD34+ cells 19, and its expression 
in the murine thymus is not abundant 20, 21, Jagged-1-mediated activation of murine thymic 
precursors does result in T/NK progenitors 20. Therefore, it cannot be excluded that Jagged-1 
does so as well in the context of the skin-explant system.
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Figure 1: Differentiation of keratinocytes results in a mixture of immature and semi mature cells. 
Keratinocytes of a representative donor were differentiated in chamber-slides for 6 days. Following 
fixation, cells were stained for the indicated cytokeratins (CK) using a panel of monoclonal (CK10, 
CK14, CK16) and polyclonal antibodies (pan). Duration of fluorescence detection was kept constant. 
Though variable, all cells were positive for CK14, while staining of CK10 and CK16 was limited to areas 
with blast-like keratinocytes.
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Figure 2: Analyses of DLL expression by immunoblot and FACS using cell-lines over-expressing 
DLL. A: Protein blots were prepared from TSt-4 thymic stromal cell-lines over-expressing human DLL1 
or 4, and incubated with polyclonal antibodies specific for DLL. Both H20 and H265 only stained lanes 
containing TSt-4-DLL1 extracts, with a main band at 78 kDa. H265 stained additional bands at 50 kDa 
and 230 kDa, which could represent processed and glycosylated DLL1, respectively. In contrast to H20, 
H265 also heavily stained the marker-lane, indicating that the specificity of this polyclonal antibody 
preparation is not limited to DLL. B: Indicated cells were harvested using trypsin-EDTA, and incubated 
with H265 and H20 with control polyclonal antibodies specific for IRF1 and ACE. Control antibodies 
were selected based on species-origin and specificity for non-surface antigens. Both H265 and H20 
showed weak, yet specific staining of TSt4-DLL1.
Figure 3: 7AAD+ keratinocytes show intense staining with any polyclonal primary antibody. 
Keratinocytes of donor C were harvested following high-density culture for 6 days, either in standard 
keratinocyte (iKer) or maturation medium (dKer). A: All cells being stained with indicated rabbit pan 
antibodies were 7AAD+. Left column shows FACS plots as used by Clark et al. 16, right column contains 
additional information regarding viability. Within experiments, the percentage of positively stained cells 
was always similar with any pan-antibody. Insert shows background staining by the secondary antibody 
used. Even though staining intensity was lower after incubation with the secondary antibody, when 
compared with unstained cells (LL quadrant of the right column), the percentage of cells with signal 
was similar. This staining-pattern was observed for all donors. B: When gated on 7AAD- cells, any 
pan- antibody stained a low percentage of keratinocytes (donor C, donor D showed similar inconclusive 
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staining profile). C: Almost all cells that were stained with H265, co-stained with H20. A nearly similar 
plot could be obtained with any pan rabbit (eg. ACE) and pan goat antibody combination (eg. NOS2), 
and invariably involved 7AAD+ cells (donor C, donor D showed similar co-staining).
Figure 4: Keratinocytes have very low expression of DLL. A: Next to FACS, Clark et al. 16 used 
immunofluorescence to demonstrate DLL expression in immature keratinocyte cultures. While the 
secondary antibody did not give any background staining (LL), there were occasional H265-FITC 
positive cells (UR), but these always proved to be DAPI negative. In contrast to DLL, immature 
keratinocytes were reliably stained for the Notch-ligand Jagged-1. B: For PCR, 4 dilutions (5x-20x-80x-
320x) were prepared from cDNA of mKer from 3 donors (A, B, and C), iKer from donor C. Positive 
controls were prepared from murine TSt-4 cells constitutively expressing DLL1 or DLL4. At 35 cycles, 
DLL4-specific PCR product was only detected in the 5x diluted samples, while mRNA encoding for 
Jagged-1 was easily amplified in 30 cycles.
A balanced co-culture? 
The system requires co-culture of keratinocytes and fibroblasts on the Statamatrix®. However, 
“matured” keratinocytes showed limited capacity to adhere to collagen-coated Statamatrices®, 
in contrast to fibroblasts, and these latter cells always overgrew in keratinocyte-fibroblast co-
cultures in matrices within 7 days (Fig. 5A and B).
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CD90
Overlay
panCK panCK
CD90
Day 5 after seeding matrixA B Week 4 after seeding matrix
10x
20x
10x
Figure 5: Keratinocytes are out-competed by fibroblasts. A: Matrix was stained for keratinocytes and 
fibroblasts using panCK and CD90, respectively, six days after matrices were seeded at a 2:1 ratio. At this 
stage, matrices were carefully seeded with HSCs. B: After 4 weeks, matrices were completely covered 
with CD90+ fibroblasts. HSC derived cells could only be retrieved from the matrix following collagenase-
dispase treatment. Fibroblasts from all donors grew similarly.
Skin-explant procedure did not result in T lineage development 
We found that HSCs (expressing either CD34+ or AC133+) were never able to differentiate 
towards T lineage cells in matrices containing isolated and cultured fibroblasts and 
keratinocytes; most HSCs did up-regulate CD7 and lost the CD34 marker, but no expression 
of early T lineage markers like CD5 (Fig. 6), nor the CD56 NK cell marker were observed 
(data not shown). In contrast, the same batches of HSCs demonstrated excellent T lineage 
differentiation capacity when grown on murine stromal cell lines expressing human DLL 22.
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Figure 6: HSCs expand, but do not differentiate in the skin-cell explants. HSCs from donor V1 and 
V2 were seeded into skin-cell explants from donor A and B. As controls, HSCs were expanded for 
1 week using a HSC expansion-mix, followed by maintenance with IL-7. For reasons unknown, cell-
numbers declined after 2-3 weeks in culture with skin-cell explants (not shown). The phenotype of 
the haematopoietic cells was analysed at various time-points after seeding, and the results of week 2 
and 4 are depicted. Of markers associated with T lineage commitment, only CD7 was detected on 20-
30%/60% of the cells in skin-cell explants/controls, and its expression-level increased from week 2 to 4.
DLL-independent development? 
As indicated, the phenotype of the differentiated HSCs suggested lack of Notch signalling, 
which could be due to the lowered keratinocyte/fibroblast ratio. Since it seems very 
difficult to alter that ratio with the published protocol, it may be difficult to routinely use 
the skin-explant procedure. However, the explant system remains unique in the fact that it 
encompasses complete T cell development resulting in functional, single-positive CD4+ and 
CD8+ T cells, which includes the poorly understood process of positive/negative selection. 
Because canonical T cell development roughly consists of 3 phases – 1) DLL-dependent T 
lineage commitment, 2) DLL-independent beta-chain selection and 3) DLL-(in)dependent 
positive/negative selection, we investigated whether T cell development could occur with cells 
that already have received DLL-signalling and are T/NK or completely T lineage committed 
22. Unfortunately, when T/NK lineage committed cells were seeded in skin-explants, most 
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became NK lineage committed CD56+ cells (Fig. 7), in the presence of additional IL-15. 
Thymocyte-like cells were never detected. When IL-15 was omitted, the viability and yield of 
the cultures were reduced considerably, and most cells lost CD5 and iCD3 expression (Fig. 
7), indicating that even in the presence of only IL-7 and Flt3-L, the keratinocyte/fibroblast 
co-cultures were not able to maintain the T lineage committed status of cells. The few cells 
remaining also displayed a CD56+ phenotype.
Figure 7: Skin-cell explants cannot maintain T lineage committed cells. HSCs from indicated donors 
were pre-differentiated on monolayers of thymic stromal cells expressing hDLL1 (see Fig. 2). After 4 
weeks, 55-65% of the cells were CD5+CD7+ (see insert), and >90% iCD3+CD45RA+ (NS). 1x105 cells 
were seeded in skin-cell explants and cultured for 2 and 4 weeks. In the presence of IL15, the population 
expanded 10-15x. Already at 2 weeks, all cells had lost expression of CD5 and become CD56+ NK 
lineage committed cells. The same phenotype was observed when IL-15 was omitted, although overall 
expansion was strongly reduced to 1-1.5x.
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Discussion
Our results clearly demonstrate that the keratinocyte differentiation procedure results either 
in fragile cells that fail to adhere to any structure or plate, or cells that do adhere but are 
outcompeted by fibroblasts within a week. Furthermore, differentiated keratinocytes do not 
express detectable levels of DLL (protein nor RNA), and therefore the T lineage commitment 
observed by Clark et al. 16 must be mediated by other factors. Jagged-1 may be responsible for 
steering development towards the T lineage of a limited fraction of CD34+ cells in their co-
culture system, because it is abundantly expressed by keratinocytes. As stated in the results 
section, certain T lineage committed stadia can complete their development into DP and SP 
T cells independent of Notch signalling 23. 
However, even if T cells can be generated ex vivo using the skin-explant system, the question 
remains whether they will be functional. Extra-thymic development of T cells has been 
described for oncostatin M (OncM) transgenic mice, where lymph nodes take over the 
function of the thymus 24. Even though in OncM mice the T cells appear to go through the 
same developmental stages as regular thymocytes, they are less functional, which may be the 
result of positive selection by other haematopoietic cells instead of thymic epithelium 25. This, 
however, remains to be elucidated for T cells derived in any in vitro cell differentiation system.
The past decade knowledge-driven research has revealed how T lineage commitment can be 
induced in HSCs in vitro, using cell-lines transfected with hDLL 8, 26, 27, or, to a certain extent, 
with recombinant hDLL 28, 29. In contrast to mouse, differentiation of human progenitors rarely 
get past the DP-stage of thymocyte development, indicating it is difficult to push them through 
the positive-negative selection process. Interestingly, experiments with human T-progenitors 
sorted as or arrested at a DN2-3-like stage, obtained from either OP9-DLL or TSt-4-DLL 
–HSC co-cultures, respectively, demonstrated that these cells were capable of rapidly 
reconstituting the thymus of Rag2-/-γc-/- mice, where they completed their maturation 22, 30. 
Similar experiments with murine T progenitors have shown that this approach considerably 
enhanced the generation of functional T cells after HSC transplantation 31, 32. This approach 
will certainly be applicable to patients in the near future, but still relies on the functional 
capacity of the thymus, which is limited in older patients. In this regard, more pragmatic 
research has resulted in several viable approaches capable of improving thymic function 33-35, 
which are now being tested in clinical trials 36, 37. The solutions to both problems concerning 
T cell reconstitution are expected to meet within the next decade.
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Conclusion
The results described by Clark et al. 16 are fascinating and unique, but remain elusive. The 
results in the current paper show that by following the published procedure we could not 
obtain enough evidence to support the basic skin-cell co-culture conditions suggested to be 
required for HSC differentiation towards mature T cells. Recent advancements in the field of 
T cell lineage differentiation and thymic rejuvenation will generate alternative procedures to 
reconstitute the T cell population following HSC transplantation of man.
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Abstract
The efficacy of donor haematopoietic stem cell (HSC) transplantations is partly reduced due 
to slow post-transplantation immune recovery. In particular, T cell regeneration is generally 
delayed, resulting in high infection-related mortality in the first years post-transplantation. 
Adoptive transfer of in vitro generated human T cell progenitors seems a promising approach 
to accelerate T cell recovery in immunocompromised patients. Ascorbic acid (AA) may 
enhance T cell proliferation and differentiation in a controlled, feeder-free environment 
containing Notch-ligands and defined growth factors. Our experiments show a pivotal role 
for AA during human in vitro T cell development. Blocking Nitric Oxide Synthase diminished 
this effect, indicating a role for the citrulline/NO cycle. AA promotes both the transition of 
proT1 to proT2 cells and of preT to double positive (DP) T cells. Furthermore, the addition 
of AA to feeder co-cultures resulted in development of DP and single positive (SP) T cells, 
whereas without AA a preT cell stage arrest occurred. We conclude that neither DLL4-
expressing feeder cells nor feeder cell conditioned media are required for generating DP T 
cells from cord blood and G-CSF mobilized HSCs and that generation and proliferation of 
proT and DP T cells is greatly improved by AA. This technology could potentially be used to 
generate T cell progenitors for adoptive therapy.
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Introduction
Haematopoietic stem cell transplantation (HSCT) is one of the current treatments of 
haematological malignancies. However, slow post-transplantation immune recovery may 
result in high infection-related mortality, especially if the donor source comes from haplo-
identical or cord blood (CB) donors 1, 2. In particular, immune reconstitution is hindered by a 
delayed T cell regeneration. Important reasons for this delay are age-related thymic involution, 
impaired thymus function and a decreased repopulation of the thymus by stem/progenitor 
cells 3-6. Only de novo T cell generation in the thymus ensures a broad T cell repertoire that 
guarantees complete immune recovery after HSCT. 
T cell development is a highly regulated process that starts with HSCs in the bone marrow and 
proceeds in the thymus. Maturation of T cell progenitors in the thymus can be divided into 
several stages. Based on the expression of CD4 and CD8, T cell development can be separated 
into double negative (DN), double positive (DP) and single positive (SP) stages 7. The DN 
stages can be subdivided based on the expression of early T cell markers with cluster of 
differentiation (CD)7 as the first marker expressed (proT1) and subsequent CD5 expression 
(proT2, previously described as DN2) 8-11. CD1a is present on T lineage committed precursors 
(preT, previously described as DN3) and is followed by expression of CD4 (immature single 
positive cells; iSP) 11-13. In the subsequent DP stage, CD3 and T cell receptor (TCR)αβ are 
expressed, and after positive and negative selection in the thymic microenvironments cells 
enter the periphery as mature naive SP T cells. Crucial for T cell development is the interaction 
of the Notch receptor on progenitor cells with Notch ligands provided by the thymic stroma 
14. Both Notch ligands Delta-like ligand-1 (DLL1) and DLL4 are able to drive T lineage 
development in vitro 15, where in vivo only DLL4 gives the instructive signal to the thymus 
seeding cells 16, 17. Due to the importance of Notch signalling during T lineage development, 
DLL-expressing feeder cells have been used in vitro to generate T cell progenitors for adoptive 
immunotherapy.
Adoptive transfer of in vitro generated (progenitor) T cells has evolved as a promising 
approach to accelerate T cell recovery in immune compromised patients. In recent years, 
methods to generate T cell progenitors in vitro have been developed 9, 11, 18. It is shown that 
these progenitors can enhance T cell reconstitution in vivo 9, 11, 19. We have reported that 
mobilized CD34+ (mCD34) cells in co-culture with thymic stroma derived TSt-4/DLL 
feeder cells differentiate into T/NK progenitors 11. Similar results have been obtained with 
CB and bone marrow derived CD34+ cells in co-culture with the bone marrow derived 
OP-9/DL1 feeder cells 9, 18. Together with some other stromal cell lines like S17/DL1 20, the 
DLL-expressing feeder cell lines have the unique capacity to support T cell development in 
contrast to other stromal cells, for example NIH3T3 expressing DLL 21. Additionally, OP-9/
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DL1 can support T cell development in vitro to the DP/SP stage in contrast to TSt-4/DLL 22. 
In vivo immune reconstitution experiments showed that TSt-4/DLL derived progenitor cells 
from mCD34+ and CB derived proT cells from OP-9/DL1 co-cultures home to the thymi 
of immune deficient mice and complete their development into mature T cells faster than 
unmanipulated stem cells 9, 11. Additionally, Eyrich et al. detected extrathymic mature T cells 
in mice after injection of T cell progenitors derived from OP-9/DL1 co-cultures 19.
Efforts have been made to generate in vitro clinical grade T cell progenitors without the use 
of feeder cells 23, 24. Ohishi et al. showed that expansion of CB CD34+ cells in the presence of 
immobilized DLL1 and cytokines resulted in the development of a CD34+CD7+ lymphoid 
progenitor population capable of CD3+ T cell reconstitution in the thymi of immune deficient 
mice 23. Moreover, a phase I clinical study with the transfer of CB CD34+ DLL1 culture derived 
progenitors showed enhanced engraftment and myeloid reconstitution 25. However, the lack 
of improvement in T cell reconstitution in these patients indicates the need for more efficient 
methods for in vitro generation of T cell progenitors.
To extend on our previous work 11, 26 we searched for factors to enhance T cell differentiation 
and proliferation, and investigated the role of ascorbic acid (AA) in the current study. Ascorbic 
acid plays a multitude of roles in the immune system and is abundantly present in T cells 27, 
but its role during human T cell development is not known. In our present study, we have 
investigated the role of different forms of AA on T cell maturation and proliferation from 
HSCs and show the influence of AA in both feeder and feeder-free conditions.
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Materials and methods
Isolation and purification of CD34+ cells
CB CD34+ and mCD34+ cells were obtained at the Maastricht University Medical Center 
after informed consent in accordance with the Declaration of Helsinki and with approval 
of the local Medical Ethical Committee (METC 12-2-044). mCD34+ cells were obtained 
from healthy volunteers treated with G-CSF (Neupogen, Amgen, Thousand Oaks, CA, 
USA). Mononuclear cells were isolated from fresh 1:1 phosphate buffered saline (PBS, PAA, 
Pasching, Austria) diluted CB by Lymphoprep (Axis shield, Oslo, Norway) density gradient 
centrifugation. CD34+ cells were enriched using immunomagnetic beads according to 
manufacturer’s instructions (CD34+ microbead kit and cliniMACS CD34+ selection kit for 
CB CD34 and mCD34, respectively, Miltenyi, Bergisch Gladbach, Germany). CD34+CD38-/dim 
cells were further purified and depleted from contaminating T and NK cells by fluorescence-
activated cell sorting using FACS ARIA (BD, Erembodegem, Belgium). For cell-sorting, the 
following antibodies were used at proper dilutions: fluorescein isothiocyanate (FITC)-anti-
CD38, phycoerythrin (PE)-anti-CD34, peridinin-chlorophyll proteins (PerCP)-anti-CD4, 
-CD8, -CD3 and allophycocyanin (APC)-anti-CD56 or horizon V450-anti-CD56 (all BD). 
To obtain sufficient number of starting cells, CB units from different healthy donors were 
obtained and pooled. Purity of mobilized and CB CD34+ cells was more than or equal to 98% 
CD34+ cells and less than or equal to 0.1% contaminating CD3/CD4/CD8 or CD56+ cells. 
Co-cultures with feeder cells
TSt-4 cells, an earlier gift of Prof. dr. H. Kawamoto (Kyoto University, Japan) were grown 
in standard RPMI 1640 medium (Sigma-Aldrich Co., St. Louis, MO, USA) containing 5% 
FBS (Greiner bio one, Kremsmuenster, Austria), 1% penicillin-streptomycin, 1mM sodium 
pyruvate, 0.1mM MEM non-essential amino acids, and 5×10−5M 2-mercaptoethanol (all 
from Invitrogen Ltd., Paisley, UK). OP-9 cells were cultured in αMEM medium reconstituted 
from powder (Life Technologies, Carlsbad, CA, USA) containing 20% FBS (Hyclone Thermo 
Scientific, Logan, UT, USA), 5g/L sodium bicarbonate (Sigma-Aldrich Co.) and 1% Penicillin/
Streptomycin (Invitrogen Ltd.). Liquid αMEM medium (Life technologies) without ascorbic 
acid was used when indicated. L-Ascorbic acid (Sigma-Aldrich Co.) was supplemented to 
RPMI 1640 and liquid αMEM medium when indicated. OP-9 cells were a kind gift from dr. R. 
Schotte and dr. B. Blom (AMC, Amsterdam, the Netherlands). mCD34+ cells were seeded at 
a density of 2.6×103 cells/cm2 on monolayers of TSt-4 cells expressing Notch ligands DLL1 or 
DLL4 or monolayers of OP-9/DL1. After addition of CD34+ cells, media were supplemented 
with human interleukin (IL)-7, stem cell factor (SCF) and FMS-like tyrosine kinase 3 ligand 
(Flt3-L, Miltenyi). Co-cultures were refreshed by half medium change 3 times per week. 
During the first week, 50ng/ml and from the second week onwards, 5ng/ml of each cytokine 
was added to the cultures. Differentiating cells were transferred to fresh monolayers every 
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week. For transfer, cells were separated from the monolayers by disruption of the monolayers 
using cell scrapers (BD), resuspension by pipetting, and filtration through a 70µm mesh (BD) 
directly onto the new monolayer. Co-cultures were maintained for 7 weeks.
Feeder-free culture
Non-tissue culture-treated culture plates (Falcon, BD) were incubated for 1h at RT with 10μg/
ml rabbit anti-human IgG Fc antibody (Jackson ImmunoResearch Laboratories, West Grove, 
PA, USA) and subsequently with DLL4:Fc (Sinobiological, Beijing, China) diluted in PBS for 
1h. For the second protocol, non-tissue culture-treated culture plates (Falcon) were incubated 
overnight at 4°C with DLL4:Fc diluted in PBS together with 5ug/ml RetroNectin (r-fibronectin 
fragment CH-296, Takara Shuzo, Otsu, Japan), washed extensively, and further incubated for 
at least 1.5h with 2% human serum albumin diluted in PBS. CD34+CD38-/dim cells were seeded 
at a density of 3.9×103 cells/cm2 and cultured in RPMI 1640, αMEM or Stemspan SFEM II 
medium (Stemcell Technologies, Grenoble, France) with or without L-ascorbic acid (L-AA) 
or 2-phospho-L-ascorbic acid (ph-AA, Sigma-Aldrich Co.) supplementation. Co-cultures 
were refreshed by half medium change 3 times per week and weekly exposed to fresh DLL4:Fc 
and fibronectin. All cultures were supplemented with human IL-7, SCF, Flt3-L (all 50ng/ml) 
and 100ng/ml thrombopoietin (TPO, all Miltenyi). Cultures were maintained for 5 weeks.
For experiments depicted in Fig. 4A, cultures were supplemented with 1mM N-acetyl-L 
cysteine (NAC), 20nM sodium selenite (Selenite) or 200µM αTocopherol acetate (αTocopherol, 
all Sigma Aldrich). Concentrations were selected based on Esteban et al. 28. For experiments 
depicted in Fig. 4D and E, cultures were supplemented with 5mM NG-monomethyl-L-
arginine-monoacetate salt (L-NMMA, Abcam, Cambridge, UK).
Flow cytometry
In vitro cultured cells were stained at indicated time points. Cells were incubated with 
antibodies at proper dilutions for 20min at RT. Staining for cytoplasmic CD3 was performed 
by first permeabilizing cells using permwash (BD). 
The following antibodies were used: CD4 (SK3), CD7 (M-T701), CD45 (HI30), TCRαβ (IP26, 
eBioscience, San Diego, CA, USA), CD38 (HB7) and CD197 (CCR7, 150503, R&D systems, 
Minneapolis, USA), all FITC-labelled; CD1a (HI149), CD7 (M-T701), CD8 (RPA-T8), CD18 
(Integrin β2, MEM-48, Immuno tools, Friesoythe, Germany), CD34 (8G12), CD45 (HI30), 
CD127 (M21), CD135 (4G8). CD162 (P-Selectin glycoprotein-1, PSGL-1, KPL-1) and CD183 
(CXCR3, 205410, R&D systems, Minneapolis, MN, USA), all PE-labelled; CD3 (SK7), CD4 
(SK3), CD8 (SK1), CD45 (2D1) and CD196 (CCR6, 53103, R&D systems), all PerCP-labelled; 
CD199 (CCR9, 112509), Alexa Fluor 647-labelled; CD3 (UCHT1), CD5 (UCHT2), CD45 
(2D1), CD110 (REA250, Miltenyi), CD117 (A3C6E2, Miltenyi), CD184 (CXCR4, 12G5) 
and CD197 (CCR7, 150503, R&D systems), all APC-labelled; CD29 (Integrin β1, TS2/16, 
Biolegend, San Diego, CA, USA), APC-Cy7-labelled; CD8 (RPA-T8), CD56 (B159) and 
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CD45 (HI30), all Horizon V450-labelled. For apoptosis detection, PE Annexin V Apoptosis 
Detection Kit was used. All antibodies, materials, and equipment were obtained from BD 
Biosciences, unless stated otherwise. A minimum of 20,000 cells per sample was measured 
with the flow cytometer Canto II (BD). Flow cytometric analysis was performed with BD 
FACS DIVA software version 6.1.2 (BD) or FlowJo software version 10.0.6 (Treestar, Ashland, 
OR, USA). Living cells were gated on forward and sideward scatter pattern with subsequent 
doublet removal.
PCR
Genomic DNA was extracted from cells using QIAamp DNA mini kit according to 
manufacturer’s protocol (Qiagen, Venlo, the Netherlands). PCR was performed in 20μl reaction 
volume containing 60ng DNA from progenitors cultured in the presence of DLL4:Fc, T cells 
from peripheral blood, CD34+ cells or CD34+ cells cultured with RetroNectin (Takara Shuzo) 
only. All PCR components were used according to manufacturer’s instructions (iTaq, BioRad, 
Hercules, CA, USA) together with 500nM of each primer (Eurogentec, Liege, Belgium). Dδ2-
Jδ1 and Vδ1-Jδ1 primers are described in Dik et al. 12. Annealing temperature of 65°C with 
3mM MgCl2 and 35 cycles were used for both primer sets. EZ load 100bp Molecular Ruler 
(Biorad) was used as marker. Dβ1.1-Jβ1.3 primers are described in Kato et al.15. Annealing 
temperature of 60°C with 1.5mM MgCl2 and 35 cycles were used. Gene ruler 100bp plus DNA 
ladder (Fermentas Thermo Scientific) was used as marker. 
Statistical analysis
Data are presented as median. All statistical analyses were performed using the Prism program 
(GraphPad Software Inc, San Diego, CA, USA). Differences between experimental conditions 
were evaluated for statistical significance with non-parametric Wilcoxon matched pairs test 
or with Mann-Whitney U test. Significance was accepted at the level of p<0.05, * p=0.01-0.05, 
**p=0.01-0.001, *** p<0.001.
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Results
Generation of CD7+ proT cells from human CD34+ cells in a feeder-free system
To evaluate the T cell differentiation potential of CD34+ cells in a system without feeder cells, 
optimal culture conditions were first determined. CB CD34+ cells were initially cultured in the 
presence of αIgG-Fc and surface-immobilized DLL4:Fc in RPMI medium as was established 
by Ikawa et al. 24. Phenotype and fold expansion of T cell progenitors were defined after 3 and 
4 weeks of culture. The optimal concentration of DLL4:Fc was found to be 5µg/ml resulting 
in the highest percentage and number of CD7 expressing cells (Fig. 1A, Supplemental Fig. 1). 
To further improve maturation of T cell progenitors, different coating protocols were tested. 
Coating with r-fibronectin fragment CH-296 (fibronectin, 5µg/ml, 29) and DLL4:Fc resulted 
in higher CD7 expression (93%) compared to the combination of rabbit-anti-human IgG-Fc 
antibody with DLL4:Fc (61%, Fig. 1B). Additionally, fold expansion in the fibronectin DLL4:Fc 
condition was 5 times higher than in the IgG condition. Therefore, in further experiments 
5µg/ml DLL4:Fc in combination with 5µg/ml fibronectin was used.
The stromal cell lines TSt-4/DLL4 15, 30 and OP-9/DL1 31 are known to support T cell 
differentiation and are always cultured in RPMI and αMEM, respectively. We therefore decided 
to compare the influence of these media on human T cell differentiation in the feeder-free 
culture (Fig. 1C and 1D). Although similar percentages of CD7+ and iCD3+ cells were present 
in both conditions, CD5+ proT2 cells were only abundantly present in αMEM (median 88%). 
Furthermore, CD7+CD1a+ preT cells were only present in αMEM medium (median 7%). In 
addition, fold expansion of T cell progenitors was 10 times increased in αMEM compared to 
RPMI after 3 weeks of culture (Fig. 1E). Fold expansions varied among different donors, but 
similar trends were observed in all experiments. Taken together, our data indicate that both 
T cell maturation and proliferation were improved in αMEM medium compared to RPMI.
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Figure 1: T lineage development of CD34+CD38-/dim CB cells after exposure to immobilized Delta-
like ligand 4 in a feeder-free culture. CB derived CD34+CD38-/dim cells were cultured in RPMI medium 
without feeder cells. Culture plates were coated with different concentrations of DLL4:Fc (µg/ml) and 
αIgG. A: Percentage and absolute number of CD7+ cells after 3 and 4 weeks of culture are shown. B: 
Percentage of CD7+ cells and expansion after 3 weeks of culture with 5µg/ml DLL4:Fc and αIgG or 5µg/
ml DLL4:Fc and fibronectin in RPMI medium are shown. Representative results of 2 experiments are 
shown. C and D: Representative flow cytometry plots (C) and percentages of n=8 experiments (D) 
shows early T cell marker expression after 3 weeks of culture in the DLL4:Fc fibronectin culture in RPMI 
or αMEM. Wilcoxon matched pairs test; p=ns for CD7, **p=0.0078 for CD7iCD3, **p=0.0078 for 
CD7CD5, *p = 0.014 for CD7CD1a. E: Fold expansion of total cells in the feeder-free culture in both 
media in the presence of DLL4:Fc fibronectin is shown. Wilcoxon matched pairs test; *p=0.0156 for 
week 2 and *p=0.0156 for week 3 (n=7).
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Ascorbic acid promotes proT1 to proT2 differentiation in the feeder-free system
Since proT2 (CD7+iCD3+CD5+) cells could develop in a feeder-free system in αMEM, but 
were almost absent in RPMI medium, the composition of both media was compared to 
reveal compounds possibly accounting for this discrepancy. The addition of different types 
or higher percentages of foetal bovine serum (FBS) to RPMI medium did not result in the 
expression of CD5 or CD1a on progenitor cells (data not shown). Another difference in 
medium composition is the presence of L-ascorbic acid (L-AA) in αMEM and its absence in 
RPMI. The natural occurring L-AA is highly unstable to atmospheric oxygen, pH, light and 
temperature 32. Therefore, the more stable form of AA, 2-phospho-L-ascorbic acid (ph-AA), 
in which a hydroxylgroup is substituted by a phosphate group, was also tested 32. To determine 
the influence of AA on T cell development, different concentrations of L-AA and ph-AA 
were added to RPMI medium and compared to αMEM (containing 284µM L-AA). CD7 
expression was slightly influenced by the addition of AA, as almost all progenitors expressed 
CD7 to a similar extent in both L-AA and ph-AA conditions after 3 weeks (Fig. 2A and 
Supplemental Fig. 2B). In contrast to CD7, the intracellular CD3 (iCD3) expression on cells 
differed substantially between αMEM and RPMI conditions (85% versus 41% iCD3+ cells, 
respectively). Strikingly, addition of both L-AA and ph-AA led to a concentration-dependent 
increase of CD5 expression on CD7+ cells. The highest percentage of CD5+ cells was present 
in the condition with 95μM ph-AA (75%). Cell proliferation substantially increased by 
the addition of AA to RPMI (Fig. 2B and Supplemental Fig. 2B), without influencing cell 
viability (Supplemental Fig. 3). Interestingly, L-AA revealed a higher toxicity compared to 
ph-AA since all cells in the presence of the highest concentration died within 1 week. Taken 
together, 95µM ph-AA was the most optimal tested concentration for both maturation and 
proliferation in the feeder-free cultures, leading to high expression of iCD3, CD5, and CD7. 
Characterization of feeder-free derived T cell progenitors
The chemokine receptor and integrin profile of generated T cell progenitors was determined 
to gain insight into the thymus-homing capacity of these cells. Expression of selected markers 
on feeder-free generated T cell progenitors was compared to TSt-4/DLL4 derived T cell 
progenitors after 3 weeks of culture. We have previously shown that the TSt-4/DLL4 derived 
progenitors are able to home to the thymus and complete T cell development in the thymi of 
immune deficient mice 11. Feeder-free generated T cell progenitors expressed the chemokine 
receptors described to be necessary for thymus homing capability. Most of the tested 
chemokine receptors had higher expression on feeder-free derived progenitors than on TSt-
4/DLL4 co-culture derived progenitors, especially CCR4, as well as the adhesion molecules 
needed for thymus entry, integrin β1, β2 and PSGL-1 (Fig. 2C). In contrast, CCR7 was lower 
expressed on feeder-free progenitors than on co-culture derived progenitors. 
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Figure 2: Ascorbic acid promotes preT cell development from CD34+CD38-/dim cells in the feeder-
free culture in the presence of DLL4:Fc and fibronectin. CD34+CD38-/dim cells were cultured for 3 
weeks in the presence of DLL4:Fc and fibronectin in RPMI medium supplemented with ph-AA or L-AA 
in different concentrations and in αMEM. A: Representative T lineage marker expression (n=2) and 
fold expansion (B) of total cells is shown, median of n=7, Wilcoxon matched pairs test p<0.0156. C: 
Chemokine receptor, integrin and PSGL-1 profile of feeder cell free derived progenitor cells and TSt-4/
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DLL4 feeder derived progenitors compared to unstained corresponding cells after 3 weeks of culture, 
values are normalized to event count. Representative plots of feeder-free (n=2) and feeder culture (n=4). 
D: D and B gene rearrangement of peripheral blood CD3+ T cells (positive control), CB CD34+CD38-/dim 
cells cultured with fibronectin (negative control) or fibronectin and DLL4:Fc in αMEM, RPMI, RPMI 
ph-AA or RPMI L-AA medium. Results for Dδ2-Jδ1,Vδ1-Jδ1 and Dβ1.1-Jβ1.3 are shown.
Next, TCR rearrangement was analysed to assess the maturation status of generated T cell 
progenitors in feeder-free derived progenitors cultured with αMEM or RPMI supplemented 
with L-AA or ph-AA. RPMI cultured progenitors only showed a weak Dδ-Jδ rearrangement 
band and no subsequent Vδ-Jδ rearrangement (Fig. 2D), while αMEM grown progenitors 
show both Dδ-Jδ and Vδ-Jδ rearrangement. Upon addition of L-AA or ph-AA to RPMI, 
progenitors showed rearrangement of both Dδ-Jδ and Vδ-Jδ, confirming the different 
maturation stage of T cell progenitors in the presence or absence of AA. In contrast to positive 
controls, 2 products were amplified from the DNA of progenitor cells. Sequence analysis had 
previously demonstrated that the larger products are partial rearrangements of the δ-locus 11. 
Rearrangement of the TCRβ locus was present in cells cultured with αMEM and RPMI with 
AA; in contrast, in RPMI conditions only a germline band was detected. Together, these data 
confirm that T cell development is further advanced in conditions with AA.
Ascorbic acid promotes T cell development in a GMP culture setting 
Besides CB CD34+, G-CSF mobilized CD34+ cells are often used in clinical HSCT due to the 
high numbers of cells that can be obtained, and as such also available for adoptive (progenitor) 
T cell therapy. Therefore, mCD34+ cells were cultured in the presence and absence of ph-AA. 
After three weeks of culture, the majority of mCD34+ cells had upregulated CD7 and iCD3 
(Fig. 3A). Furthermore, a clear cell population co-expressing CD5 and CD1a was observed, 
whereas in culture without AA, cells expressed less CD7 (maximal 52%), less iCD3 (maximal 
22%) and were unable to upregulate CD5 (Fig. 3A). Expansion of G-CSF mobilized progenitors 
was only detected in the presence of ph-AA (median 4 folds), albeit lower than of CB cells 
(Fig. 3B). Together, the positive influence of AA on T cell proliferation and maturation was 
clearly observed.
To examine T cell development in feeder-free good manufacturing practice (GMP) 
conditions, CB CD34+ cells were cultured in serum-free medium (Stemspan®) with or without 
95µM ph-AA. In general, less T cell progenitors (CD7+) developed in Stemspan® medium 
compared to the serum containing media. The addition of ph-AA to the culture increased 
the percentage of CD7, iCD3 and CD5 expression (Fig. 3C). CD1a expression was hardly 
influenced. Furthermore, expansion of total cells was positively influenced by the addition of 
ph-AA (504 to 4,648 fold, Fig. 3D). Thus, CB CD34+ stem cells can be expanded in serum-free 
medium under the positive influence of AA. 
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Figure 3: Ascorbic acid promotes T cell development in a GMP culture condition. A: T cell progenitor 
marker expression and fold expansion (B) of G-CSF mobilized CD34+CD38-/dim cells after 3 weeks of 
DLL4:Fc fibronectin culture in RPMI or RPMI with 95µM ph-AA. Median of n=2 and n=6 with 2 and 
4 different donors, respectively, for RPMI and RPMI ph-AA are shown. C: T cell progenitor marker 
expression and expansion (D) of CB CD34+CD38-/dim cells in Stemspan® medium with and without 
95µM ph-AA. Representative results of n=2 are shown.
Other antioxidants than AA lack the potential to drive preT cell development
To investigate whether the effect of AA on T cell maturation was due to its antioxidant function, 
four other antioxidants were tested (Fig. 4A). CD7 and iCD3 expression were minimally 
influenced by the addition of the different antioxidants compared to RPMI. Interestingly, 
CD5 co-expression was also similar to standard RPMI and did not increase upon addition 
of different antioxidants than ph-AA. Furthermore, antioxidants other than AA did not have 
a positive influence on expansion of the progenitor cells (Fig. 4B). Taken together, from the 
investigated antioxidants, only AA was able to drive preT cell development. 
Cytokine receptor expression is not altered in the presence of AA
To examine whether the influence of AA on maturation and proliferation of T cell progenitors 
was due to alterations of cytokine receptor expression, the receptors of cytokines provided 
to the culture were analysed in the presence or absence of ph-AA. The expression of CD110 
(TPO Receptor), CD127 (IL-7 Receptor α) and CD135 (Flt) were not differentially expressed 
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upon addition of ph-AA to the culture (Fig. 4C). Although CD117 (SCF Receptor) expression 
differed between the conditions, when evaluating proT1 (CD7+CD5-) and proT2 (CD7+CD5+) 
progenitors separately, no difference was observed (Fig. 4C). Therefore, the difference in 
expression of the whole population can be explained because the RPMI culture contains more 
proT1 cells that express more CD117.
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Figure 4: Mechanism of action of ascorbic acid on T lineage differentiation of CB CD34+CD38-/dim 
cells in the feeder-free culture in the presence of DLL4:Fc and fibronectin. A: Flow cytometric analysis 
of CD7, iCD3, CD7CD5 expression on CB derived progenitor cells and fold expansion (B) after 3 weeks 
of DLL4:Fc fibronectin culture in the presence of different antioxidants. C: Flow cytometric analysis 
of CD110, CD127, CD135 and CD117 expression on CB derived progenitor cells cultured in RPMI or 
RPMI ph-AA. Representative data of n=5 are shown. D: Flow cytometric analysis of CD7, iCD3, CD5 
and CD1a expression on CB derived progenitor cells in the presence of ph-AA and L-NMMA after 2 
weeks of culture. Mann Whitney U test, n=4, *p<0.05 and corresponding fold expansion after 3 weeks 
of culture (E).
Blockage of the citrulline/NO cycle results in less T cell progenitor development
Since AA has been shown to increase nitric oxide (NO) production in endothelial cells 33 and 
because NO is involved in the differentiation of T helper cell populations 34-35, the role of the 
citrulline/NO pathway 36 was investigated during early T cell development. NG-monomethyl-
L-arginine-monoacetate salt (L-NMMA), an L-Arginine analogue that competitively inhibits 
nitric oxide synthase (NOS), was added to the culture in the presence of ph-AA. Blocking 
NO production resulted in less T cell development, indicated by significantly decreased 
percentages of CD7, iCD3, CD5 and CD1a expression compared to cells in the presence of 
ph-AA only (Fig. 4D). Furthermore, the positive effect on proliferation mediated by ph-AA 
was abolished in the presence of L-NMMA. These results hint for a role for the citrulline/NO 
pathway during T cell development driven by AA.
Ascorbic acid is a key factor in DP T cell development in feeder cell co-cultures
We have previously reported that development of mCD34+ cells is blocked at the pro/preT cell 
stage in co-culture with TSt-4/DLL 11. Since AA results in the progression of T cell maturation 
in the feeder-free system, the effect of AA was also investigated in the TSt-4/DLL4 co-culture 
system, which is normally performed in standard RPMI medium lacking AA. Our previously 
published results with mCD34+ cells were confirmed with CB CD34+ cells (Fig. 5A, upper 
panels). In the standard condition, CD7, iCD3 and CD5 were expressed but CD4, CD8, TCRαβ 
and CD3 were absent. Upon addition of L-AA, both CD5 and CD1a expression increased 
(Fig. 5A, lower panels). Interestingly, in contrast to the standard condition, iSP CD4+ (CD3-) 
cells were detected in the presence of L-AA (26%) together with a percentage of CD4+ and 
CD8+ DP cells (12%). TCRαβ+CD3+ cells were also present in the condition with L-AA (6%). 
Most of these cells were CD4+CD8+ positive as visualized after backgating. Moreover, CD4+ 
and CD8+ SP cells were present, in populations of 10 and 24%, respectively.
Since DP cells could develop in the TSt-4/DLL4 feeder cell system that never before showed 
support of DN to DP maturation, it was further studied if DP/SP cells could develop in the 
OP-9/DL1 co-culture system due to the presence of L-AA in αMEM medium. To this end, 
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different formulations of αMEM were used. Liquid αMEM without AA was supplemented 
with fresh L-AA to the same concentration present in the standard powder αMEM. Without 
L-AA, CD7+CD5+ cells developed, although less efficiently than in αMEM with L-AA (Fig. 
5B). Moreover, CD1a expressing cells were almost absent in the condition without L-AA. 
Additionally, only with the addition of L-AA, iSP (69%) and CD4+CD8+ DP cells were 
detected (27%). TCRαβ+CD3+ cells were also present (14%), most of these cells appear to be 
CD4+CD8+ DP (88%), even minor populations of CD4 and CD8 SP cells were detected of 10% 
and 2%, respectively. Strikingly, in both feeder cell cultures the full range of T cell development 
was only observed in the presence of AA indicating that AA is the crucial component that 
promotes maturation of T cells in vitro.
Feeder cells are not necessary to generate CD4+CD8+ DP T cells from HSCs
Since the development of DP T cells seems to rely on AA and not on feeder cells, later stages of 
T cell development were investigated in the feeder-free culture. In standard RPMI conditions 
CD4+CD8+ DP, TCRαβ or CD3 expressing cells could never be detected. In contrast, cells 
cultured in RPMI plus AA and αMEM did not arrest as preT cells expressing CD7, iCD3 
and CD5 but were able to upregulate CD4 and CD8 (7% for RPMI plus ph-AA or L-AA, 
Fig. 5C). Furthermore, a small population of TCRαβ+CD3+ cells was detected (2%). Together, 
these observations further indicate that feeder cells and feeder cell conditioned media are not 
necessary for generation of DP T cells from human stem cells.
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Figure 5: Effect of ascorbic acid on late T cell development in feeder cell co-cultures with TSt-
4/DLL4 or OP-9/DL1 cells and feeder-free culture with CB CD34+CD38-/dim cells. A and B: Flow 
cytometric analysis of T lineage markers of progenitor cells after 7 weeks of culture on TSt-4/DLL4 (A) 
and OP-9/DL1 (B) with and without ascorbic acid after 5 weeks of co-culture. CD4, CD8, CD3 and 
TCRαβ expression was analysed on CD7+ cells. TCRαβ+CD3+ population is backgated on CD8 and CD4 
expression. Representative plots of n=3 are shown. C: Flow cytometric analysis of CD4, CD8, CD3 and 
TCRαβ expression on CD7+ cells after 5 weeks of DLL4:Fc fibronectin culture of CB CD34+CD38-/dim in 
different media, RPMI, RPMI 95µM ph-AA and RPMI 285µM L-AA. Representative plots are shown 
(n=3 out of 9).
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Discussion and Conclusion
This study shows a pivotal role for ascorbic acid during in vitro human T cell development 
as it promotes proT1 to proT2 cell transition as well as progression from DN to DP T cells 
in both feeder and feeder-free cultures. Furthermore, we show that feeder cells or feeder cell 
conditioned media are not required for in vitro generation of DP T cells. Finally, AA has a 
beneficial role in the differentiation of mobilized and CB HSCs in serum-free medium. These 
findings might be of great importance for the development of an efficient clinical method for 
in vitro generation of T cell progenitors.
The effect of AA on early T cell development was studied in the feeder-free DLL4:Fc culture. 
CD34+ cells cultured in RPMI showed a block in the very early CD7+ proT1 cell stage. To 
our knowledge, only Reimann et al. 13 showed up to 10% CD5 proT2 expressing cells on 
immobilized DLL4 23, 29, 37 and it is unknown if the medium used contained AA. Culture 
medium has a major effect on T cell differentiation. Six et al. showed that fresh reconstituted 
αMEM medium from powder resulted in more DP T cells in the OP-9/DL1 co-culture 
system compared to ready-to-use αMEM 38. This observed effect could be due to AA, which 
decays rapidly 39. Fresh medium contains more AA that can have a beneficial effect on T cell 
development. Here, we confirm the influence of medium on T cell development since the 
proT2/preT cell (CD7+CD5+CD1a+) development occurred only in the presence of αMEM. 
By adding AA to RPMI medium, we show that AA is responsible for this effect. Ph-AA results 
in more T cell development and proliferation than L-AA. Ph-AA is taken up by the cells after 
phosphatases remove the phosphate group, after which it enters the cells as L-AA. The removal 
of the phosphate group is the rate limiting step in this process and therefore ensures that ph-
AA is available for the cells 32. Therefore, the influence of AA on T lineage development can be 
maintained longer. Our results thus show that addition of AA to the feeder-free culture results 
in more proliferation and improved T lineage development. We are able to culture a large 
population of CD7+CD5+CD1+ proT2/preT cells in the absence of feeder cells, while others 
mainly observed upregulation of CD7. 
Furthermore, we show that it is possible to generate T cell progenitors from G-CSF mCD34+ 
cells in the feeder-free system. The mCD34+ population is a highly clinical relevant population, 
since cell numbers obtained via G-CSF mobilization and subsequent leukapheresis are much 
higher compared to CB CD34+ cells (average ~35x106 and ~0.2x106 after CD34+CD38dim/neg cell 
sorting respectively). However, since CB cells can expand more than 1,000 fold, both CD34+ 
populations (patient dependent) can be a suitable source for adoptive T lineage therapy. 
However, preferred usage of each population in the clinic remains to be proven as the homing 
capacity, the maturation potential and the number of cell divisions in each population is likely 
to be different and has not been determined in the current study.
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The expression patterns of molecules important for thymus homing on feeder-free generated 
T cell progenitors largely resemble the phenotype of TSt-4/DLL4 derived T cell progenitors. 
Feeder-free generated T cell progenitors strongly expressed CCR4, CCR9, CXCR3, CXCR4, 
Integrin β1/β2 and PSGL-1, while CCR6 and CCR7 were slightly upregulated. Since, the 
feeder culture derived cell population is able to migrate to the thymus and give rise to fully 
mature T cells 11, it seems more than likely that also feeder-free generated T cell progenitors 
possess this capacity. Chemokine receptors, integrins and PSGL-1 are involved in migration 
and entry to and within the thymus, and can further be involved in maturation of T cell 
progenitors 40. CXCR4 has a role in cell egress from the bone marrow, the earliest step of 
migration to the thymus since anti-CXCR4 antibodies reduce stem cell migration (reviewed 
in reference 41). The key molecules involved in murine thymic settling are CCR7, CCR9 and 
PSGL-1, although the precise mechanism is not yet unravelled. Thymus seeding cells appear to 
require expression of CCR7, CCR9 or both for T lineage development 40. Therefore, it remains 
unknown whether the low CCR7 expression on our progenitor cells could be compensated by 
CCR9 or even by high PSGL-1 expression or other integrins. Additionally, in vivo experiments 
in immune deficient mice need to confirm the potency of the feeder free derived progenitor 
cells to home to the thymus and complete their maturation. 
Taken together, we are capable of generating proT2/preT cell precursors, confirmed with 
surface marker expression, chemokine receptor and integrin profile and TCR rearrangement 
pattern, in the presence of ascorbic acid and importantly without the use of any feeder cells. 
We earlier argued that these cells are the ideal population to inject into patients, because of 
their retained thymus homing capacity and further education in the thymus to prevent the 
emergence of auto-reactive T cells 11.
Because of the effectiveness of AA in the early T lineage stages, we also decided to investigate 
the role of AA in the later stages of T cell development. TSt-4/DLL and OP-9/DL1 feeder cells 
can support T cell development to a different extent. We argue, based on our results, that 
this is caused by different media used in these cultures and not because of unique properties 
of these feeder cells. Usually, cell lines and cultures are established in a particular medium 
without paying attention to its content. Indeed, the addition of AA to the TSt-4/DLL4 culture 
resulted in the generation of DP T cells, whereas the removal of AA from the OP-9/DL1 culture 
abrogated the capacity to produce DP and SP cells in these cultures. The effect of AA could 
be cell intrinsic on the feeder cells. However, we demonstrated that in the presence of AA 
DP T cells could develop from both CB and mCD34+ cells without any feeder cells. We thus 
show that feeder cells are not needed for differentiation, but that simple cues such as Notch 
signalling, cytokines, ascorbic acid and perhaps other fresh media components are sufficient 
to drive in vitro generation of DP T cells. However, more signals seem to be necessary for 
proper TCRαβ upregulation and the development of SP T cells in the feeder-free culture, for 
example, the presence of MHC molecules. MHC-tetramers, anti-CD28, anti-CD3 and OP-9/
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DL1 conditioned medium have been required for the generation of antigen specific cytotoxic 
CD8+ cells in the feeder-free system 42. This suggests that our current system could possibly 
be used for the generation of antigen specific T cells. All together these data suggest that the 
unique 3D thymus structure is not necessary for complete T cell differentiation. However, the 
thymus microenvironments facilitate positive and negative selection of generated thymocytes 
and ensure a broad T cell repertoire 43. 
Recently, Manning and colleagues demonstrated a role for AA in murine DP T lineage 
development 44. These data correlate well with our study using human cells, where we 
show an important role for AA not only in DP T lineage development, but also in early T 
lineage development. Manning et al. show that the effect of AA is likely through epigenetic 
modulation of gene expression, possibly via the enhancement of enzyme activity of methyl 
marks on regulatory regions of the DNA 44. Recently, others have shown that besides 
transcriptional regulation dynamic epigenetic regulations control T cell development in 
murine progenitor cells 45, 46. Our findings indicate that it is indeed not the general antioxidant 
function of AA that is likely to drive T cell development. However, based on our L-NMMA 
NOS blocking experiments, it seems likely that the citrulline/NO cycle plays a role during T 
cell development. To confirm this indication, extensive research has to be performed. Since 
AA has many mechanisms of action, it would be likely that not one mechanism solely can 
account for the enormous influence of AA on T cell development. Currently we are performing 
extensive molecular studies to further elucidate the mechanism by which AA induces T cell 
development, thus far a definite conclusion cannot be drawn. 
In conclusion, we unravelled an important role for AA during several steps of T cell 
development. Both CB and G-CSF mobilized CD34+ cells have the capacity to become preT 
cell progenitors in a well-defined, feeder-free culture in the presence of Notch ligands, defined 
cytokines, and AA. In this system, AA induces the transition from proT1 to proT2/preT cells 
and greatly enhances cell expansion. Moreover, DP cells develop as well. Furthermore, we 
show that only in the presence of AA, DP and even SP cells develop in co-culture with OP-9/
DL1 and TSt-4/DLL4. In the absence of AA in these feeder cultures, T cell progenitors arrest 
as CD4CD8 negative. Together, these findings indicate that feeder cells or co-culture derived 
conditioned media are not crucial to direct DP T cell development but that AA is a driving 
force in this process. 
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Supplemental information
Supplemental Figure 1: Gating strategy. Lymphocyte life gate based on SSC and FSC area. Removal of 
doublets based on FSC-h/FSC-w and SSC-h/SSC-w. When indicated, CD7+ cells were gated.
Supplemental Figure 2: Influence of ascorbic acid on T lineage development from CD34+CD38-/dim 
cells in the feeder-free culture in the presence of DLL4:Fc and fibronectin. A: CD7, iCD3, CD7CD5 
expression and fold expansion (B) of CB CD34+CD38-/dim cells after 2 weeks of culture in the presence of 
different L-AA or ph-AA concentrations (µM). Representative results are shown (n=2).
Supplemental Figure 3: Influence of ascorbic 
acid on viability of T cell progenitors in the 
feeder-free culture in the presence of DLL4:Fc 
and fibronectin. Percentage of Annexin V and 
7AAD positive cells cultured in the presence or 
absence of ph-AA are shown (n=3).
ME
M
 RP
MI
L-A
A 
94
.6
L-A
A 
28
3.9
L-A
A 
85
1.7
L-A
A 
25
55
.1
ph
-A
A 
94
.6
ph
-A
A 
28
3.9
ph
-A
A 
85
1.7
ph
-A
A 
25
55
.1
1
10
100
1000
Fo
ld
 e
xp
an
si
on
0 1000 2000 3000
0
20
40
60
80
100
M
%
  C
D
7C
D
5
0 1000 2000 3000
0
20
40
60
80
100
M
%
 iC
D
3
0 1000 2000 3000
0
20
40
60
80
100
M
%
 C
D
7
A
B
L-AA
ph-AA
MEM
An
ne
xin
 V
An
ne
xin
 V/
7A
AD
0
20
40
60
80
100
RPMI
RPMI ph-AA
Pe
rc
en
ta
ge
 o
f t
ot
al
Ascorbic acid promotes proliferation 
of NK cell populations in culture 
systems applicable for 
NK cell therapy
        6
Mirelle J.A.J. Huijskens, Mateusz Walczak, Subhashis Sarkar,
Florance Atrafi, Birgit L.M.G. Senden-Gijsbers, Marcel G.J. Tilanus, 
Gerard M.J. Bos, Lotte Wieten and Wilfred T.V. Germeraad
Submitted for publication.
142
                     
          6
Chapter 6
Abstract
Natural killer (NK) cell based immunotherapy is a promising treatment for a variety of 
malignancies. However, generating sufficient cell numbers for therapy remains a challenge. 
To achieve this, optimization of protocols is required.
Three different methods were used to study the influence of 2-phospho-L-Ascorbic Acid (AA) 
on NK cell generation. Mature NK cells were expanded from peripheral blood mononuclear 
cells (PBMCs) in the presence of OKT-3 and IL-2. NK cell progenitors were generated from 
CD34+ haematopoietic stem cells (HSCs) or from different T/NK cell progenitor populations. 
Generated NK cells were extensively phenotyped and functionality was determined by 
cytotoxicity assay. 
Addition of AA resulted in more proliferation of NK cells without influencing NK cell 
functionality. In more detail, PBMC derived NK cells expanded 2,362 fold (median, range 
90–31,351) in the presence of AA and were capable of killing tumour cells under normoxia 
and hypoxia. Moreover, HSCs derived NK cell progenitors matured faster in the presence of 
AA, which was also observed in the NK cell differentiation from early T/NK cell progenitors. 
These results demonstrate that mature NK cells proliferate faster in the presence of AA, 
resulting in higher cell numbers with accurate functional capacity, required for adoptive 
immunotherapy. In addition, these data suggest that also differentiation from different stem/
progenitor cell sources can be positively influenced by AA. 
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Introduction
Natural killer-cell based immunotherapy is a promising approach for treatment of 
malignancies. Natural killer (NK) cells can kill cancer cells without the need for prior direct 
sensitization 1-3 and without causing graft-versus host disease (GVHD) 4. NK cells are a subset 
of cytokine producing cytotoxic innate lymphoid cells that express CD56 and lack expression 
of CD3 4. A well-balanced mechanism to recognize and kill infected or malignant cells while 
tolerating healthy cells makes infusion of NK cells a feasible method to treat malignancies 5-6.
Preclinical and clinical studies have shown that, if infused in large numbers, NK cells can 
be used to eliminate malignant cells 7. Both autologous and allogeneic NK cells are able to 
effectively eliminate cancer cells in vitro 8, 9. Furthermore, it has been shown that IL-2 activated 
NK cells from patients are effective against autologous cancer cells in vivo in a mouse model 
10. The beneficial effect on prolongation of survival in a tumour-bearing mice model has been 
demonstrated to be dependent on the number of infused syngeneic NK cells 11. Although 
infusion of autologous NK cells is shown to be safe, only limited efficacy is shown in several 
clinical trials 7, 12, 13. A more powerful approach proposed by Ruggeri and colleagues showed 
that allogeneic NK cell transfer leads to higher tumour cytotoxicity in acute myeloid leukemia 
because of KIR-ligand mismatching, which lowers the activation threshold of NK cells 14-15. 
Similar effects have also been seen in responses to solid tumours in both a mouse model and 
in patients 16, 17. Taken together, adoptive NK cell studies demonstrate the possibilities of NK 
cell therapy for a variety of cancers but many indicate the necessity of sufficient cell numbers 
because of limited in vivo responses 18-19.
NK cells for immunotherapy can be derived from several sources, e.g. from peripheral blood, 
(induced) stem cells, cord/placental blood or bone marrow. Clinical studies using enriched 
peripheral blood NK cells show that it is not possible to produce sufficient numbers of NK 
cells, with the right purity and state of activation 20, 21. To overcome this problem, in vitro 
expansion of NK cells is currently under investigation. Different methods for expansion have 
been developed to obtain NK cells for infusion, which is extensively reviewed by Cheng et al. 
7. Although great improvements in different methods of NK cell expansion and generation 
have been achieved, for example with certain cytokine cocktails and culture instruments, 
clinical success is still limited indicating that it is critical to search for additional approaches 
to improve NK cell maturation and/or proliferation to obtain sufficient numbers of properly 
selected NK cells for immunotherapy 7, 19. Besides the number of NK cells, also purity of the 
NK cell product (to prevent GVHD), culture time (reducing cost of the clinical product) and 
phenotype of the NK cells are important areas for improvement. The latter is essential since 
we showed in multiple myeloma and in breast cancer that KIR-ligand mismatched NK cells 
are much more efficient in eliminating tumour cells than matched NK cells 16, 22. However, to 
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obtain sufficient numbers of this relatively infrequent NK cell population requires efficient ex 
vivo expansion. 
Previously, we have shown that T/NK cell progenitors can develop from HSCs in co-
culture with feeder cells 23. In another recent study, we have demonstrated that especially 
phosphorylated ascorbic acid (AA) has a positive effect on T/NK cell progenitors; T(/NK) 
cell progenitors mature further and, importantly, proliferate faster in the presence of AA 24. 
Therefore, we hypothesized in the current study that AA can be used to improve ex vivo NK 
cell expansion protocols. To test the hypothesis, three different culture methods were applied.
In the first method, mature NK cells are expanded from peripheral blood mononuclear cells 
(PBMCs). In the second method, HSCs are cultured with feeder cells in NK cell skewing 
conditions. In the third method, NK cells are generated from T/NK cell progenitors 23. 
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Materials and Methods
Cell lines
TSt-4 cells, an earlier gift of Prof. dr. H. Kawamoto (Kyoto University, Japan), were grown 
in standard RPMI 1640 medium (Sigma-Aldrich Co., St. Louis, MO, USA) containing 5% 
FBS (Greiner bio one, Kremsmuenster, Austria), 1% penicillin-streptomycin, 1mM sodium 
pyruvate, 0.1mM MEM non-essential amino acids, and 5×10−5M 2-mercaptoethanol (all from 
Invitrogen Ltd., Paisley, UK), referred to as complete RPMI medium. K562 cells (ATCC) 
were cultured in RPMI 1640 medium (Gibco, Breda, the Netherlands) supplemented with 
10% FBS (Integro, Zaandam, the Netherlands), 100U/ml penicillin (Gibco) and 100mg/ml 
streptomycin (Gibco). All cultures were maintained at 37⁰C in humidified air containing 5% 
CO2. 
NK cell expansion from PBMCs 
Peripheral blood mononuclear cells (PBMCs) were isolated from healthy adult donors using 
Lymphoprep (Axis Shield, Oslo, Norway). PBMCs, containing NK cells, were expanded in 
CellGro SCGM medium (CellGenix, Freiburg im Breisgau, Germany) supplemented with 5% 
human serum (BioWhittaker Lonza, Basel, Switzerland), 1000U/ml penicillin and 100mg/
ml streptomycin (Gibco), 10ng/ml anti-CD3 monoclonal antibody (OKT-3) and 1000IU/
ml IL-2 (both from Miltenyi, Bergisch Gladbach, Germany). Cells were cultured in 6-well 
plates in a humidified incubator at 37⁰C, 5% CO2, with an initial total culture volume of 2ml/
well with a total number of 2x106 cells/well. Parts of the cultures were supplemented with 
50µg/ml AA, a dose determined previously 24. Every 3-4 days medium was refreshed together 
with addition of freshly prepared AA. When required, cells were counted and replated to the 
starting concentration. The cultures were maintained for 3-4 weeks. 
Isolation of CD34+CD38-/dim haematopoietic stem cells
Both cord blood (CB) and G-CSF mobilized CD34+ cells were obtained at the Maastricht 
University Medical Center after informed consent in accordance with the Declaration of 
Helsinki and with approval of the local Medical Ethical Committee (METC 12-2-044) and 
used in experiments depicted in Figures 3 and 4. Mobilized CD34+ cells were obtained from 
healthy volunteers treated with G-CSF (Neupogen, Amgen, Thousand Oaks, CA, USA). 
Mononuclear cells (MNCs) were isolated from the CB using Lymphoprep (Axis Shield, Oslo, 
Norway) density gradient centrifugation. CD34+ cells were enriched using immunomagnetic 
beads according to the manufacturer’s instructions (Miltenyi). CD34+CD38-/dim haematopoietic 
stem cells from both sources were further purified and depleted from contaminating T and 
NK cells by fluorescence-activated cell sorting using the FACS ARIA (BD, Erembodegem, 
Belgium). For cell-sorting, the following antibodies were used: fluorescein isothiocyanate 
(FITC)-anti-CD38, phycoerythrin (PE)-anti-CD34, peridinin-chlorophyll proteins (PerCP)-
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anti-CD4, -CD8, -CD3 and allophycocyanin (APC)-anti-CD56 or horizon V450-anti-CD56 
(all antibodies from BD). Purity of both sources of CD34+ cells was more than or equal to 
98% CD34+ cells and less than or equal to 0.1% contaminating CD3/CD4/CD8 or CD56+ cells.
Generation of NK cell progenitors from haematopoietic stem cells
NK cell progenitors were generated from sorted CD34+CD38-/dim stem cells. Stem cells were 
co-cultured with TSt-4 feeder cells in complete RPMI medium supplemented with 10% 
FBS (Greiner Bio One), 100ng/ml SCF, 100ng/ml Flt-3L, 50 ng/ml TPO (all Miltenyi) and 
20ng/ml IL-15 (R&D systems, Minneapolis, MN, USA) in the first week of culture and 
subsequently with 50ng/ml TPO, 20ng/ml IL-15 and 200IU/ml IL-2 (Proleukin, Novartis, 
Basel, Switzerland). Parts of the cultures were supplemented with 50µg/ml 2-phospho-L-
Ascorbic acid (AA, Sigma-Aldrich Co.). Medium with cytokines and AA was refreshed every 
3-4 days. Cells were transferred on freshly prepared TSt-4 monolayers every 2 weeks.
Generation of NK cell progenitors from T/NK cell progenitors
NK cell progenitors were generated from T/NK cell progenitors as depicted in Supplemental 
Figure 3. T/NK cell progenitors were generated from sorted CD34+CD38-/dim cells on TSt-4/
DLL4 feeder cells in the medium supplemented with SCF, Flt-3L, TPO and IL-7 as described 
earlier 23. After 21 days of culture, CD7-CD5-, CD7+CD5- and CD7+CD5+ populations were 
separated by fluorescence-activated cell sorting using FACS ARIA (BD). Furthermore, CD56+ 
cells were depleted from all sorted populations. For sorting, cells were labelled with the 
following antibodies: CD7 (M-T701), CD5 (UCHT2) and CD56 (B159, all from BD). Purity 
of all sorted populations was higher than 97% (Supplemental Fig. 3). Sorted progenitors were 
co-cultured with TSt-4 feeder cells in the presence of 100ng/ml SCF, 100ng/ml Flt-3L, 50ng/
ml TPO and 20ng/ml IL-15 in the first week of culture and then with 50ng/ml TPO, 20ng/ml 
IL-15 and 200IU/ml IL-2. Parts of the cultures were supplemented with 50µg/ml AA. Medium 
was changed every 2-3 days with fresh supplements.
Flow cytometry analysis of NK cells and NK cell progenitors 
The following antibodies were used for phenotypic analysis of NK cells and NK cell 
progenitors: CD11a/LFA1 (HI111), CD16 (3G8), CD45 (HI30), CD57 (TB01, DAKO), 
CD158e/3DL1 (DX9, Miltenyi Biotec) all FITC-labelled; CD45 (HI30), CD158b (2DL2/3 
(Miltenyi), CD159c/NKG2C (134591, R&D systems), CD244/2B4 (R&D systems), CD253/
TRAIL (RIK-2.1, Miltenyi), CD335/NKp46 (9E2), all PE-labelled; CD45 (2D1) and CD159a/
NKG2A (Z199, Beckman Coulter), PerCP-labelled; CD45 (2D1), CD158a/2DL1 (143211, 
R&D systems), CD178/FASL (NOK-1, Miltenyi), CD184/CXCR4 (12G5), CD226/DNAM1 
(102511, R&D systems) CD314/NKG2D (BAT221, Miltenyi) all APC-labelled; CD45 (2D1) 
and CD3 (SK1) APC-Cy7-labelled; CD45 (HI30) and CD56 (B159) Horizon V450-labelled. 
Isotypes of the equivalent antibodies were used as control references. All antibodies, materials, 
and equipment were obtained from BD Biosciences, unless stated otherwise. Samples were 
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measured with the flow cytometer FACS Canto II (BD). Flow cytometric analysis was 
performed with BD FACS DIVA software version 6.1.2 (BD) or FlowJo software version 
10.0.6 (Treestar, Ashland, OR, USA). Living cells were gated on forward and sideward scatter 
pattern with subsequent doublet removal.
Cytotoxicity assay 
The cytotoxic potential of NK cells was determined in a kill assay as described previously 
25. K562 target cells were labelled with 3,3’-Dioctadecyloxacarbocyanine perchlorate (DiO, 
Sigma-Aldrich Co.). Both effector and target cells were individually pre-incubated for 14-16h 
at 21% or 0-2% O2 and subsequently combined at different effector to target ratios (E:T) in 
96-well round-bottom plates in duplicate. After 4h, samples were measured with the FACS 
Canto II (BD) and cell death of DiO+ target cells was measured with propidium iodide (PI, 
Sigma-Aldrich Co.). Specific cytotoxicity was determined by the equation: (% PI+ target cells 
- % spontaneous PI+ cells) / (100 - % spontaneous PI+ cells) *100. The cytotoxic potential of 
NK cell progenitors was only studied in normoxic conditions.
Statistical analysis
Data are presented as median. All statistical analyses were performed using the Prism program 
(GraphPad Software Inc, San Diego, CA, USA). Differences between experimental conditions 
were evaluated for statistical significance with the non-parametric Wilcoxon matched pairs 
test. Significance was accepted at the level of p<0.05 and indicated with * and p<0.01 with **.
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Results
Ex vivo expansion of NK cells is enhanced by addition of ascorbic acid
To investigate whether ascorbic acid (AA) has an effect on the proliferation of mature NK 
cells, NK cells from total PBMCs were expanded in the presence of AA, IL-2 and OKT-3 
(anti-CD3). At the start of the culture, 2.9 to 20.4% of CD56+ cells were present (Fig. 1A and 
B). Although variation existed among different donors, the percentage of CD56+ cells for all 
donors in both conditions was higher at day 21 of the culture compared with day 0 (Fig. 1B). 
Generally, two different culture phenotypes were observed. One resulted in a high percentage 
of NK cells, while the other showed comparable percentages of CD3+ cells and CD56+CD3+ 
cells (Fig. 1A-B). Addition of AA did not influence the percentage of CD56+ NK cells as 
compared to day 21 in the absence of AA. However, NK cells proliferated more efficiently 
in the presence of AA and the total fold expansion (number of NK cells at day 21 / number 
of NK cells at day 0), was higher in AA supplemented cultures than in cultures without AA 
(Fig. 1C; p=0.0156). In summary, these data show that AA improves ex vivo proliferation of 
mature NK cells resulting in a 2,362 fold (median, range 90–31,351) expansion of NK cells in 
three weeks of culture.
Ex vivo expanded NK cells produced in the presence of ascorbic acid are functional
To characterize the functionality of ex vivo expanded mature NK cells, both phenotype and 
cytotoxic capacity of these cells were studied. Detailed analysis of several activation, inhibitory, 
functional, homing and maturation receptors was performed by flow cytometry on day 0 and 
day 21 of culture. Representative histograms from a selected donor for all analysed receptors 
are shown in Supplemental Figure 1. Expression of NKp46, CD16, KIR3DL1 and KIR2DL1 
were not influenced by in vitro culture (Fig. 2A). However, expanded cells expressed more of 
the activation receptors NKG2D, DNAM-1 and 2B4 compared to day 0 NK cells. Furthermore, 
higher percentages of NKG2C+ cells were present at the end of the culture. Additionally, higher 
percentages of CD56+ cells expressed the inhibitory receptor NKG2A, while the expression of 
KIR2DL2/3 differed after culture (Fig. 2A). Expanded NK cells were characterized by lower 
expression of CD57. Moreover, TRAIL, LFA-1, CXCR4 and LFA1 expression were increased 
on CD56+ cells after culture. Comparison of receptors present on NK cells cultured in the 
presence or absence of AA revealed that AA did not influence the phenotype of the expanded 
NK cells (Fig. 2A).
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Figure 1: Ascorbic acid enhances proliferation of mature NK cells. NK cells were expanded in vitro 
from PBMCs in medium supplemented with OKT-3 and IL-2 for 3 weeks in the presence or absence of 
AA. Percentage of CD56+CD3- NK cells and CD3+CD56- T cells on different days of culture from two 
representative donors are shown (A). Percentages of CD56+CD3- NK cells in the presence or absence of 
AA are shown (n=7, p=0.0156 D0 versus D21 control, p=0.0313 D0 versus D21 AA, B). Fold expansions 
of CD56+ NK cells generated in the presence or absence of AA on day 21 of culture are shown (n=7, 
p=0.0156, C).
The ex vivo expanded NK cells were able to efficiently lyse leukemic K562 cells and the amount 
of lysis was comparable for NK cells expanded with or without AA (Fig. 2B). For clinical 
application, NK cell products should be able to kill tumour cells in a suppressive tumour 
environment. Hypoxia is a tumour associated factor and we recently published that hypoxia can 
severely reduce the killing capacity of unactivated NK cells, but upon IL-2 activation, NK cells 
did kill tumour cells in the hypoxic environment 25. To investigate whether supplementation 
with AA influenced the killing capacity of NK cells, we performed killing experiments under 
normoxia and hypoxia. Also under hypoxic conditions, (IL-2) expanded NK cells were able 
to lyse target cells, indicating that expanded NK cells are efficient in eliminating tumour cells 
under more physiological conditions (Fig. 2C). There was no significant difference in the 
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cytotoxic capacity of NK cells cultured in the presence of absence of AA (Fig. 2C). 
Taken together, these data indicate that in the presence of AA during the expansion of NK 
cells, the phenotype was not influenced. Importantly, NK cells expanded in the presence of 
AA expressed all required receptors and were fully functional.
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Figure 2: NK cells expanded in the presence of ascorbic acid express all required activation 
and inhibitory molecules and are functional. NK cells were expanded from PBMCs in medium 
supplemented with OKT-3 and IL-2 and in the presence or absence of AA. After 3 weeks of culture, 
expanded NK cells were stained with phenotypic markers. Combined data from 4 different donors is 
shown. Significance is indicated with * for p<0.05 and ** for p<0.01 (A). Specific cytotoxicity of NK cells 
expanded with or without AA was measured on day 21 of culture. NK cell progenitors (effector) and 
K562 leukemic target cells were mixed in different E:T ratios and killing of target cells was measured 
after 4h incubation. Specific cytotoxicity of NK cells both under normoxia (21% O2, B) and hypoxia 
(0.2% O2, C) is shown, p values indicate no significant differences p=0.5 normoxia 1:1, p=0.75 normoxia 
1:10, p=0.85 hypoxia 1:1 and p=0.25 hypoxia 1:10.
Ascorbic acid improves the generation and expansion of NK cell progenitors from 
haematopoietic stem cells
Besides the expansion of mature NK cells, NK cells can also be generated from stem 
or progenitor cells. To investigate whether AA has an effect on the generation of NK cell 
progenitors from HSCs, NK cell progenitors were generated from CD34+CD38-/dim HSCs co-
cultured with TSt-4 feeder-cells in NK cell skewing conditions in the presence or absence of 
AA in two independent experiments. In the presence of AA, cells acquired CD56 expression 
faster compared to the cells cultured without AA. After 28 days of culture, 60.1% of all (life-
gated) cells were CD56+ cells in the presence of AA while only 10.8% were CD56+ without AA 
(Fig. 3A, Supplemental Fig. 2). After 35 days of culture, the vast majority of cells expressed 
CD56 (78.3%) in the presence of AA, while the percentage of CD56+ only marginally 
increased to 15.8% in the absence of AA. Furthermore, NK cell progenitors generated in the 
presence of AA had higher expression of activating receptors including NKp46 and NKG2D, 
while expression of inhibitory receptors (KIR2DL1, KIR2DL2/3, KIR3DL1 or NKG2A) 
was comparable in both conditions as indicated by mean fluorescence intensity (MFI, Fig. 
3B). Only in the presence of AA, a small population (2.7%) of KIR2DL2/3 was observed, 
suggestive of a more mature NK cell population. At day 35 of culture, AA supplementation 
had also resulted in a higher fold expansion (809 fold) of CD56+ NK cell progenitors (number 
of CD56+ cells at day 35 / number of CD56+ cells at day 0) compared to the control condition 
without AA supplementation (78 fold; Fig. 3C). These two independent experiments support 
our observation that AA enhances proliferation of NK cells. In addition, they suggest that 
AA positively influences maturation and proliferation of NK cell progenitors generated from 
HSCs.
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Figure 3: Ascorbic acid stimulates NK cell maturation and expansion from haematopoietic stem 
cells. NK cell progenitors were generated from CD34+CD38-/dim cells in co-culture with TSt-4 feeder 
cells. Maturation of NK cells was monitored by CD56 staining on different culture days in the absence 
(gray lines) or presence of AA (black lines) (A). Several activating and inhibitory receptors present on 
CD56+ cells were analysed with flow cytometry on day 35 of culture (B). Representative results of n=2 
are shown. Fold expansion of CD56+ cells after 35 days of in vitro culture is shown (C). 
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Ascorbic acid improves the generation of NK cell progenitors from T/NK cell 
progenitors
To provide further support for the beneficial role of AA in NK cell expansion systems, the 
influence of AA on the capacity to generate NK cell progenitors from T/NK cell progenitors 
was studied. T/NK cell progenitors were produced from HSCs in co-culture with TSt-4/DLL4 
feeder cells in two independent experiments. HSCs were first co-cultured with TSt-4/DLL4 
feeder cells in T cell skewing conditions. After 21 days of culture, three populations of T 
cell progenitors were sorted based on expression of CD7 and CD5 (CD7-CD5-, CD7+CD5- 
and CD7+CD5+) and were depleted of CD56+ cells. The purity of all obtained progenitor 
populations was higher than 97% (Supplemental Fig. 3). Hereafter, the different progenitor 
populations were cultured in NK cell skewing conditions. CD56+ NK cell progenitors were 
successfully generated from both CD7-CD5- and CD7+CD5- progenitors (Fig. 4A). Remarkably, 
NK cell progenitors could barely be generated from the most mature CD7+CD5+ population. 
Regardless of the presence or absence of AA, these progenitors died when cultured in NK 
cell skewing conditions. AA increased the percentage of CD56+ NK cell progenitors obtained 
from both early T/NK cell progenitor populations, especially from the most immature CD7-
CD5- population, as shown by analysis on different days during in vitro culture (Fig. 4A). The 
CD7+CD5- population already contained 42 and 60% of CD56+ cells at day 7, without and 
with AA, respectively. This percentage further increased to approximately 90% at the end of 
the culture for both conditions. At day 35, 22% and 94% CD56+ cells were generated from 
CD7-CD5- cells in the absence and presence of AA, respectively. 
Phenotypic analysis of generated NK cell progenitors from the CD7-CD5- and CD7+CD5- 
progenitors revealed that cells generated in the presence of AA expressed slightly more of the 
activating receptors NKp46 and NKG2D (Fig. 4B). Furthermore, AA increased expression 
levels of the inhibitory receptor NKG2A. The inhibitory receptors KIR2DL1 and KIR3DL1 
were not altered upon AA addition on CD56+ cells derived from both the CD7-CD5- and 
CD7+CD5- populations (Fig. 4B). Additionally, a small percentage of CD56+ cells (2-4%) 
was KIR2DL2/3+ in the presence of AA in both the CD7-CD5- and CD7+CD5- populations, 
suggestive of a more mature NK cell subset, while this population was absent without 
AA. Furthermore, proliferation of NK cell progenitors generated from the CD7-CD5- and 
CD7+CD5- progenitors was positively influenced by addition of AA. In the presence of AA, 
a 5-6 fold higher number of NK cell progenitors was generated as compared to the control 
condition without AA (Fig. 4C.) Moreover, generated NK cell progenitors whether cultured 
in the presence or absence of AA, were able to kill K562 leukemic cells (Fig. 4D), suggesting 
that AA does not alter NK cell functionality.
Together these data provide initial proof of concept that AA improves in vitro generation of 
NK cell progenitors from early CD7-CD5- and CD7+CD5- progenitors. In contrast, CD7+CD5+ 
cells can barely give rise to NK cell progenitors, regardless of AA supplementation.
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Taking the experiments on differentiation to NK cells from early progenitors (HSCs and CD7-
CD5- T/NK cell progenitors) provided in Figure 3 and 4 together, in four out of four experiments 
a positive effect of AA was observed (Supplemental Fig. 4; p=0.0286). This suggests that the 
positive influence of AA is not merely on proliferation but also on differentiation. 
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Figure 4: Ascorbic acid promotes NK cell maturation from T cell progenitors. NK cell progenitors were 
generated from different T cell progenitor populations in co-culture with TSt-4 feeder cells. Maturation 
of NK cells, in the absence (gray lines) or presence of ascorbic acid (black lines), was monitored by CD56 
staining on different culture days (A). Several activating and inhibitory receptors present on CD56+ cells 
were analysed on day 35 of culture (B). Representative results of 2 independent experiments and donors 
are shown. Expansion ratios of CD56+ cells generated in the presence of AA compared to control on day 
35 of culture are shown (C). Specific cytotoxic activity of NK cell progenitor generated with or without 
AA was measured on day 35 of culture. NK cell progenitors (effector) and K562 leukemic target cells 
were mixed in different E:T ratios and killing was measured after 4h incubation (D).
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Discussion and Conclusion
This study demonstrates an important role for phosphorylated ascorbic acid on the expansion 
of NK cells. We show that the expansion of NK cells from peripheral blood is significantly 
increased in the presence of AA, resulting in functional NK cells capable of killing tumour 
cells under normoxia and hypoxia. Based on this observation, we additionally investigated 
whether AA has a positive influence on NK cells generated from HSCs in two different 
systems. In the first system we observed that the generation of NK cell progenitors from 
HSCs in the presence of AA seemed faster, resulting in a more pure NK cell population and 
in 900 fold more NK cells compared to the condition without AA. In the second system, we 
observed that the earliest CD7-CD5- and CD7+CD5- populations, but not the more mature 
CD7+CD5+ population, can be used to efficiently differentiate into CD56+ NK cells capable of 
killing tumour cells. This generation, especially in the earliest T cell progenitor population, 
is greatly enhanced in the presence of AA. Although the sample size was limited, the data 
obtained in the latter two systems were in line with the data obtained with peripheral blood 
NK cells, further supporting the concept that AA has a positive effect on NK cell proliferation 
and suggesting a positive influence on NK cell differentiation. Together, these results indicate 
a positive role for AA in in vitro NK cell culture systems. Because AA is an inexpensive and 
readily available compound, our data provide proof of concept that AA supplementation can 
be an easy way to improve NK cell expansion protocols resulting in higher cell numbers as 
required for adoptive immunotherapy. 
Different culture methods for the production of NK cells for immunotherapy exist and are 
currently under investigation 7, 19. These methods can roughly be divided in mature NK cell 
products (e.g. PBMC derived) or immature NK cell products (e.g. from HSCs or progenitor 
cells). The expansion method for mature NK cells started with PBMCs cultured in the 
presence of IL-2 and OKT-3. While IL-2 can act on both T and NK cells, OKT-3 (anti-CD3) 
presumably first exerts its effect on the T cells present in the culture, that subsequently create 
a milieu favourable for NK cell expansion e.g. in a contact or cytokine dependent manner. 
T cells disappear from these cultures, likely due to exhaustion (Wieten et al., unpublished 
observations). In combination with a mature phenotype of the expanded cells and the ability 
of these cells to kill cancer cells, this population is suggested to be the most suitable for therapy. 
However, donor variation has to be taken into account. In our hands, expansions from some 
donors resulted in high NK cell percentages and relatively low CD3 T cell percentages, while 
others resulted in increased though less than 50% NK cells in the presence of high numbers 
of CD3+ T and CD3+CD56+ NKT cells. To prevent GVHD, CD3+ T cells should be excluded 
from the product. Nonetheless, AA improved expansion in all donors to an average of ~ 6,000 
fold. Others have shown in clinical trials that PBMC derived expanded NK cells are safe and 
capable of exerting anti-tumour effects 7. The benefit of using mature NK cell products is 
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that donor and patients can be mismatched for their KIR receptors, which is promising for a 
greater anti-tumour effect 26.
Because of the positive effect on mature NK cell expansion, we additionally investigated the 
influence of AA in other NK culture systems to find proof of concept. Also in directing cells 
in the NK cell lineage from both HSCs and T cell progenitors, a positive influence of AA 
was observed. On the one hand, it seems that addition of AA results in faster generation of 
NK cells; on the other hand, even after long culture in the absence of AA, less NK cells are 
observed. This suggests that AA makes more cells sensitive for differentiation into the NK cell 
lineage, possibly by increasing IL-15R expression on NK cells. However, in our previous study 
describing the effect of AA on T cell differentiation, we did not see receptor upregulation 
after AA treatment of the relevant receptors studied in that system 24. We therefore expect the 
mechanism to be more complicated than upregulation of cytokine receptors.
NK and T cells share a common progenitor 27. We previously showed that cells in a mixed T/
NK cell progenitor population derived from HSCs had the potency to become NK cells 23. In 
this latter study, the complete progenitor population was used. Here, we show that only the 
early CD7-CD5- and CD7+CD5- cells gave rise to expanding NK cell populations. Only very 
few NK cells derived from the CD7+CD5+ could be detected. These cells died within the first 
weeks of culture and were not able to expand, regardless of the presence or absence of AA. 
This suggests that these cells have lost most of their NK cell potential and are more committed 
to the T cell lineage compared to the more immature populations. It is believed that PreT 
cells, expressing CD7, CD5 and CD1a are T lineage committed 28. The NK cells observed in 
the culture could be impurities of CD56+ cells or developed from more immature T/NK cell 
progenitors that were still present in the culture. Another explanation is that the CD7+CD5+ 
stage is still heterogeneous and that only a minor fraction gave rise to NK cells; for example 
cells can further be divided based on iCD3, CD1a expression or T cell receptor rearrangement 
status 29.
Currently, NK cell progenitors produced from HSCs and T/NK cell progenitors are co-
cultured with feeder cells, which require selection of NK cells before clinical use in patients. 
We recently established a feeder-free culture system where in the presence of AA, T cells can 
be generated and adapting the growth factors to an NK cell skewing profile may likely be 
applicable 24. The high purity of the NK cells obtained in these systems due to the presence 
of AA is a great advantage. Moreover, in the presence of AA the expansion of NK cells from 
HSCs is increased by a 100 fold. The generated NK cells in these systems are still progenitors, 
since they do not express KIR receptors (except for minor populations <5% in the presence 
of AA). However, a recent study revealed that NK cells generated from HSCs in a clinical 
setting do have the capacity to inhibit growth of leukemic cells resulting in prolonged survival 
in a murine tumour model 30. Furthermore, it has been shown that CD34+ HSC-derived NK 
158
                     
          6
Chapter 6
cells do not show acute side effects upon injection in patients, unfortunately no anti-tumour 
activity of the NK cells was measured probably because of insufficient NK cell numbers 31. 
Another advantage of the generation of NK cells from HSCs is that a minor fraction of the 
same HSCs injected for HSCT in the patient could be used for the generation of NK cells 
minimizing the risk of rejection of the NK cells.
Regardless of the source or preparation of the NK cells, they have to be able to kill tumour cells 
in vivo. Since many years there have been investigations in the tumour microenvironment and 
abundant knowledge has been generated on escape mechanisms from the immune system by 
tumour cells. One of these factors of the tumour microenvironment is hypoxia, which has 
been shown to contribute to therapy resistance of malignant cells 32, 33. Previously, we showed 
that the killing capacity of NK cells is reduced under hypoxia, which can be restored by IL-2 
activation of the NK cells 25. Here, we show that IL-2 activated expanded mature NK cells kill 
cancer cells under hypoxia, also in the presence of AA, confirming the functionality in a more 
physiological relevant setting.
Others already succeeded in generating clinical grade NK cells applicable for therapy, as 
extensively reviewed by Cheng et al. 7. Media regularly used for NK cell expansions are 
Glycostem, RPMI 1640, DMEM and CellGro SCGM 7, 19. While in general some commercially 
available cell culture media already contain AA, most of the media used for NK cell expansion 
do not. Furthermore, if present, AA is in the non-phosphorylated form, which is less stable 
and has far less potency to stimulate cells to proliferate than the phosphorylated compound 
24, 34. Therefore, our observations strongly suggest the controlled addition of phosphorylated 
AA in any NK cell expansion system will be advantageous, and if already present, optimized 
concentrations are recommended. Potentially, this could result in faster expansion of NK cells 
resulting in higher yields of NK cells in a shorter culture time. This will lead to a marked cost 
reduction and the availability of a higher number of NK cells for immunotherapy. Our recent 
results show that only subpopulations of the NK cell pool (KIR-ligand mismatched NK cell 
subsets) are efficient effector cells 22. Because these subsets have a relatively low frequency, 
really high cell numbers are needed to be infused into patients. Fortunately, AA is available in 
clinical grade and could immediately be added to existing NK cell culture methods. 
In summary, AA promotes the proliferation of NK cell populations in different culture 
systems without affecting their functionality. These findings are relevant for the improvement 
of methods to generate sufficient NK cells for adoptive therapy.
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Supplemental information
Supplemental Figure 1: NK cells expanded in the presence of ascorbic acid express all required 
activation and inhibitory molecules. NK cells were expanded from PBMCs in the presence of OKT-
3 and IL-2 and in the presence (black lines) or absence of AA (grey lines). After 3 weeks of culture, 
expanded NK cells were stained with several phenotypic markers, one representative donor of n=7 is 
shown. Dotted line represents phenotype of NK cells at day 0.
Supplemental Figure 2: Gating strategy of NK cell generation from haematopoietic stem cells Cells 
were first gated on FSC and SSC area to select the lymphocyte population. Subsequently, doublets were 
removed in the FSC-H, FSC-W and SSC-H and SSC-W plots. Then, cells were gated on the expression 
of CD56.
Supplementary figure 1 – Huijskens et al. – Top
Supplementary figure 2 – Huijskens et al. – Top
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Supplemental Figure 3: Generation of different populations of T cell progenitors. Sorted 
CD34+CD38-/dim stem cells were co-cultured with TSt-4/DLL4 feeder cells for 3 weeks. On day 21 cells 
were stained with anti-CD7 and -CD5 antibodies and 3 different T cell progenitor populations were 
sorted: CD7-CD5-, CD7+CD5- and CD7+CD5+. All sorted populations were depleted of CD56+ cells. A 
representative pre-sort and post-sort purity of all three populations is shown (n=2).
Supplemental Figure 4: Ascorbic acid promotes differentiation towards NK cells from progenitor 
cells. Percentages of CD56+ cells generated from HSCs or early T/NK progenitors (CD7-CD5-) after 
35 days of culture in NK cell skewing conditions from experiments depicted in Figure 3 and 4 in the 
absence (control) or presence of AA. Experiments were combined and analysed resulting in n=4 and 
p=0.0286.
Supplementary figure 3 – Huijskens et al. – Top
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Abstract
Ascorbic acid (AA) has a crucial role in cellular immune responses. Patients treated with 
chemotherapy and/or haematopoietic stem cell transplantation (HSCT) have low immune 
cell counts for weeks to months. Meanwhile, patients are highly susceptible to infections 
resulting in high mortality. Here, we show that patients with a haematological malignancy, 
either treated with chemotherapy or with autologous/allogeneic HSCT, have highly significant 
reduced serum AA levels compared to healthy controls. It might be of clinical relevance to 
study the function and recovery of immune cells after treatment, its correlation to AA serum 
levels and the possible effect of AA supplementation.
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Introduction
Vitamin C or ascorbic acid (AA) is an essential water-soluble vitamin with many functions 
1,2 and has a crucial role in cellular immune responses 3. Patients treated with chemotherapy 
and/or haematopoietic stem cell transplantation (HSCT) have low immune cell counts for 
weeks to months 4. Especially allogeneic haplo-identical or cord blood transplantation results 
in a T cell regeneration time up to a year. Meanwhile, patients are highly susceptible to 
infections resulting in high mortality. We previously showed that human in vitro generated T 
cell progenitors home faster than stem cells to the thymus and mature completely in mice 5, 
making T cell progenitors an interesting therapy to prevent infections in such patients. While 
optimizing the in vitro T cell generation procedure, we recently discovered the importance 
of AA during this process 6. In the presence of AA, early haematopoietic progenitors commit 
and mature into T cells and proliferate faster. Moreover, we showed that AA enhances 
proliferation and maturation of NK cells 7. As AA has a major influence on (re)generation of 
immune cells, we executed an observational study in which AA serum values of patients with 
haematological malignancies treated with and without HSCT were compared with those of 
healthy volunteers.
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Materials and methods
Patients and controls
Basic patient characteristics are shown in Table 1. AA levels were measured in left-over serum 
samples of 42 non-selected haemato-oncology patients admitted to the hospital because of 
treatment or complications. Samples were taken of all patients admitted on the day routine 
blood samples are taken. Blood serum, as side product, does not need ethical approval in 
the Netherlands, under the Dutch Code for Proper Secondary Use of Human Tissue. The 
individuals from whom the samples originated did not object to their use, an option that is a 
standard procedure in our hospital. Results of blood samples (AA levels) were anonymous to 
the investigators except for one of the authors (GMJB) who - as part of the treating physicians 
team - was aware of the clinical conditions and AA levels of all the patients, so correlation of 
the parameters could take place. As control group, healthy volunteers working in the hospital 
donated blood samples for reference values for our laboratory. The AA levels measured were 
used for reference values for our hospital. These healthy donors agreed to donate their blood 
for research purposes and had signed an informed consent. This study was performed in 
accordance with the Declaration of Helsinki and according to the Dutch Code for Proper 
Secondary Use of Human Tissue 8.
Ascorbic acid measurements 
Serum AA was indirectly determined by measuring ferrous ion and 2,4,6-tris(2-pyridyl)-s-
triazine (Fe2+-TPTZ, Sigma-Aldrich). This reaction product is formed by nonspecific reduction 
of the corresponding ferric ion complex (Fe3+-TPTZ) by biological reducing agents such as 
AA at pH 3.6. AA was specifically quantified by pretreating one of a pair of replicate samples 
with the enzyme ascorbate oxidase (Sigma-Aldrich), oxidizing AA to dehydroascorbic acid, 
then reacting both samples with Fe3+-TPTZ and measuring the difference in absorbances 
at 600nm on the Cobas Mira Plus (Roche, Basel, Switzerland). The AA concentration was 
calculated from a standard addition curve with a 10µM detection limit.
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Table 1: Characteristic of the patients.
Patient characteristics HSCT Non-HSCT Total
n 26 16 42
Sex; male/female 15/11 7/9 22/20
Age; median (range), year 56.5 (39-72) 62.5 (40-71) 59 (39-72)
Disease
     AML 8 8 16
     ALL 2 2 4
     CML 1 1
     CLL 1 2 3
     DLBCL 1 1
     MM 6 6
     Myelofibrosis 1 1
     NHL 6 4 10
HSCT
     Autologous 10
     Allogeneic 16
GVHD 7
HSCT: Haematopoietic stem cell transplantation; AML: Acute Myeloid Leukaemia; ALL: Acute 
Lymphatic Leukaemia; CML: Chronic Myeloid Leukaemia; CLL: Chronic Lymphoid Leukaemia; 
DLBCL: Diffuse Large B Cell Lymphoma; MM: Multiple Myeloma; NHL: non-Hodgkin Lymphoma; 
GVHD: Graft versus host disease. The non-transplanted patients were all admitted for chemotherapy 
treatment, except for one patient with CLL that was treated with prednisone only. The patients with MM 
and autologous transplantation were conditioned with high dose Melphalan and the patient with NHL 
undergoing autologous transplantation received BEAM conditioning. All patients undergoing donor 
transplantation were treated with Fludarabine and low dose total body irradiation, with or without 
anti-thymocyte globulin, depending on the Human Leukocyte Antigen mismatch. Only the one patient 
<40 years of age was treated with intensive chemotherapy regimen (Busulfan and Cyclophosphamide).
Statistical analysis
Data are represented as median with corresponding interquartile range and compared with 
the Mann-Whitney U test; p<0.05 was considered statistically significant. Determinants of 
AA serum levels were corrected with regression analysis. Analyses were performed with 
Prism (GraphPad Software Inc) and IBM SPSS (SPSS).
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Results
Healthy volunteers had serum AA levels of 65µMol/L (median, 95% CI 61.56-69.46), while a 
significant decrease was observed in patients with haematological malignancies who had AA 
serum levels of 20.5µMol/L (median, 95% CI 21.27-32.68, Fig. 1A). Eight patients (19% of 
total patients) had AA serum values <11.4μMol and are considered to be AA deficient 9. The 
patient group was slightly older than the control group. After correction for age and sex the 
difference in serum AA was still significant (p<0.0001, Fig. 1B). 
Within the patient group (although subgroup sizes are small), patients treated with HSCT or 
chemotherapy/prednisone did not have significantly different serum AA values, nor was there 
a difference between patients after autologous transplantation with high dose chemotherapy 
or allogeneic transplantation with non-myeloablative conditioning for all except one patient 
(Fig. 1C-D). Furthermore, within the allogeneic HSCT group, no difference was observed in 
patients suffering from GVHD (Fig. 1E). 
Additionally, low serum AA values were not only observed during the acute phase of disease 
but even up to 360 days after transplantation in a patient admitted because of GVHD (Fig. 
1F).
.
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Figure 1: Serum ascorbic acid levels. A: Serum ascorbic acid values of controls and patients are 
represented as µMol/L. Data were compared with Mann-Whitney U (p<0.0001). For seven patients 
with undetectable AA levels (<10μMol/L), 10μMol/L was appointed as AA value. B: Age (years) and 
serum AA values (µMol/L) of controls and patients. The regression coefficient of AA comparing healthy 
controls to patients with haematological malignancies is -38.5µMol/L AA (95%CI -45.29 - -31.78). After 
correction for age and sex, being -34.4µMol/L (95%CI -43.04 - -25.81) with p<0.0001 comparing controls 
and patients. C: Serum AA values (µMol/L) of HSCT and non-HSCT patients (p=0.63). D: Serum AA 
values of allogeneic versus autologous HSCT. Significance was tested with Mann Whitney U test and 
results in p=0.83. E: Serum AA values (µMol/L) of allogeneic HSCT patients suffering from GVHD or 
not (p=0.87). F: Serum ascorbic acid values of HSCT patients plotted to day of AA measurement after 
HSCT (p=0.58).
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Discussion and Conclusion
We show that patients with a haematological malignancy, either treated with chemotherapy 
or with autologous or allogeneic HSCT have highly significant reduced serum AA levels 
compared to healthy controls. Recently was shown that patients receiving allogeneic HSCT 
have low serum AA levels in the acute phase post-transplantation 10. We show that low AA 
levels are also present in the chronic phase post-transplantation. Furthermore, our findings 
are not limited to HSCT patients, but are also convincing for non-transplanted patients. 
Human AA levels depend on dietary intake; therefore limited food intake following treatment 
may explain the observed vitamin C deficiency. Moreover, impaired metabolism is observed 
in cancer patients 11. Although AA serum levels in the patients are low, it should be considered 
that intracellular levels of leukocytes might not be reflected by serum levels since immune cells 
might accumulate AA 12. However, serum measurements are the current gold standard and it 
is accepted that values <11.4μMol/L indicate vitamin C deficiency 13, present in a substantial 
proportion of our patient group. Serum AA values of patients with GVHD after allogeneic 
HSCT – all with the gastrointestinal tract involved – were not further decreased compared to 
patients without GVHD, with the limitation of small group sizes and therefore with a small 
power to detect differences.
Since AA is crucial for immune function and for in vitro development and expansion of T and 
NK cells from stem cells 6,7,12, it might be of clinical relevance to study the function and recovery 
of immune cells after treatment, its correlation to AA serum levels and the possible effect of 
vitamin C supplementation. Not only in patients with intensive chemotherapy regimens but 
also with less intensive regimens, where recovery of granulocytes is often a limiting factor for 
adequate dosing of chemotherapy regimens responsible for substantial morbidity. Whether 
oral vitamin C supplementation will give the desired increase in serum levels is an important 
concern. Therefore, it might be necessary to use intravenous supplementation as it can 
increases plasma AA levels by ~30-70 fold because of bypassing the renal absorptive system 14. 
In conclusion, we show that patients with haematological malignancies have significantly 
reduced serum AA values compared to healthy controls, possibly influencing their immune 
status. Additionally, AA deficiency might also account for other disease symptoms in these 
patients 15.
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Chapter 8
Introduction
The global growing incidence of cancer is an important problem. Cancer is one of the major 
causes of death in the Western world and even the second cause of death in developing 
countries. Even though cancer mortality is declining because of more effective early detection 
in combination with early treatment, the burden on society remains enormous. Because 
not all cancers can be cured with conventional methods like surgery, chemotherapy and 
radiotherapy, an urgent need for other therapies exists. More recently, other therapies like 
immunotherapy became of great interest. The major aims of immunotherapy are to trigger the 
patient’s immune system to enhance the response against cancer cells or to supply immune 
cells or components to the patient providing a strong immune reaction after administration. 
Great improvements have already been made in the field of immunotherapy. The most 
successful and applied cellular immunotherapy is haematopoietic stem cell transplantation 
(HSCT), where the complete immune system of the patient is deleted and rebuild from donor 
stem/progenitor cells. However, most other cellular immunotherapies are only effective in 
certain patient populations and many therapies are still in pre-clinical stages, leaving great 
room for improvement. Furthermore, the success of certain immunotherapies like allogeneic 
mismatched HSCT that can result in complete remission is hampered by post-treatment 
complications, in this case immune deficiency resulting in high morbidity and mortality 
because of uncommon and opportunistic infections.
Initially, we aimed to develop specific T cells against pathogens that are most common to cause 
infections after HSCT. Unfortunately, these attempts were unsuccessful as reported in chapter 
4. Therefore, a stromal based system using TSt-4/DLL was set up that resulted in the generation 
of T cell progenitors capable of homing to the thymus and maturing into single positive T cells 
1. The major aim of this thesis is the development of a clinical grade culture method to produce 
T cell progenitors suitable for the adoptive transfer to immunocompromised patients after 
HSCT. The idea is that patients can be protected by an adequate but temporary mature T cell 
pool, obtained from in vitro generated T cell progenitors that mature and undergo selection in 
the thymus of the patient, and are capable of combating infections. This temporary T cell pool 
should be present until new definitive T cells have developed from the graft stem cells able to 
protect the patient from infections.
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The unique environment of the thymus
In chapter 2 we studied the network formation during normal thymus development in the 
mouse. We showed that hypoxia contributes to the mesenchymal network development 
required for the unique thymus structure. For many years it was believed that T cells can 
only develop in the three dimensional (3D) environment of the thymus. However, the 
overexpression of Delta like ligand (DLL) on stromal cells resulted in feeder cell based cultures 
capable of supporting in vitro T cell development 1, 2. In the OP-9 based system, even single 
positive mature T cells can develop 3-5. Moreover, in chapter 5 we described the development 
of HSCs towards early CD4+CD8+ double positive T cells even in the absence of stromal 
cells. This culture requires the presence of medium, cytokines, vitamin C and immobilized 
DLL4:Fc to mimic the thymus environment. However, in our system we were not able to 
generate mature single positive T cells expressing CD3 and TCR, indicating that the current 
culture components are not sufficient to fully replace the thymic environment. As shown 
recently in another culture setting, the addition of tetramers, anti-CD28, anti-CD3 and OP-9/
DL1 conditioned medium did result in a very small population of antigen specific T cells 6, 
indicating that especially for proper positive and negative selection, the unique environment 
of the thymus is still required. Especially for the efficient generation of a T cell pool with a 
broad TCR repertoire, interactions with thymic epithelial cells and dendritic cells are essential.
Generation of sufficient cell numbers for therapy by stem cell 
expansion
As source of stem cells, both peripheral blood stem cells and more recently cord blood (CB) 
stem cells are used for HSCT. Stem/progenitor cell numbers obtained from peripheral blood 
via granulocyte-colony stimulating factor (G-CSF) mobilization and subsequent leukapheresis 
are much higher compared to CB CD34+ stem cells. For proper engraftment, injection of high 
numbers of stem/progenitor is required. Therefore, expansion of the relative small CB stem/
progenitor cell product before transplantation could lead to better engraftment. However, not 
only for HSCT but also for adoptive immune therapy, great cell numbers are required. So in 
general, in vitro stem cell expansion could improve the therapeutic applicability of certain 
adoptive cell based therapies.
In chapter 3, we show that a simple blockage of early B cell differentiation results in the 
generation of induced leukocyte stem cells; a stem cell like population with great expansion 
potential and the capacity to differentiate into leukocyte lineages. This straightforward 
method does not require the reprogramming or de-differentiation as is necessary to induce 
pluripotent stem (iPS) cells via introduced expression of four transcription factors, namely 
OCT4, SOX2 with KLF4 and c-Myc, or NANOG and LIN28 in mice and humans 7, 8. This 
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system holds great promises to generate enough cells for adoptive cell therapy, as these cells 
still have the capacity to differentiate into mature immune cells. 
Based on our findings in chapter 5 and 6 where we show that vitamin C increases expansion of 
both T/NK progenitor cells and mature NK cells, the controlled addition of vitamin C to these 
experiments could have resulted in even more efficient stem cells expansion. Furthermore, 
Esteban et al. showed that the generation of iPS cells in both mouse and human is enhanced 
in the presence of vitamin C 9.
In the current study, a retroviral approach to introduce Id3 is used, required for the block in 
B cell development resulting in induced leukocyte stem cells. For clinical application, a more 
safe method of Id3 introduction has to be applied. This also holds true for the therapeutic 
usage of induced pluripotent stem cells. Genes that are retro- or lenti-virally introduced in 
the genome permanently integrate at a random place, which could cause harmful mutations 
potentially resulting in tumour formation. Moreover, gene therapy could result in inactivation 
or activation of host genes, resulting in tumour development as shown in patients 10, 11. 
Furthermore, integration could cause tumour formation in mice by reactivation of for example 
the oncogene c-Myc, used for iPS cell generation 12. Current research focusses on methods 
to circumvent genome integration by the use of Adenovirus, Sendai virus, small molecules, 
direct protein introduction and mRNA delivery (reviewed in reference 13). Although, the 
Sendai virus method results in comparable efficiency, the costs and labour intensiveness are 
major drawbacks. Unfortunately, the other methods show less efficiency than retro- and lenti-
viruses. Although these methods need further improvement and additional research, they are 
nonetheless more suitable for the use of clinical grade cell products than integrating methods.
In addition to our above mentioned stem/progenitor cell expansion method, other methods 
are of great interest. Initial stem cell expansion protocols using cytokine cocktails showed 
limited fold expansions, therefore other systems aiming at the expansion of haematopoietic 
stem cells are introduced. For example the DLL1 system, which results in expansion of 
progenitor cells. However, these cells favour rapid but transient myeloid reconstitution in vivo, 
making them not useful for e.g. T cell reconstitution and long-term repopulation 14. Recently, 
the addition of StemRegenin1 to this system resulted in a further increase in expansion of 
these stem/progenitor cells, however, it remains to be determined if this cell population has 
(myeloid and/or lymphoid) repopulation ability in humans 15. 
Other methods, for example copper chelators, mesenchymal co-cultures, aryl hydrocarbon 
receptor antagonists, PGE2 stimulation, small molecules, epigenetic reprogramming by 
valproic acid, have also been used resulting in an increase of stem/progenitor expansions 
16-20. However, most of these cell products are thus far only tested in mice. Therefore, clinical 
studies have to confirm the safety of these products and have to define if these expanded cell 
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products result in clinical improvements. De Lima et al. already performed such clinical trial 
with copper chelator tetraethylenepentamine ex vivo expanded CB cells. Despite engraftment 
and safety, no improved clinical outcome/faster engraftment was observed 19. Another clinical 
trial using a different expansion method, where a CB unit is co-cultured with mesenchymal 
stem cells and injected together with an non-manipulated CB unit into patients with an 
haematological malignancy, resulted in safe engraftment and resulted in faster neutrophil and 
platelet recovery 20. Unfortunately, no improvement in long-term repopulation was observed; 
these cells only came from the non-manipulated CB unit. Although results are promising 
concerning early repopulation, further improvement of long-term repopulation is required. 
Moreover, it has to be considered whether in vitro expanded cells still have sufficient 
engrafting and self-renewal ability in vivo. In addition to previous mentioned human data, 
some murine data is available concerning engraftment. It was shown that ex vivo expansion of 
CB progenitor cells impaired their repopulating ability in immune deficient mice 21. However, 
details about the used expansion protocol and cell numbers are unfortunately not provided. 
Another study showed that engraftment and lineage potential of human stem/progenitor 
cells in immune deficient mice expanded in the presence of an aryl hydrocarbon receptor 
antagonist is reduced 22. 
One reason for reduced engraftment could be a limitation in the amount of cell divisions of 
expanded cells. Since the injected stem/progenitor cells have already divided multiple times 
in vitro, cells could potentially have aged too much to still have the capacity to proliferate 
in vivo where perhaps also less stimuli (e.g. cytokines) are present. During cell division, the 
end of chromosomes, named telomeres, shorten, enhancing cellular aging and eventually 
resulting in cell senescence 23. In germ cells, stem cells and actively dividing cells a special 
reverse transcriptase called telomerase is active, synthesizing telomeres 24. Human HSCs show 
telomerase activity and undergo telomere shortening upon aging 25-27. It might be interesting 
to investigate the result of in vitro expansion on telomere length of stem/progenitor cells, and 
the influence of telomere length on the repopulation ability. Although influencing telomerase 
activity of cell products sounds tempting, this could result in tumour induction since 80% of 
human cancer overexpress telomerase 28.
Recapitulated, evaluation of expanded stem/progenitor cells, with any produced method, 
should be addressed before clinical trials are started. Furthermore, it can be tested if these 
expanded cell products are suitable as starting material for the generation of specialized 
adoptive cellular products like (progenitor) T cells or NK cells. As mentioned previously, 
enormous cell numbers are required for immunotherapy. When expansion of, in our case, T 
and/or NK cells is not sufficient, first expansion of stem cells and subsequent differentiation of 
stem/progenitor cells could result in adequate cell numbers required for therapy.
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T cell recovery after HSCT
T cell reconstitution after HSCT can occur via thymus dependent and thymus independent 
mechanisms. The thymus independent reconstitution occurs via homeostatic peripheral 
expansion (HPE) of mature T cells that survived treatment regimen or expansion of mature T 
cells from the graft. However, the T cell repertoire of this population is limited. Furthermore, 
the high expansion induced by relative high homeostatic cytokine levels (because of low T 
cell counts and decreased consumption) and recognition of endogenous antigens results in 
a high number of apoptotic cells 29. The HPE can provide some initial immune competence, 
but is insufficient for broad range and long-term protection 30. CD4+ T cell recovery is less 
efficiently supported by HPE because of the increase in peripheral interleukin (IL)-7 levels, 
resulting in a prolonged CD4+ T cell cytopenia 31. CD8+ T cells are more sensitive to HPE 
and therefore recover quicker, although the TCR repertoire and the number of naive T cells 
remain abnormal for months to years 32.
Only de novo thymus dependent T cell generation can result in a naive T cell pool with a 
broad TCR repertoire. Unfortunately, delivery of progenitors to the thymus limits T-lineage 
reconstitution after transplantation 33. Furthermore, the thymus structure is influenced by 
treatment regimen and GVHD 34. Moreover, age associated thymic involution is accompanied 
by a decreased thymus size and function resulting in slower recovery after treatment, especially 
affecting older patients. The generation of naive T cells from the thymus requires 6-12 months 
in child patients and may take even up to several years in adult patients 35, 36. 
The skin explant system for the production of T cells
For a long time it was believed that a 3D environment is required for T cell development. 
The skin-explant system uses human skin-derived fibroblasts and keratinocytes grown on 
a 3D scaffold, resembling the structure of the thymus. Although in theory, this system is 
applicable and also clinical grade because the patient’s own skin cells can be used, we were not 
able to reproduce previously published results 37, as reported in chapter 4. We showed that 
keratinocytes did express the Notch ligand Jagged-1, however, expression of Delta like ligands 
(DLL), known to be required for proper T cell development was very low 38. Furthermore, 
skin derived cells could lead to possible T cell contamination in this system as skin has been 
reported to be a large storage place for T cells 39 that may be difficult to remove in the isolation 
procedure . More recently, two other studies reported on similar skin-explant systems to 
generate T cells 40, 41. One study used commercial available keratinocytes and fibroblasts 41 
and the other study showed that by using keratinocytes and fibroblast cell lines in a similar 
3D system, T lineage development from CD34+ cells could be observed 40. In this latter study, 
elevation of DLL4 expression on the keratinocyte cell lines when cultured on the matrix was 
observed in some experiments, what could contribute to the observed T lineage development 
in contrast to our culture with primary cells where very low DLL expression was observed. 
183
                     
      8
General Discussion
Strangely, T lineage development was only observed from CB CD34+ cells and not from 
peripheral HSCs 40. The first study only used peripheral HSCs, however, the purity of this 
population was around 80% when seeded in the culture, resulting in possible contaminating 
mature T cells from the donor’s blood. Furthermore, in both studies the efficiency of T lineage 
development was very low and also not the complete range of T cell development was observed 
40, 41. Unfortunately, these limitations in combination with difficult reproducibility, designate 
this system still inappropriate for the generation of sufficient cell numbers for adoptive T cell 
therapy. 
Adoptive T cell progenitor therapy 
Previously, we showed that G-CSF mobilized stem cells differentiate to proT2/preT T cells 
in co-culture with TSt-4/DLL4 feeder cells 1. Importantly, we showed that these early T cell 
progenitors homed to the thymus in immune deficient mice faster than non-manipulated 
stem cells. We earlier argued that these cells are the ideal population to inject into patients, 
because of their retained thymus homing capacity and further education in the thymus to 
prevent the emergence of auto-reactive T cells.
In chapter 5, we developed a clinical applicable feeder free culture system resulting in a large 
progenitor population from both CB and G-CSF mobilized HSCs similar to progenitors 
obtained in co-culture with TSt-4/DLL4. It needs to be confirmed whether these cells are 
capable of homing to the thymus and complete their education in vivo. Therefore, a next step 
is to inject these cells into immune deficient mice. Based on the similar phenotype of both 
progenitor populations in vitro it is likely that the cells generated in the feeder free culture 
are also capable of this migration and maturation. In our previous study, we did not observe 
mature T cells in the periphery of the injected mice. Up till now, only few studies found mature 
T cells in the periphery after injection of T-cell progenitors 42. This could be because of the 
thymic selection process where the majority of the thymocytes die because of neglect (~65%) 
or negative selection because of reaction to self (~90%) 43. The injection of more cells could 
possibly result in adequate cell numbers surviving selection and being able to exit the thymus. 
However, the species difference between mice and men could also result in limited to no 
egress of human T cells from the murine thymus. Perhaps human thymocytes do not have the 
proper chemokine/integrin profile to egress from the murine thymus. It is debatable whether 
the peripheral T cells found in these studies came directly from the thymus, or developed in 
the periphery. It is shown that T cell maturation can occur in gut associated tissues after bone 
marrow transplantation in mice 44. Unfortunately only limited studies are available on murine 
extrathymic T cell development and researchers remain skeptical about this phenomenon and 
its contribution to T cell immunity 45. In humans, it is shown that tonsils can support early 
T cell development resulting in T/NK cell progenitors 46. Also for humans, further research 
is required to confirm extrathymic T cell development, the contribution of these cells, and 
whether this knowledge can be used for future therapies generating the T cell pool of patients.
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One phase I clinical study with the transfer of CB CD34+ DLL1 culture derived progenitors 
showed enhanced engraftment and myeloid reconstitution 14. However, the lack of 
improvement in T cell reconstitution in these patients indicates that these progenitor cells, 
only expressing CD7 (proT1), were probably not committed enough to the T cell lineage. We 
obtain more mature T cell progenitors (proT2/preT T cells) in a similar system, perhaps these 
cells could result in better T cell reconstitution.
The route of injection should also be considered. Intravenous injection of human T cell 
progenitors, which is used in several mouse studies, does result in thymus repopulation. 
Though, direct intrathymic injection could give better results. At least in mice, intrathymic 
injection of stem/progenitor cells in a bone marrow transplant setting results in the generation 
of peripheral mature SP T cells 47. Moreover, in a severe combined immune deficient (SCID) 
mouse model, intrathymic injection of bone marrow progenitors resulted in long-term 
thymopoiesis while intravenous injection only resulted in short-term thymopoiesis, probably 
because of decreased thymic entry 48. 
In summary, when human T cells are indeed capable of migration to (when injected 
extrathymically) and maturing in the human thymus, it needs to be confirmed that enough 
cells will pass thymic selection and egress the thymus resulting in a diverse T cell pool capable 
of exerting proper T cell immunity. Moreover, it needs to be determined if a single injection 
of T cell progenitors together with the transplant will result in sufficient improvement of 
thymopoiesis and T lineage recovery, or that multiple injections are required. Multiple 
injections could be required when cells show limited in vivo self-renewal capacity or expansion 
resulting in a limited T cell population insufficient to provide broad immunity.
Other strategies to enhance T cell recovery after HSCT
Besides T cell progenitor therapy, other therapies are currently under investigation aiming 
to enhance T cell recovery in patients with low T cell counts. Some therapies aim at adoptive 
cellular therapy, while others try to improve T cell production or expansion with cytokines and 
growth factors within the patient. Research also focusses on the improvement of thymopoiesis 
by targeting the thymus.
Donor lymphocyte infusion
Donor lymphocyte infusions (DLIs) have been broadly used for anti-tumour therapy, and to 
a lesser extent to provide immunity to pathogens after HSCT. Unfortunately this therapy is 
limited by the low frequencies of specific T cells for pathogens that often cause post-transplant 
infections. Furthermore, in a haplo-identical setting the occurrence of GVHD limits the use 
of these cells 49.
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The depletion of alloreactive T cells, allodepletion, enhances the safety of DLI. Alloreactive 
donor T cells can be activated against major human leukocyte antigen (HLA)-incompatible 
antigens by mixed lymphocyte reactions (MLRs). These activated T cells upregulate specific 
molecules, for example CD25 or CD69, and can subsequently be removed or eliminated using 
antibody magnetic depletion, apoptosis induction, immunotoxin-conjugated antibodies 
or by photodepletion 49. Some clinical trials using allodepleted T cells have already been 
performed in the last decades, whereby infusion of 8x105 allodepleted cells/kg are found 
to be safe 50. Additionally, 3 patients showed specific antiviral responses. However, another 
clinical trial with alloreactive depleted DLI resulted in severe GVHD in some patients 51. 
A phase I clinical trial using photodepletion to remove alloreactive T cells, indicated that 
allodepleted DLI resulted in accelerated T cell reconstitution and decreased the incidence 
and severity of infections 52. Our clinical group participated in a phase II study using the 
photodepletion technology. Unfortunately, this procedure failed because insufficient vital 
cell numbers could be given back to the patients (Kiadis Pharma, unpublished results). At 
present, a new clinical trial has started with improved technology. Stringent allodepletion 
is required to achieve safety. Especially when there is a large mismatch between donor and 
recipient, robust allodepletion is required, since only few alloreactive T cells (<105/kg) can 
already induce severe GVHD. In addition, suicide genes have been introduced in pre-clinical 
settings, for example inducible human caspase 9, that can be activated with small molecules 
to induce apoptosis for example when GVHD would be initiated in vivo 53. Several clinical 
trials using the concept of suicide genes are performed, as reviewed in reference 54, and are in 
general found to be safe. However, results are variable because of difficulties in standardizing 
the culture procedure. Interestingly, Vago and colleagues reported that T cell suicide gene 
therapy resulted in the recovery of thymic activity, contributing to immune reconstitution 55. 
The selection of sufficient cell numbers for therapy remains a struggle, since only 10 percent 
or less of cells survive after allodepletion. Techniques increasing safety, like suicide genes, 
even further reduce these numbers.
Besides in vitro depletion of alloreactive T cells, a concept of in vivo depletion has been 
introduced into the clinic. After transplantation, cyclophosphamide is given to the patient, 
selectively depleting in vivo activated T cells. This technology has been successfully 
introduced in the context of haplo-identical transplantation where because of the HLA 
mismatch rapid in vivo activation of donor T cells, and therefore elimination of these T cells by 
cyclophosphamide, can be expected 56-58. Two studies will soon start in our clinical department 
where cyclophosphamide will be administered to haplo-identical transplanted patients 
suffering from acute myeloid leukaemia and multiple myeloma. Furthermore, currently it is 
tested in the Netherlands whether this technology will also work in a transplantation setting 
with less extensive HLA mismatches (HOVON 96). Of course, it still needs to be proven that 
this concept will prevent GVHD caused by alloreactive T cells and will lead to accurate T cell 
reconstitution sufficient to overcome infectious related mortality after transplantation.
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Specific cytotoxic T cells
The adoptive transfer of ex vivo expanded T cells with pathogen specificity is another approach 
to generate immunity after HSCT. Especially cytotoxic T lymphocytes (CTLs) directed 
against Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) are investigated. Clinical 
trials with CMV CTLs show that administration is safe and that also anti-viral responses 
are detected in certain patients 59. Besides these encouraging results, responses decline after 
weeks resulting in only short-term protection and even reactivation of CMV occurred in 
some cases 60. EBV specific therapy is successful to treat post-transplant viral EBV-associated 
lymphoproliferative disorders 49. More recently, tri-virus specific CTLs against CMV, EBV 
and Adenovirus were developed. Infusion of these cells was safe and showed activity to all 
three viruses 61. The presence of the antigen in vivo is very important for the efficiency of these 
therapies; otherwise fast decline in specific T cell levels occurs resulting in loss of protection. 
Furthermore, production time and complexity, competition of multiple antigens for the 
production of multi-viral therapy and the potential risk of GVHD caused by infused T cells 
are difficulties concerning this approach. Furthermore, the wide range of pathogens patients 
can encounter after HSCT requires the production of a large variety of pathogen specific T 
cells for infusion.
Cytokines and growth factors for the stimulation of T cells and/or the thymus
Several cytokines and growth factors are involved in peripheral T cell survival and expansion, 
and others in thymus development and regeneration and could therefore be used to enhance 
immunity after HSCT.
Keratinocyte growth factor (KGF), for example, is a fibroblast growth factor and induces 
proliferation of thymic epithelial cells (TECs) in the thymus 62. KGF administration increases 
thymic cellularity in aged mice, furthermore administration to HSCT treated mice show an 
increase in naive T cells counts 63, 64. Additionally, KGF administration induces peripheral 
expansion of regulatory T cells in mice after transplantation 65. Moreover, GVHD disease is 
ameliorated upon KGF administration before bone marrow transplantation 66 and improves 
allogeneic bone marrow engraftment in mice 67. A study in Rhesus Macaques confirmed the 
positive effect of KGF administration on thymopoiesis 68. Clinical trials are performed to assess 
the effect of KGF in patients; mainly an ameliorating effect on mucositis has been observed as 
reviewed in reference 69. After allogeneic HSCT no influence was observed on the incidence 
of GVHD, infections or mortality, indicating that the immune reconstitution of these patients 
was not improved 70. Currently, additional clinical trials are ongoing investigating whether 
KGF administration improves thymic immune reconstitution following haplo-identical 
transplantation in patients.
In mice, Flt-3L enhances thymus dependent T cell regeneration and also enhances thymus 
recovery 71, 72. Moreover, Flt-3L administration resulted in better immunocompetence 
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against murine CMV in bone marrow transplanted mice 73. Also stem cell factor (SCF) was 
capable of improving thymopoiesis after stem cell transplantation in mice 74. Unfortunately, 
combined administration of SCF and KGF in Rhesus Macaques resulted in severe adverse 
effects, including severe weight loss and respiratory failure 68. Interestingly, IL-22 has recently 
been found to drive endogenous thymus regeneration in mice 75. Further pre-clinical and 
clinical studies should address whether these cytokines are safe and can also stimulate human 
thymopoiesis after chemotherapy and/or HSCT.
The most studied cytokine concerning immune reconstitution is IL-7. Mutation in the 
IL-7 receptor results in severe combined immunodeficiency with absence of T cells. IL-7 is 
produced by stromal cells in the bone marrow and thymus, keratinocytes, intestinal epithelial 
cells and dendritic cells 30, 76. In the thymus, IL-7 is required for proliferation and survival, 
in the periphery it has proliferative and anti-apoptotic effects and is a regulator of T cell 
homeostasis 77. Although an increase in peripheral IL-7 levels is already present during 
lymphopenia, therapies aim at far higher levels. Clinical trials have proven the safety of IL-7 
administration and showed that IL-7 promoted expansion of peripheral T cells and increased 
TCR repertoire diversity in refractory cancer patients starting with a T cell count of 300cells/
mm3 78, 79. Perales and colleagues performed a clinical trial supplementing IL-7 in patients 
receiving HLA-matched allogeneic HSCT, also resulting in an increase of peripheral T cell 
counts 80. Both studies did not result in increased thymus size and thymopoiesis. Because 
there was no change in TREC levels, it is thought that IL-7 administration had primarily an 
effect on peripheral expansion, especially on effector memory T cells. Further (randomized) 
studies are required to extend on these findings and determine if IL-7 treated patients show 
clinical benefits. Moreover, additional studies in patients treated with other types of HSCT 
(Haplo or CB) should be performed. One concern of this last example is that this therapy 
could contribute to GVHD, by inducing expansion of allogeneic T cells. 
Hormones and sex steroids influencing the thymus
Administration of growth hormone (GH) or insulin-like growth factor-1 (IGF-1) inverts 
thymic involution and supports TEC proliferation in mice 81, 82. In HIV-infected patients, GH 
administration increased thymus size, thymic output and augmented the number of naive 
CD4+ T cells 83. Whether this therapy could also improve thymic cellularity and output in 
HSCT patients is currently under investigation.
One of the main causes of thymic involution is believed to be the increased production of 
sex steroids after puberty. Sex steroid ablation either by surgical or chemical (with antagonist 
against luteinizing hormone releasing hormone, LHRH-A) castration in aged mice increased 
thymic cellularity, improved thymic architecture and increased peripheral T cell counts 84. 
Also in patients prior to receiving autologous or allogeneic HSCT, LHRH-A accelerated 
engraftment, augmented thymopoiesis and immune regeneration without causing GVHD 
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85. Even though in the autologous HSCT setting an increase in disease-free survival was 
observed, unfortunately, there was no increase in patient survival. Further studies should 
address a longer follow up time (>12 months) and test whether different administration 
schemes could lead to an increase in patient survival.
Thymus crafting
The creation of a new thymus could result in the life long development of a naive polyclonal 
T cell repertoire after HSCT. Efforts have been made for example by placing specific murine 
TECs under the murine kidney capsule, resulting in the formation of a thymus, capable of 
producing T cells 86, 87. This specific TEC population expresses the MTS24 surface glycoprotein 
and specifies primordial TECs, especially abundant in embryonic thymi. Unfortunately, 
the human equivalent of these cells is still unknown. Thus far, human studies using foetal 
thymic tissue of cultured TECs transplanted in patients of allogeneic HSCT were unsuccessful 
88. Recent studies have been more successful; here transplantation of cultured thymic 
fragments in DiGeorge patients resulted in mature T cells exerting immune responses to a 
variety of antigens 89, 90. However, patients remain immune deficient for at least 6 months 
after transplantation 90. Unfortunately, human thymi are only limited available. Recently, 
also a system using vascularized tissue chambers was introduced. In mice, these chambers 
containing human thymic cells show murine and human T cell production 91. However, this 
method is still in the pre-clinical phase. Furthermore, it needs to be considered that not only 
thymic atrophy limits thymopoiesis, but perhaps more critically a major limitation in the 
generation of T cells is the generation of thymic seeding progenitors 33.
In conclusion, much progress in the field of T cell immune reconstitution is achieved. However, 
various therapies are still in a pre-clinical phase and current clinical trials still need additional 
follow up or additional studies before final conclusions can be drawn. Concerning the best 
approach, probably a combination of the discussed approaches will result in optimal T cell 
recovery. This approach should address both thymopoiesis, in combination with providing 
thymic seeding progenitors for example by adoptive T cell progenitor therapy.
Not only cancer patients receiving HSCT as part of their cancer therapy could benefit from 
therapies improving T cell reconstitution. Also other patients receiving HSCT for example 
as part of their auto-immune disease, SCID, amyloidosis, anemia, and thalassemia treatment 
could benefit from adoptive T cell progenitor therapy. Furthermore, it could be suitable 
for patients with decreased T cell immunity like patients with acquired immunodeficient 
syndrome (AIDS).
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NK cell therapy
Although the initial focus of this thesis was to develop a clinical grade T cell progenitor therapy, 
we also studied NK cells because of the positive effects observed on T cell progenitors and their 
expansion mediated by vitamin C. Adoptive NK cell therapy is not aimed to improve immune 
reconstitution but opted as alternative cancer therapy. Pre-clinical and clinical studies by our 
group 92-94 and others have shown that, if infused in large numbers, NK cells can be used to 
eliminate malignant cells, reviewed in reference 95. Interestingly, it was recently shown that 
in vivo regulatory T cell depletion improves acute myeloid leukaemia clearance by high-dose 
haplo-identical NK cell therapy 96. As already mentioned previously, one option to produce 
sufficient cell numbers for therapy is to generate a large batch of stem/progenitor cells and 
subsequently differentiate them to the cells of interest. Another method is to expand the cells 
of interest directly. In chapter 6 we show that in the presence of vitamin C the expansion of 
both NK cells differentiated from stem/progenitor cells as well as mature NK cells is greatly 
enhanced without influencing their phenotype or cytotoxic capacity. However, the systems 
used in this study were not yet clinical applicable and therefore, further clinical translation 
is required. Currently, we are working with a closed bioreactor system to expand mature NK 
cells that are constantly exposed to fresh medium and IL-2. Potentially, vitamin C can also 
increase the expansion of NK cells in this system. It needs to be tested whether these cells, 
expanding in high folds, still have the proper NK cell phenotype and are able to exert their 
cytotoxic capacity in vitro and in vivo. Thereafter, clinical trials can be started to address the 
feasibility of this NK cell product in patients.
Vitamin C
In chapters 5 and 6 we show that ascorbic acid/vitamin C has a pivotal effect on both T and 
NK cell maturation and expansion. Vitamin C is not only important for the expansion of these 
cells, but also for the differentiation from HSCs into these cells. This is especially pronounced 
in T cell development, where a block in early development in the proT1 stage occurs in the 
absence of vitamin C. Finding this prominent role for vitamin C in in vitro lymphocyte 
development, we hypothesized that patients with low lymphocyte counts, for example after 
chemotherapy and/or stem cell transplantation might have low vitamin C levels. In chapter 7 
we were able to confirm this hypothesis. Indeed, patients with haematological malignancies 
treated with chemotherapy and/or stem cell transplantation do have significantly reduced 
serum vitamin C levels persisting at least up to 1 year after treatment. Of course, further 
research is required to investigate whether there is a link between vitamin C levels and 
lymphocyte counts. It might be of clinical relevance to study the function and recovery of 
immune cells after treatment in respect to vitamin C serum levels and the possible effect of 
vitamin C supplementation. Since vitamin C has many functions, patients could in general 
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benefit from vitamin C supplementation as shown recently by Kletzel and colleagues who 
showed that 6 out of 19 patients with chronic GVHD suffered from vitamin C deficiency. 
Vitamin C supplementation of these patients resulted in a decrease in mucositis and in an 
increase of their ability to eat, improving patient’s wellbeing 97. 
Functions of vitamin C
Vitamin C is required for multiple biochemical and physiological processes. For example in 
collagen synthesis, carnitine synthesis, serving as co-factor for norephinephrine production, 
being essential for the synthesis of catecholamines and cholesterol catabolism 98. Furthermore, 
vitamin C is an important antioxidant, as it scavenges free radicals 99. Humans are not able to 
synthesize vitamin C because of a lack of the enzyme gulonolactone oxidase and are therefore 
dependent on supplementation via their diet. Vitamin C deficiency is for example associated 
with fatigue, inflammation of the gums, scurvy, anemia, poor wound healing and infections 
98. Because of its water solubility, administration in high doses is generally non-toxic 100. 
Vitamin C and the immune system
The vitamin C concentration in immune cells is 10-100 fold higher compared with serum 
101, 102 and rapidly decreases during infection 103, suggesting an important role for vitamin C 
during infection. In murine studies, vitamin C improves resistance to infections caused by 
bacteria and viruses 104, although the role for vitamin C in human infections is still debatable. 
Many studies are performed concerning the common cold, where vitamin C reduces the 
severity and duration of infection, however, it does not have a prophylactic effect 105.
There is great uncertainty about the precise effect of vitamin C on immune functions. 
Unfortunately, implications are often generalized and based on single studies performed 
around the seventies. Here, some findings concerning vitamin C are listed. Vitamin C does 
have an effect on the cell mediated immune response in humans as investigated in Crohn’s 
disease patients 106. While in the latter study, no effect on the humoral response was observed, 
decreased IgG and IgM levels in elderly can be restored by vitamin C supplementation 107. 
Vitamin C also influences neutrophil function by for example affecting chemotaxis and 
phagocytosis in mice 108. Moreover, decreased phagocyte function of aged human neutrophils 
can be restored by vitamin C supplementation 107. Furthermore, vitamin C stimulates the 
IL-12 production of murine DCs resulting in the differentiation of T helper cells 109 and 
stimulates CD8+ memory T cell production 110. After toxin chemical induced reduction of NK, 
T and B cell function, vitamin C supplementation can restore cellular function in humans 111. 
Additionally, vitamin C increases T cell proliferation in vitro 112 and inhibits T cell apoptosis by 
decreasing their sensitivity to death signals 113. An interesting finding is that although thymus 
and spleen tissue in general have moderate vitamin C levels 103, patients supplemented with 
vitamin C have a larger thymus 114. Unfortunately, no further studies concerning the thymus 
and vitamin C are conducted to our knowledge.
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The working mechanism of vitamin C concerning its role on immune cells is partially 
understood. Immune cells are very sensitive to oxidative stress because of their high content 
of fatty acids in their cell membranes and their reactive oxygen species (ROS) production 115. 
Vitamin C can protect cells because of its antioxidant properties. Since vitamin C is involved in 
many different pathways and has many functions, it is highly unlikely that only its antioxidant 
capacity can result in a multitude of effects on the immune system. As we show in chapter 
5, other antioxidants did not result in the improvement of T cell development. We showed 
that vitamin C seems to be involved in the citrulline/NO pathway in T cell progenitors, as its 
blockage resulted in less T cell development and proliferation. Additionally, Manning and 
colleagues hint for vitamin C as epigenetic regulator during murine T cell development 116. 
Although there are quite some leads concerning vitamin C’s function, further research is 
required to study how vitamin C precisely influences all these components of the immune 
system. This knowledge could result in further therapy strategies interfering with the immune 
system.
Vitamin C supplementation
Since Linus Pauling presented vitamin C as a panacea in the early seventies, many 
supplementation studies have been performed. Because of its high safety profile and 
inexpensiveness, vitamin C is a very appealing supplement for the prevention or treatment of 
certain diseases.
As already mentioned before, vitamin C supplementation does not result in prophylaxis of the 
common cold, however, it reduces the severity and duration of infection 105. However, when 
people are exposed to cold stress or extreme physical exercise, vitamin C supplementation 
does have a prophylactic effect 105. For other infections, for example pneumonia, evidence at 
this moment is too weak to advocate for a prophylactic effect of vitamin C 117. 
Vitamin C is also tested as cancer therapy in patients. In several studies, intravenous 
administration of vitamin C is used. With this method, plasma vitamin C levels can be 
increased by ~30-70 fold because of bypassing the renal absorptive system 118. When present 
in such a high concentration, vitamin C’s antioxidant role switches to a pro-oxidant role by 
producing the reactive oxygen species hydrogen peroxide 119. Normal cells have multiple 
mechanisms to neutralize hydrogen peroxide, while tumour cells lack these mechanisms, 
making them vulnerable for high vitamin C concentrations 119. Unfortunately also here, results 
are not conclusive yet, although some promising results are already achieved, reviewed in 120.
In summary, the role of vitamin C in the immune system still needs to be thoroughly 
investigated. Above mentioned studies advocate that vitamin C at least influences the immune 
system. Together with our own findings, it supports our previous proposal to investigate the 
supplementation of HSCT patients with vitamin C to faster recover their immune system.
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Conclusions
Taken together, the results presented in this thesis contribute to the current progress in the 
field of immunology in relation to immune therapy. As described throughout this chapter, the 
discussed results require further research before our proposed cell therapies will be available 
in the clinic. 
The current developed retroviral method blocking B lineage development resulted in the 
generation of leukocyte stem cells. Future research should focus on optimizing this method 
to a clinical applicable, non-integrating method. Furthermore, the long-term repopulation 
capability of ex vivo expanded stem and progenitor cells needs to be addressed.
We also described a clinical grade culture method to generate T cell progenitors from CB 
and G-CSF mobilized stem cells. Research should focus on the validation of adoptive T cell 
progenitor therapy in mice and humans; whether in vitro generated progenitors indeed mature 
to functional T cells in murine infection models. Subsequent human studies are required 
to verify the potential benefit of T cell progenitor therapy. Moreover, will these cells have a 
broad enough TCR repertoire to protect patients after HSCT from infections? Additionally, 
combinational therapies consisting of the enlargement of the thymic seeding progenitor 
population in combination with thymic rejuvenation strategies could be addressed.
In this thesis, we describe that vitamin C is important in both in vitro T and NK cell 
development and expansion. We also report that patients with haematological malignancies 
have decreased vitamin C levels compared to healthy controls. Therefore, it would be of great 
interest to investigate whether vitamin C supplementation can contribute to the immune 
reconstitution in patients receiving cancer therapy.
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Cancer is one of the major causes of death in the world. The treatment of the majority of the 
cancer patients consists of a combination of surgery, chemo- or radiotherapy. Not all cancers 
can be cured with these conventional methods, therefore, other therapies like immunotherapy 
became of great interest. The major aims of immunotherapy are to trigger the patient’s immune 
system to enhance the response against cancer cells or to supply immune cells or components 
to the patient that provide a strong immune reaction after administration.
We performed a fundamental study of the thymus, as described in chapter 2, to obtain 
further understanding of thymus development, which could be helpful in the development 
of therapeutic strategies aiming at thymus rejuvenation, potentially resulting in increased 
thymopoiesis. In this chapter we show that during normal thymus development, fibroblast 
– that are of mesenchymal origin – ingrowth occurs towards areas where crosstalk between 
thymic epithelial cells and thymocytes is abrogated. Additionally, we provide candidate factors 
that are potential important in thymus mesenchymal network formation.
For adoptive cellular immunotherapy, the generation of high cell numbers of interest is often 
a requirement as well as a limitation of current protocols. In order to provide sufficient cell 
numbers, attempts to expand haematopoietic stem cells are of great value and of great interest. 
By first expanding haematopoietic stem cells and subsequent differentiation towards specific 
cell types, higher total cell numbers of interest can be generated. In chapter 3, we provide 
a method for haematopoietic progenitor expansion. A simple blockage of differentiation 
by overexpression of the ID3 transcriptional inhibitor in haematopoeitic stem cells in 
combination with B cell inducing culture conditions, results in a cell population with arrested 
differentiation and great self-renewal capacity. Since these cells are capable to differentiate into 
various cell types in an in vivo mouse model, these cells could be used as potential starting 
population for different kinds of cell therapies. 
T cell progenitor therapy aims at a more rapid recovery of a patient’s T cell pool after 
receiving haematopoietic stem cell transplantation (HSCT) as cancer treatment. Although, 
the combination of chemotherapy and HSCT is successful to eliminate cancer in certain 
cases, opportunistic infections cause high morbidity and mortality among these patients. 
This high infection incidence is caused by the patient’s low T cell counts due to slow recovery 
of the T cells from the stem cell graft. A process that can take up from several months to 
years. Adoptive T cell precursor therapy could provide faster recovery of patient’s T cell 
pool and thereby provide protection for infections. In chapter 4 we reply on a skin-explant 
method for the generation of T cells as described by Clark and colleagues 1. We show that 
keratinocytes express minimal Delta Like Ligand (DLL), while this signalling is essential 
for T cell differentiation and commitment. We concluded that the method by Clark et al. is 
unfortunately not suitable for the production of T cells. Meanwhile, it was shown by us and 
others that haematopoietic stem cells derived from healthy volunteers have the capacity to 
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differentiate to T cell progenitors in the presence of certain growth factors in co-culture with 
DLL+ murine stromal cell 2-5. It was also shown that these T cell progenitors are capable to 
migrate to the thymus of immune deficient mice faster than unmanipulated stem cells.
Murine stromal-cell based systems for cell therapy production are less suitable for clinical 
application. Therefore, we aimed to generate a culture method without the use of retrovirally 
transduced murine stromal cells overexpressing Delta ligands in chapter 5. Here, we generated 
a system consisting of plate bound DLL4:Fc, fibronectin and a cytokine cocktail resulting in 
the differentiation of haematopoietic stem cells to T cell progenitors. Nonetheless, these T cell 
progenitors did not reach the same maturation stage as in the stromal cell culture validated 
previously 2. Consequently, we searched for factors that could make up for this difference. 
We found that ascorbic acid, also known as vitamin C, improves not only maturation of T 
cell progenitors but also improves the proliferation of these cells. Additionally, we show that 
different haematopoietic stem cell sources, cord blood and G-CSF mobilized stem cells, have 
the capacity to differentiate into T cell progenitors in the developed system. The differentiation 
and expansion of both cell sources are improved by ascorbic acid, proposing a clinical grade 
culture system for the generation of T cell progenitors that could improve the patient’s 
immunity after stem cell transplantation. Moreover, we show a role for ascorbic acid in the 
transition from double negative to double positive T cells. We show that the discrepancy in 
the extent of supporting T cell development between TSt-4/DLL4 (ProT2/PreT) and OP-9/
DL1 (DP/SP) is because of the presence of ascorbic acid in the later co-culture. Furthermore, 
we concluded that Delta ligand expressing feeder cells nor conditioned media are required for 
DP T cell development when culturing stem cells with plate bound DLL4, a defined cytokine 
cocktail and ascorbic acid.
T and natural killer (NK) cells share a common progenitor. NK cell therapy is another cellular 
immunotherapy for cancer that is currently under investigation. NK cells have an important 
role in cancer immunosurveillance and can eliminate tumour cells. However, cell numbers 
required for adoptive therapy are enormous. In chapter 6, we show that ascorbic acid has a 
positive influence on the expansion of peripheral NK cells, a finding that can be of great value 
for the improvement of the production of adoptive NK cell therapy. Moreover, we provide a 
culture methods were NK cell progenitors can be generated from haematopoietic stem cells or 
T(/NK) cell progenitors, processes that are improved by ascorbic acid. Since ascorbic acid is 
an inexpensive and clinical grade available compound, it can easily be implemented in clinical 
protocols and clinical trials. 
Because of the positive effect of ascorbic acid on both T and NK cell development and 
expansion, we determined ascorbic acid serum concentrations in patients with haematological 
malignancies. We show in chapter 7 that patients treated with autologous/allogeneic stem cell 
transplantation and/or chemotherapy have significantly reduced serum ascorbic acid levels 
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compared to healthy controls. This interesting observation makes further research to the 
possible correlation of ascorbic acid serum levels and the function and recovery of immune 
cells plausible. Moreover, the effect of ascorbic acid supplementation on these parameters 
would be interesting to investigate.
The findings described in this thesis contribute to the current promising progression in the 
field of cellular immunotherapy. Therapies that could improve the life expectancy of patients 
with cancer in the near future and should therefore be of main interest for current research 
and clinical translation.
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Kanker is wereldwijd een van de belangrijkste doodsoorzaken. De meerderheid van 
behandelingen voor kankerpatiënten bestaat uit een combinatie van chirurgie, chemo- of 
radiotherapie. Helaas kunnen niet alle vormen van kanker met de conventionele methodes 
adequaat worden behandeld en genezen. Derhalve is de ontwikkeling van nieuwe vormen van 
therapie, zoals immuuntherapie, noodzakelijk. Immuuntherapie activeert het immuunsysteem 
van de patiënt, zodat de afweerreactie tegen de kankercellen toeneemt. Tevens kan extra 
toediening van immuuncellen of componenten de afweerreactie versterken. 
Hoofdstuk 2 behandelt een fundamentele studie over de zwezerik, oftewel de thymus, om 
meer inzicht te verkrijgen in de ontwikkeling van dit orgaan. Informatie welke uiteindelijk 
zal kunnen bijdragen aan de ontwikkeling van therapeutische strategieën die zich richten op 
thymus verjonging, gekenmerkt door een verhoogde T cel productie. T cellen zijn essentieel 
voor de specifieke afweer tegen pathogenen. In het hoofdstuk laten we zien dat tijdens normale 
thymus ontwikkeling, fibroblasten (embryonale bindweefselcellen) ingroeien naar gebieden 
waar communicatie, ook wel crosstalk genoemd, tussen thymus epitheelcellen en thymocyten 
afwezig is. We beschrijven kandidaat factoren welke mogelijk essentieel zijn voor het vormen 
van het mesenchymale netwerk in de thymus.
Voor adoptieve cellulaire immuuntherapie zijn een hoog aantal cellen vereist. Het vergroten 
van de productie van immuuncellen kent momenteel een grote belangstelling, echter zijn 
er nog steeds beperkingen aan de huidige protocollen. Er zijn vele pogingen gedaan om 
hematopoëtische stamcellen eerst te laten vermeerderen om ze vervolgens te differentiëren 
naar specifieke, gewenste cel typen, resulterend in een groter aantal cellen van interesse. In 
hoofdstuk 3 dragen we een methode voor om hematopoëtische voorloper cellen te laten 
vermeerderen. Een eenvoudige blokkering van differentiatie in stamcellen, bereikt door de 
overexpressie van de transcriptie remmer ID3 in combinatie met B lymfocyt inducerende 
condities, resulteert in een celpopulatie met geremde differentiatie en een grote capaciteit tot 
zelfvernieuwing, beide kenmerken van een stamcel. Deze cellen zijn in staat te differentiëren 
tot diverse celtypes in een muismodel, waardoor ze potentieel bruikbaar zijn als startpopulatie 
voor verschillende therapieën, waaronder adoptieve voorloper T cel therapie. Voorloper 
T cel therapie heeft als doel de populatie T cellen van de patiënt na een hematopoëtische 
stamcel transplantatie (HSCT) sneller te herstellen. Hoewel de combinatie van chemotherapie 
en HSCT in bepaalde gevallen afdoende is om kanker te elimineren, sterven veel van de 
patiënten aan (opportunistische) infecties. Deze hoge infectie-incidentie is te wijten aan de 
lage T cel waarden van de patiënt door trage ontwikkeling van T cellen vanuit het stamcel 
transplantaat, een herstel dat maanden tot jaren kan duren. Wij hanteerden de hypothese 
dat adoptieve voorloper T cel therapie sneller herstel van de T cel populatie van de patiënt 
bewerkstelligt en op deze wijze bescherming biedt tegen infecties. Hoofdstuk 4 reageert op 
een in de literatuur beschreven kweek methode waar huidcellen op een driedimensionale 
matrix gekweekt worden, waarin een goede productie van geschikte T cellen mogelijk zou 
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zijn 1. Onze studie wijst op een groot aantal problemen en geeft als belangrijkste verklaring voor 
het falen van de productie van T cellen dat keratinocyten het eiwit Delta Like Ligand (DLL) 
minimaal tot expressie brengen, terwijl deze signalering essentieel is voor T cel differentiatie 
en toewijding. Derhalve concludeerden we dat de door Clark et al. beschreven methode niet 
geschikt is voor de productie van T cellen voor therapeutische doeleinden. Bovendien hebben 
wij en anderen aangetoond dat hematopoëtische stamcellen van gezonde vrijwilligers kunnen 
differentiëren naar voorloper T cellen in de aanwezigheid van geselecteerde groeifactoren 
in co-cultuur met DLL+ stromale cel lijnen uit muizen 2-5. Deze voorloper T cellen kunnen 
na injectie naar de thymus van immuundeficiënte muizen migreren en doen dit bovendien 
sneller dan niet-gekweekte stamcellen. 
Kweekmethodes welke gebaseerd zijn op retroviraal getransduceerde stromale cellen uit 
muizen voor de productie van celtherapie producten zijn minder geschikt als therapeutische/
klinische toepassing. Hoofdstuk 5 introduceert een kweekmethode welke geen gebruik 
maakt van stromale cellen uit muizen. Dit systeem, bestaande uit plaat-gebonden DLL4:Fc, 
fibronectine en een medium met geselecteerde groeifactoren, resulteerde in de differentiatie 
van stamcellen naar voorloper T cellen. Deze T cel voorlopers verkregen een minder 
gevorderd rijpingspatroon vergeleken met de cellen geproduceerd in de stromale cel 
gebaseerde methode. De zoektocht naar factoren die dit rijpingsverschil kunnen overbruggen, 
leverde het nieuwe inzicht dat ascorbinezuur (vitamine C) zowel de rijping als de proliferatie 
van de voorloper T cellen verbetert. Differentiatie van verschillende stamcel bronnen, 
zowel G-CSF gemobiliseerde als navelstrengbloed stamcellen, bezitten de capaciteit om tot 
voorloper T cellen te ontwikkelen in het opgezette systeem. De differentiatie en expansie van 
beide celbronnen wordt tevens verbeterd door ascorbinezuur. Hierbij introduceren we een 
klinisch toepasbaar kweeksysteem, bruikbaar voor de productie van voorloper T cellen die 
het afweersystem van de patiënt na HSCT kunnen versterken. Bovendien tonen we een rol 
voor ascorbinezuur aan in de overgang van CD4+CD8+ dubbel negatieve (DN) naar de verder 
gerijpte CD4+CD8+ dubbel positieve (DP) T cellen. Het verschil in het kunnen ondersteunen 
van T cel ontwikkeling tussen het TSt-4/DLL4 (ProT2/PreT cellen) en het OP-9/DL1 (DP/
CD4 of CD8 enkel positief (SP) cellen) kweeksysteem, komt door de aanwezigheid van 
ascorbinezuur in het medium van deze laatste co-cultuur. We concluderen daarom dat 
Delta ligand tot expressie brengende stromale cellen niet nodig zijn voor vroege DP T cel 
ontwikkeling. Een gedefinieerd systeem waarin stamcellen gekweekt worden met DLL4:Fc, 
vier  bekende groeifactoren en ascorbinezuur volstaat voor T cel differentiatie.
T cellen en natural killer (NK) cellen delen een gemeenschappelijke voorloper. NK cel 
therapie is een cellulaire immuuntherapie tegen kanker welke momenteel onderzocht 
wordt. NK cellen hebben onder andere een belangrijke rol in immuun controle en kunnen 
bovendien kankercellen elimineren. Het aantal cellen nodig voor therapie is enorm. 
Hoofdstuk 6 beschrijft dat ascorbinezuur een versterkende rol heeft op de expansie van 
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perifere NK cellen, een ontdekking van grote waarde voor het verbeteren/versnellen van 
de productie van NK cellen voor therapie. Ook laten we zien dat voorloper NK cellen 
gedifferentieerd uit hematopoëtische stamcellen of voorloper T cellen ook positief worden 
beïnvloed door ascorbinezuur. Omdat ascorbinezuur goedkoop en klinisch beschikbaar is, 
kan het gemakkelijk worden geïmplementeerd in huidige klinische protocollen en klinische 
trials. 
Door het positieve effect van ascorbinezuur op zowel T als NK cel ontwikkeling en expansie 
hebben we de ascorbinezuurwaarden uit serum bepaald van patiënten met hematologische 
maligniteiten, vanwege de mogelijke invloed hiervan op het herstel van het immuunsysteem. 
Hoofdstuk 7 beschrijft dat patiënten behandeld met chemotherapie of autologe/allogene 
stamcel transplantatie inderdaad significant verlaagde ascorbinezuur serumwaardes hebben. 
Deze interessante bevinding maakt verder onderzoek naar de mogelijke correlatie tussen 
ascorbinezuur serumwaardes en de functie en herstel van immuuncellen plausibel. Ook het 
effect van ascorbinezuur op deze parameters is interessant om te onderzoeken.
De bevindingen beschreven in deze thesis dragen bij aan de veelbelovende vooruitgang 
in het veld van immuuntherapie. Deze therapieën kunnen bijdragen aan een verbeterde 
levensverwachting van patiënten met kanker in de nabije toekomst en zijn daarom van 
essentieel belang voor huidig onderzoek en klinische vertaling.
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Cancer is one of the major causes of death in the Western world and the second cause of 
death in developing countries, with a global growing incidence of 22.2 million estimated cases 
in 2030 1-3. In 2012, 14.1 million people were diagnosed with cancer and 8.2 million cancer 
deaths were counted worldwide 4. Even though cancer mortality declines because of more 
effective, early detection in combination with early treatment, the burden on society remains 
enormous. The economic burden consists of costs associated with for example prevention, 
health-care and productivity losses due to morbidity and mortality. The estimated total cancer 
costs in the European Union were € 126 billion in 2009 5. Besides the economic burden, the 
social burden of cancer affecting the quality of life of both patients and their caregivers should 
also be acknowledged.
Because not all cancers can be cured with the current treatment protocols, an urgent need 
for novel therapies exists. More recently, therapies like immunotherapy became of great 
interest. Although great progress in the past decades has been made (e.g. the introduction 
of monoclonal antibodies), immunotherapy is often only effective in certain patients and 
only results in moderate prolonged survival instead of complete remission. Among cellular 
immunotherapies, adoptive T cell progenitor therapy and natural killer (NK) cell infusion are 
of great interest and are described in this thesis.
For adoptive cellular immunotherapy, the generation of high cell numbers of interest is often a 
requirement as well as a limitation. To treat for example a patient of 70 kg, somewhere between 
70x106 to 700x106 cells are believed to be required for a single dose of T cell progenitors. In 
order to generate such great cell numbers, attempts to expand haematopoietic stem cells are 
of importance and of great interest.
In chapter 3 we provide a method to expand haematopoietic stem cells. For human cells, 
this resulted in 160 fold more cells. Subsequent differentiation towards specific cell types 
could result in higher total cell numbers for therapy. However, since these cells produced 
by manipulation with a retroviral construct, first an alternative method should be generated 
to meet good manufacturing practices (GMP) and ensure safety. Nevertheless, this method 
provides a good basis for further research.
In chapter 5, we propose a clinical grade culture system for the production of T cell 
progenitors that can easily be translated to a clinical product and that could strengthen the 
patient’s immune system after stem cell transplantation. Although stromal cell based systems 
that were previously developed by others and us could potentially be used for the generation 
of cellular therapy, getting approval for such product would be difficult, expensive and time 
consuming. Especially because cellular products are rather new and no extensive regulations 
are written. Moreover, the potential risks are not completely known. The stromal-based co-
cultures use murine stromal cells lines that are retrovirally transduced to overexpress Delta 
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Like ligand. EMA and FDA advise against the use of products of animal origin, although it is 
not prohibited. In this case, the use of both the stromal cells and the FCS required to produce 
the cellular product will be debatable. Another concern is that the stromal cells are retrovirally 
transduced. Although these cells will not be in the actual product, it has to be assessed 
whether viral load is present in the cell products to assure safety. Besides safety regulations, 
there are other concerns regarding this product. Prior sorting to eliminate stromal cells and 
to select the proper T cell populations is required, which are as said time consuming and 
expensive. Moreover, reproducibility in a system with cell lines and FCS is more difficult than 
in a feeder- and serum-free culture. It is know that FCS and even cell lines have large batch 
to batch variation, resulting in lower reproducibility, increase in quality control and thereby 
increasing costs. 
To circumvent the indicated undesired components, we generated a system using plate bound 
DLL4:Fc, fibronectin and a growth factor cocktail to differentiate haematopoietic stem cells 
to T cell progenitors, which can be clinical applicable. We discovered that ascorbic acid, 
also known as vitamin C, improves maturation of T cell progenitors and also improves the 
proliferation of these cells. Adoptive T cell progenitor therapy could provide faster recovery 
of patient’s T cell levels and thus providing protection against infections. Currently, the low 
T cell levels of patients and subsequent infections account for high morbidity and mortality 
of these patients 6. Moreover, the use of T cell progenitors is not limited to cancer patients, 
but could also be used to improve the immune system of other immunocompromised patient 
groups like AIDS patients. A first step towards the development of a clinical product would 
be the verification of the T cell progenitors in vivo in a humanized mouse model. Hereafter, 
production needs to be scaled up to obtain sufficient cell numbers for human cell infusions. 
Currently, the product is produced in 96 or 48 well plates resulting in limited yield and high 
maintenance. Culturing in special bags or bioreactors with controlled supplementation of 
required nutrients and cytokines could increase yield and reduce handling time resulting in 
a better product with less costs. Moreover, progenitor T cells need to be produced in a GMP 
facility before clinical trials can be initiated. Clinical trials should asses if injection of both 
stem cells and progenitor T cells will result in a faster recovery of the patient T cell pool and 
if this leads to reduced infection incidence. 
Another cellular immunotherapy that is currently under investigation is NK cell therapy as 
treatment for types of cancer that are not curable by the conventional therapies as surgery, 
chemotherapy or radiation. Cell numbers required for adoptive therapy are estimated to run 
in the billions especially because only a minor population of the total NK cell fraction is 
capable of eliminating tumour cells 7-8. In chapter 6, we show that ascorbic acid has a positive 
influence on the expansion of peripheral NK cells, a finding that can be of great value for the 
improvement of the production of adoptive NK cell therapy. The generation of more cells in 
a shorter time could lead to a better cost-effective product. Since ascorbic acid is already a 
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FDA-approved compound, this can easily be implemented in clinical protocols and clinical 
trials. First, the current proposed culture method needs to be upgraded to a GMP compliant 
method. Currently, this is performed in our lab in collaboration with the German company 
Zellwerk. The culture system is a bioreactor in a GMP qualified safety cabinet with a constant 
supply of fresh media. Also glucose, pH, temperature are constantly monitored and adjusted 
if needed. Currently, NK cells generated in this bioreactor are evaluated on their proliferative 
capacity, phenotype and function. After subsequent verification of our results in vivo mouse 
models, phase I clinical trials will be started. 
As mentioned shortly, for both T cell progenitor and NK cell therapy, clinical product 
translation is still required. For GMP, products need to be prepared in closed systems in 
special facilities with high quality control and standardized protocols. Before starting clinical 
research, approval by the Medical Research Ethical Committee needs to be granted. Financial 
support for the trial can be obtained from private funding or funding from organizations 
like the Dutch Cancer Society (KWF) and the Cancer research Fund of the Limburg Health 
Foundation. To ultimately bring these products to the patients, charities will not be able to 
provide sufficient money to pay for the involved costs. It is foreseen that spin-off companies 
that attract venture capital can bring these needed therapies several steps further. Phase III 
clinical trials will need so much money that the big pharmaceutical companies will be needed 
to further co-develop the products. 
Besides the developed and improved culture methods to generate cells applicable for adoptive 
cellular therapy, we investigated the vitamin C status of patients with a haematological 
malignancy. In chapter 7 we show that these patients, either treated with stem cell 
transplantation and/or chemotherapy have significantly reduced vitamin C levels. This 
information has a high new value and further research could be performed to investigate 
whether these low vitamin C levels correlate to patients’ lymphocyte counts. This information, 
especially in combination with the in vitro effects of vitamin C shown in chapter 5 and 6, could 
therefore be used to start clinical trials. For example, the effect of vitamin C supplementation 
on lymphocyte recovery and infection incidence could be studied. Since vitamin C is 
inexpensive to produce, readily available, known for many years and already proven to be 
safe when supplemented in high doses, clinical trials could be initiated fast. Furthermore, it 
would be of great interest to investigate the effect of vitamin C supplementation on thymus 
regeneration, potentially resulting in increased thymic output and higher T cell levels. 
These findings contribute to the current promising progress in the field of cellular 
immunotherapy. Our results promise a good feasibility; however, these data need to be 
strengthened with in vivo experiments with our proposed clinical products. Subsequently 
clinical trials need to demonstrate the scientific and clinical value of these therapies. Cellular 
immunotherapies require patient specific products that are labour-intensive and therefore 
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high costs will be involved in the production 9-10. Since several cellular immunotherapies are 
already in use, for example stem cells for transplantation and a dendritic cell based vaccine 
for prostate cancer (Provenge®), cellular immunotherapies already prove to be effective. This 
opened the road for novel therapies as proposed in this thesis. These therapies could improve 
the life expectancy of patients with cancer in the near future and should therefore be of main 
interest for current research and clinical translation.
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